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ABSTRACT 
Human cytomegalovirus (HCMV) is a ubiquitious herpes virus and a serious pathogen 
within immunocompromised populations. HCMV is the leading cause of infectious 
congenital disease. Without an effective vaccine much work is put into designing 
alternative treatment approaches. Current HCMV treatments include nucleoside 
analogues and recently the terminase inhibitor, letermovir. These treatments have 
unwanted side effects and HCMV can become resistant to them. This fact mandates 
production of alternative treatment approaches. In chapter two we use antiviral peptides 
to inhibit cytomegalovirus infection. Our peptides are highly efficient at inhibiting in vitro 
derived CMV, but they lack efficacy in vivo. The ineffectiveness is due to the inability to 
inhibit cell-to-cell spread. We must stop cell-to-cell spread to stop CMV. Cell-to-cell 
spread is the major mechanism by which CMV disseminates throughout the body. 
Innate immune cells mediate the CMV dissemination process, reviewed in chapter one. 
Interestingly, HCMV has evolved immunomodulatory proteins that enhance innate 
immune cell trafficking to infection sites. One protein of interest is the viral chemokine 
vCXCL-1. This protein is known to attract immune cells in vitro, but in vivo the function 
is unknown. Using the mouse model and murine cytomegalovirus (MCMV) we 
investigate vCXCL-1's in vivo functions. In chapter three we report that mice infected 
with a recombinant MCMV expressing vCXCL-1 at high levels had attenuated viral 
dissemination. We speculated this was due to abnormal vCXCL-1 expression. In 
chapter four we engineer a new recombinant MCMV expressing vCXCL-1 under control 
of the murine chemokine promoter MCK2, ensuring relatively normal physiological 
expression of vCXCL-1. This recombinant virus has increased viral dissemination 
kinetics compared to wild type viruses and altered inflammatory profiles. Increased 
dissemination is slightly reliant on the murine neutrophil which we report is able to 
harbor, transfer, and replicate MCMV. This work supports the hypothesis that vCXCL-1 
is a virulence factor. Infection of immune compromised mice with our new recombinant 
MCMV was lethal in more than 50% of infected animals, while all animals infected with 
parental virus survived. This work sheds light on important aspects of CMV entry and 
dissemination, which could prove vital when designing future HCMV treatments. 
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CHAPTER I: INTRODUCTION THERE IS ALWAYS ANOTHER WAY! 
CYTOMEGALOVIRUS' MULTIFACETED DISSEMINATION SCHEMES. 
  
 
 
2 
A version of this chapter was originally published by Joseph W. Jackson  and Tim 
Sparer: 
 
 Jackson, J.W. and T. Sparer, There Is Always Another Way! Cytomegalovirus' 
Multifaceted Dissemination Schemes. Viruses, 2018. 10(7). 
 
My use of we in this chapter refers to my coauthors and myself. My primary 
contributions include (1) researching the topic and (2) writing of this review article 
 
Abstract  
Human cytomegalovirus (HCMV) is a β-herpes virus that is a significant pathogen within 
immune compromised populations. HCMV morbidity is induced through viral 
dissemination and inflammation. Typically, viral dissemination is thought to follow 
Fenner’s hypothesis where virus replicates at the site of infection, followed by 
replication in the draining lymph nodes, and eventually replicating within blood filtering 
organs. Although CMVs somewhat follow Fenner’s hypothesis, they deviate from it by 
spreading primarily through innate immune cells as opposed to cell-free virus. Also, in 
vivo CMVs infect new cells via cell-to-cell spread and disseminate directly to secondary 
organs through novel mechanisms. We review the historic and recent literature pointing 
to CMV’s direct dissemination to secondary organs and the genes that it has evolved for 
increasing its ability to disseminate. We also highlight aspects of CMV infection for 
studying viral dissemination when using in vivo animal models. 
1. Introduction 
 Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus with a 50–90% 
seroprevalence rate in the adult human population [1]. While HCMV infection is usually 
asymptomatic, severe disease can result from primary infection or viral reactivation from 
latency in immune compromised hosts [2,3]. HCMV infection in immunocompromised 
persons can result in interstitial pneumonia, gastroenteritis, retinitis, organ transplant 
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rejection, or death [4,5]. HCMV is also a leading cause of congenital disease [6,7]. Upon 
in utero infection, the child can exhibit microcephaly or severe sequelae, or both, 
including hearing loss, mental retardation, and learning disabilities [8–10]. Whether 
infection is due to primary infection or reactivation, HCMV disease is caused through 
viral dissemination and inflammation. Therefore, understanding the basics of CMV’s 
lifecycle will provide new avenues for interventions, which could limit HCMV diseases. 
 HCMV uses several routes to spread within the populous. Vertical transmission 
occurs through transplacental and intrapartum transmission [10–12] through breast 
feeding from an infected mother to the child [13–16]. Horizontal transmission occurs 
through organ transplantation of an infected organ or contact with infected bodily 
secretions (i.e., saliva, breast milk, urine, etc.) [17–20]. Following initial exposure, 
HCMV is thought to undergo a brief leukocyte-associated viremia during which organs 
such as the lung, spleen, and liver become seeded and productively infected [2,3]. This 
sequence of events has historically been termed primary viral dissemination. Following 
primary dissemination, the virus undergoes a sequential dissemination (i.e., secondary 
dissemination) in which HCMV infects tissues such as the salivary glands, breasts, and 
kidneys [3]. Because the virus is spread via bodily fluids, it is presumed that HCMV 
targets these organs in order to infect new hosts. Figure 1.1 is the historical overview of 
HCMV dissemination. In an immunocompetent person the infection is contained, but like 
all herpes viruses, the virus remains latent for the host’s lifetime. Because a substantial 
portion of the human population is infected with HCMV, this leaves a large pool of 
people with latent infections. These individuals are potentially susceptible to viral 
morbidity if immunocompromised and HCMV reactivates. How, when, and why HCMV 
reactivates is unknown but for a complete review on HCMV latency see Sinclair and 
Poole [21]. 
 Dr. Frank Fenner, studying mouse pox, postulated that during a viral infection the 
virus would replicate at the infection site, then disseminate to the regional lymph nodes, 
followed by replication in blood filtering organs. These organs would then produce large 
quantities of virus that results in disease [22,23]. This longstanding hypothesis assumes 
that virus undergoes a gradual increase in viral burden throughout the host, which  
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Figure 1.1. Overview of human cytomegalovirus (HCMV) dissemination. 
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eventually leads to disease. Data from mouse CMV (MCMV) models point to a different 
in vivo scenario. During the course of an MCMV infection, the virus undergoes a 
biphasic viremia in which the virus briefly appears in circulation, disappears, and 
eventually reappears in the blood [24]. Another CMV characteristic which 
contradictsFenner’s model, is that CMV infection is cell mediated and cell-free virus has 
little to no effect on the course of infection [25–28]. However, the exact mechanism by 
which HCMV travels through the body is unknown. This is complicated by HCMV’s 
multifaceted dissemination and the limitation of studying HCMV in vivo. Due to the 
latter, we will rely on discoveries in animal models to uncover mechanisms for CMV 
dissemination. HCMV disease is linked to dissemination and inflammation; therefore, if 
we understand viral dissemination it could help to understand HCMV pathogenesis. In 
this review, we will focus on key events and influential cell types in cytomegalovirus 
dissemination from both HCMV and small animal models. 
2. Transmission and Initial Infection 
 HCMV infection is dependent on direct contact with infected bodily secretions. 
HCMV is shed in urine, breastmilk, and genital secretions in order to transmit to a new 
host [1]. It is presumed that most individuals acquire HCMV orally [29,30]. A rhesus 
model of CMV demonstrated that rhesus CMV oral infection leads to infection and 
subsequent transmission to new hosts [31]. This begs the questions: What is the 
primary infection site? Is it the oral cavity, the lungs, or the gut? Farrell et al. compared 
intranasal and oral infection models using MCMV [32]. They demonstrated that MCMV 
infection in either case resulted in an upper respiratory tract infection and not infection 
of the mouse gut. This points to intranasal infection as a more natural route for CMV 
infections. 
 After the virus breaches the host’s external barriers, it enters a host cell and 
begins replication. This is the initial step in viral dissemination; MCMV directly infects 
alveolar macrophages and type 2 alveolar epithelial cells after intranasal inoculation 
[33]. By extrapolation, these cell types are potentially the initial cells infected following 
HCMV transmission. HCMV entry into epithelial cells and macrophages is mediated by 
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endocytosis and the subsequent pH-dependent fusion with the endosomal membrane. 
This is facilitated by the viral envelope glycoproteins gB, gH/gL/gO, and the pentameric 
complex gH/gL/UL128, UL130, UL131A [34–38]. Upon entry into the epithelial cell, the 
virus undergoes its lytic cycle, generating infectious viral progeny that infect other 
susceptible cell types such as fibroblasts, endothelial cells, dendritic cells, and other 
innate immune cells including alveolar macrophages [39,40]. During this initial stage, 
the virus is spread locally either by cell-free virus or via cell-to-cell spread [41]. Cell-to-
cell spread is mediated in part by the HCMV gene US28 [42]. This mechanism of 
spread requires direct contact between an infected cell and an uninfected cell. 
Interestingly, human clinical isolates do not release cell-free infectious progeny, but are 
still capable of efficient spread throughout a monolayer [43]. This hints that in vivo, 
HCMV prefers cell-to-cell spread [43,44]. As we will discuss, many of the innate immune 
cells which aid in CMV dissemination are efficiently infected via cell-to-cell infection but 
not with cell-free virus [45,46]. The process of cell-to-cell spread will be further 
discussed in chapter two.  
3. Cell-Mediated Dissemination 
 When HCMV spreads to innate immune cells, the second stage of HCMV viral 
dissemination commences (i.e., systemic spread). Endothelial cells (ECs) influence cell-
to-cell spread [45,46]. Naïve innate immune cells (i.e., monocytes or neutrophils) are 
readily infected when migrated across an infected EC layer [47]. Additionally, infected 
ECs encourage the adherence of innate immune cells to the endothelium by increasing 
expression of adhesion molecules such as ICAM-1, vCAM-1, and others [48,49]. The 
increase in adhesion molecules increases the interactions between naïve monocytes or 
neutrophils, or both, and infected ECs, thereby increasing the likelihood of cell-mediated 
infection [48]. HCMV infection of ECs also increases vascular permeability of the 
endothelium, which in turn increases contact between innate immune cells and ECs 
[48]. This leads to increased HCMV infection of these cells. Cell-mediated infection of 
monocytes and neutrophils is dependent on the presence of a functional pentameric 
complex (i.e., gH/gL/UL128, UL130, UL131A). HCMVs lacking these genes are unable 
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to enter ECs and by extension unable to be transferred to monocytes or neutrophils 
[47]. This reiterates that without viral entry, the dissemination process is crippled. 
 For infection of neutrophils, Gerna et al. proposed a membrane fusion between 
the neutrophil and the infected ECs [50]. The membranes fuse generating micro pores 
between the two cells. These pores will allow the virus to be shuttled from the infected 
endothelial cell into the neutrophil. This mechanism of viral acquisition is similar to 
trogocytosis, a process through which intracellular bacteria spread from cell to cell [51]. 
This is one of the roles that ECs play in dissemination [52–54]. Infected ECs may also 
play a more direct role in dissemination. Infected ECs can detach from the vasculature 
and enter the blood stream. These detached ECs are referred to as giant endothelial 
cells, which are capable of productive viral replication [53,54]. They can potentially 
transfer virus to uninfected organs within the narrow venules where cell-to-cell contact is 
more prevalent. However, the MCMV mouse infection model did not show direct EC 
involvement during dissemination [25]. In the second stage of HCMV viral 
dissemination, innate immune cells could have a role, but in what capacity these cells 
contribute to hematogenous spread of HCMV is still controversial. 
 HCMV viremia is mostly cell associated [3]. HCMV DNA has been found in 
serum and plasma of infected transplant recipients, but these are highly fragmented 
genomes implying that they are not infectious virions [55,56]. In support of cell-
associated viremia, depletion of leukocytes from blood products derived from 
seropositive donors prior to blood transfusion prevents HCMV transfer [57,58]. In 
addition, there are numerous reports indicating that peripheral blood leukocytes harbor 
infectious HCMV [59–63]. These studies demonstrated that infectious virus was able to 
be isolated from both the mononuclear and polymorphonuclear (PMN) factions. This led 
to the hypothesis that CMVs use both monocytic cells as well as PMNs to disseminate 
throughout the body. In order for these cells to play any part in dissemination the innate 
immune cells must travel to the primary infection site, become infected, and then leave 
to infect other tissues. 
 In general, viral infection leads to an influx of cells such as monocytes and PMNs 
at the infection site, which could provide additional targets to aid viral dissemination. 
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However, this response is amplified during HCMV infection. CMVs have evolved to 
manipulate the immune system for its benefit. The plethora of immunomodulatory 
proteins that HCMV encodes is outside of the scope of this review, but a comprehensive 
review can be found here [64,65]. However, we will focus on CMV’s immunomodulatory 
proteins which potentially aid in viral dissemination. In order to infect innate immune 
cells, these cells must be attracted to the infection site. CMVs accomplish this through 
chemokine homologues. Chemokines are small activating and attracting proteins that 
generate a chemical gradient necessary for cellular chemotaxis [66,67]. It is 
hypothesized that CMVs recruit innate immune cells to the infection site in order to 
infect them and use them to egress from the primary infection site. 
 HCMV encodes two known CXC chemokine homologues and a potential CC 
chemokine homologue. UL146 and UL147 encode the CXC homologues, vCXCL-1 and 
vCXCL-2, respectively. While there is no functional data for vCXCL-2, vCXCL-1 has 
been extensively studied [68–73]. vCXCL-1 is a functional homologue of human 
chemokines CXCL8, CXCL1, and CXCL2, depending on the source of the vCXCL-1 
protein. It signals primarily through the CXCR2 chemokine receptor, but those with 
higher affinity of CXCR2 can also bind via CXCR1 [68,70]. A few potential CXCR2+ 
target cells include PMNs, inflammatory monocytes, and ECs [67,74–77]. Recently, 
Yamin et al. reported that vCXCL-1 can elicit a response through the CX3CR1 
chemokine receptor [70]. Natural killer (NK) cells, which are CXCR1/CX3CR1 positive, 
responded to vCXCL-1 using both receptors [70]. While there is limited data as to 
whether NK cells are capable of harboring, replicating, or transferring HCMV, CXCR2+ 
cells can function as dissemination vehicles. 
PMNs 
 PMNs (i.e., neutrophils) are the highest expressing CXCR2+ cells within the 
body. PMNs can harbor and transfer infectious HCMV [62,63,78]. In fact, the highest 
viral titers in the blood have been found within the PMN fraction [59,79]. Although PMNs 
are capable of harboring and transferring infectious HCMV, it is a non-productive 
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infection [50,80]. These observations have been supported in a variety of animal models 
[24,81,82]. 
 PMNs are rarely infected directly with cell-free virus [83]. Therefore, it appears 
that PMN infection is completely dependent on cell-to-cell spread [45,50]. HCMV 
transfer to PMNs is regulated by the presence of UL146 and UL147. This implies that 
UL146 and UL147 may have additional functions besides chemotaxis [47]. After viral 
exposure, PMNs have an increased life span and express a pro-survival secretome 
[83]. Interestingly, PMNs exposed to cell-free virus release pro-inflammatory factors that 
induce monocyte recruitment and drive monocyte differentiation [83]. This could allow 
the neutrophil to “amplify” the immune response, which would bring in additional targets 
for infection and dissemination. 
 Two hypotheses could explain the role of PMNs in the course of primary CMV 
dissemination. One, PMNs directly disseminate HCMV or two, HCMV uses them 
indirectly. In the second scenario the neutrophil is recruited to the primary infection site 
where it encounters cell-free CMV. This interaction induces the PMN to secrete 
molecules that recruit other innate immune cells to the primary infection site [83]. These 
other immune cells are potentially better targets and will then be the primary CMV 
dissemination vehicle. Another role that PMNs might play during HCMV’s lifecycle is 
aiding dissemination after reactivation from latency. As reviewed in Reference [21], 
bone marrow is a major reservoir for latent HCMV [84]. Upon CXCR2 stimulation, 
neutrophils egress from the bone marrow [85]. Because vCXCL-1 has high affinity for 
CXCR2 [68,70], upon reactivation HCMV could use vCXCL-1 to stimulate neutrophils to 
leave the bone marrow and subsequently systemically disseminate HCMV. In this 
scenario, vCXCL-1’s main role is dissemination following reactivation from latency. 
Monocytes and Macrophages 
 The monocyte is another myeloid-derived innate immune cell implicated in 
HCMV dissemination. Historically monocytes have been considered the major cell type 
for HCMV dissemination [2,3,86]. Monocytes are short-lived blood phagocytes that are 
precursors for inflammatory macrophages, inflammatory monocytes, and dendritic cells 
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[87]. Like neutrophils, monocytes do not support productive HCMV replication 
[61,79,88,89]. However, productive monocyte infections have been reported once they 
have differentiated [90,91]. When naïve monocytes are exposed to either infectious 
HCMV or UV-inactivated virus they spontaneously undergo monocyte to macrophage 
differentiation [86,92]. These macrophages are capable of productive viral replication 
[93,94], so it seems logical that HCMV has evolved a mechanism for inducing monocyte 
to macrophage differentiation. Even though monocyte infection is not productive, they 
are capable of transferring infectious HCMV to uninfected cells in vitro [46]. The 
mechanism of this transfer is currently unknown. Infected monocytes also have reduced 
migration capacity as well as an impeded capacity to recruit other immune effectors, 
which would allow additional contact time to spread the virus as well as dampening 
immune activation [95]. 
 As with the HCMV vCXCL-1 for neutrophil recruitment, HCMV has evolved ways 
to attract monocytes to the infection site. HCMV encodes a CC chemokine homologue, 
pUL128. It is part of the pentameric entry complex, but purified pUL128 induces 
monocyte migration [96]. How this migration occurs and which chemokine receptor(s) is 
involved is unknown [97]. Because patrolling monocytes are CX3CR1 positive [87], it is 
possible that vCXCL-1 could elicit a monocyte response through this receptor. In 
addition, there are CXCR2+ monocytes [76,77,98] that could be responsive to vCXCL-1 
as well. Monocytes are activated by and migrate towards CXCL8 (IL-8), to which 
vCXCL-1 is a functional homologue [77]. Therefore, HCMV could potentially elicit a 
monocytic response via a variety of different mechanisms and use these monocytes to 
aid in viral dissemination. Figure 1.2 summarizes the mechanisms that neutrophils and 
monocytes could play in viral dissemination. 
4. Dissemination in Animal Models 
 Because the majority of HCMV infections are asymptomatic, studying primary 
dissemination in humans has been limited almost exclusively to in vitro and ex vivo 
analysis. A major characteristic of β-herpesviruses is their species specificity, meaning 
that HCMV is unable to productively replicate within another species [99–101]. Without 
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the ability to use HCMV directly in animal models, animal CMVs have been used to 
study the mechanism of dissemination in vivo with these results extrapolated to HCMV 
characteristics and mechanisms. We will focus on small animal models of CMV infection 
because the majority of dissemination research has been carried out in them. 
The Mouse Model 
 Predominantly MCMV has been used to draw conclusions about CMV 
dissemination. The mouse model is appealing for studying dissemination because 
MCMV has similar infection and pathogenesis to HCMV [102], MCMV contains 
homologues or orthologues, or both, of many HCMV genes, the mouse has a well-
characterized immune system, and there are numerous reagents available including 
transgenic and knockout mice [103]. 
 Like HCMV dissemination, innate immune cells mediate MCMV dissemination. 
MCMV encodes a potential functional homologue of UL128 called m131. Both of these 
genes encode proteins that function as part of an entry complex and contain a CC 
chemokine motif [104]. The m131 transcript spliced with m129 form part of the entry 
complex referred to as MCK2. Like pUL128 [96], MCK2 has been shown to attract 
monocytes [105,106], pointing to the monocyte as a conserved dissemination vehicle 
across species. It is hypothesized that MCK2 functions through the chemokine receptor 
CX3CR1 as infection of micelacking CX3CR1 on monocytes, dendritic cells, and NK 
cells [107] had greatly reduced viral dissemination to the salivary gland while primary 
dissemination was not impacted. It should be noted that when wild type mice were 
infected with mutant MCMV lacking MCK2, CX3CR1+ inflammatory monocytes were 
recruited to the infection site. However, the recruitment of CX3CR1+ patrolling 
monocytes was impeded. This indicates that the recruitment of all CX3CR1 innate 
immune cells is not solely reliant on MCK2. Therefore, it is likely that the initial systemic 
viral dissemination can progress without MCK2, but distal dissemination to the salivary 
gland is dependent on the recruitment of specific CX3CR1 positive immune cells [28]. 
This data further contradicts Fenner’s hypothesis. The MCMV secondary dissemination  
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Figure 1.2. Graphical representation of direct cellular dissemination and the 
neutrophil amplifier model. 
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and primary dissemination are two independent events with potentially different cellular 
mediators as opposed to the sequential events which Fenner proposed. 
 Farrell et al. showed that dendritic cells (DCs) are responsible for salivary gland 
dissemination [27]. Both humans and mouse monocytes are capable of differentiating 
into DCs [108]. Therefore, it is possible that CX3CR1 monocytes are recruited to the 
infection site, become infected, and differentiate into DCs [109]. Although this 
differentiation of monocyte → DC could be the key, there could also be a different DC 
population that re-enters the circulation and is responsible for salivary gland 
dissemination [27]. Subsequent salivary gland infection and dissemination is also 
dependent on the MCMV M33 chemokine receptor homologue [27,110]. Likewise, 
HCMV has evolved a number of cytokine and chemokine receptor homologues, 
however their impact on dissemination has yet to be determined. A full review of these 
molecules and their functions or potential functions can be found in Reference [97]. 
 While MCMV encodes a CC chemokine homologue it does not have a CXC 
chemokine homologue. This has limited the research on the role of neutrophils during 
MCMV infection. As discussed in chapter 3 recombinant MCMV’s overexpressing 
vCXCL-1 did not alter primary dissemination kinetics, however these viruses were 
impeded in their ability to efficiently infect the salivary gland [111]. These data point to a 
role of vCXCL-1 in dissemination, but overexpression of the chemokine induces an 
abnormal inflammatory environment, which halts normal salivary gland dissemination. 
Additionally, when neutrophils were depleted there was no significant impact on either 
primary or secondary dissemination implying that this effect is not neutrophil mediated 
[111]. Without a recombinant virus expressing vCXCL-1 under native conditions, it is 
difficult to discern the impact that neutrophils and the viral chemokine play in 
dissemination using this MCMV recombinant overexpressing expressing vCXCL-1, but 
this work points to differences between primary and secondary dissemination 
mechanisms. Here, in chapter 4 we demonstrate that expressing the viral chemokine, 
vCXCL-1, at correct physiological levels greatly enhances CMV dissemination and 
virulence.  
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 The route of inoculation and immune control is often overlooked when studying 
dissemination. Mice are usually infected intraperitoneally, intravenously, or 
subcutaneously with MCMV [3]. However, infection via different inoculation routes yields 
different disease outcomes. For example, subcutaneous infection of CX3CR1-deficient 
mice limited salivary gland dissemination. When these same mice were infected 
intraperitoneally, the virus reached normal salivary gland titers [28]. When infecting mice 
intranasally (i.e., a more natural route), there was the expected cell-associated viremia 
but the virus did not infect the abdominal visceral organs (i.e., spleen, liver) [32]. This is 
unlike other infection routes where these organs are infected to relative high titers 
[24,28]. Therefore, in order to appropriately study dissemination in an animal model the 
route of inoculation should be taken into consideration. 
 In the mouse model, many of the immune cells that impact viral dissemination 
also function as viral controllers. This makes studying the cell types responsible for 
dissemination more difficult, even with all the tools the mouse model has to offer. In 
order to study the impact of specific innate immune cells on dissemination, immune cell 
populations can be depleted. The goal is to deplete the cells and measure an expected 
reduction in viral dissemination. Depletion experiments evaluating the monocytes’, 
macrophages’, and NK cells’ impact on dissemination resulted in exacerbated 
dissemination and increased viral burden within the organs [112–114]. This evidence 
highlights the importance of understanding that immune cells contribute multiple 
functions during the course of CMV infection and that they are not just vehicles for 
dissemination. 
 Other Small Animal Models 
 Dissemination in other small animal models has not been studied as in depth as 
MCMV. However, both rat CMV (RCMV) and guinea pig CMV (GPCMV) support 
observations from MCMV or ex vivo HCMV infections. Rat infection with RCMV showed 
that dissemination is reliant on infected PMNs and monocytic cells in the blood [81]. As 
with MCMV, RCMV’s r129 and r131 also encode CC chemokines. R129 protein induces 
macrophage, PBMC, and lymphocyte (more specifically naïve CD4+ T cell) migration 
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and activation and increases transplant vascular sclerosis [115]. r131 increases the 
number of macrophages at the infection site and is needed to efficiently disseminate to 
the salivary gland [116]. The RCMV chemokine receptor, R33, functions similar to its 
counterpart M33 in MCMV. R33 plays an important role in inducing inflammatory 
responses that contribute to viral dissemination and accelerates transplant rejection 
[117,118]. 
 The GPCMV gene, gp1, encodes a CC chemokine as well. This chemokine, 
GPCMV-MIP, [119] is similar to human MIP-1 (macrophage inflammatory protein-1) and 
binds human CCR1 [120]. Knocking out gp1 in the GPCMV genome resulted in 
decreased inflammation and reduced hearing loss in pups compared with those infected 
with WT virus [121,122]. When mice were infected with a gp1 knockout virus, it served 
as an attenuated vaccine, which inhibited transplacental transmission of GPCMV [123]. 
These results highlight the importance of viral chemokines in CMV spread and viral 
pathogenesis as well as its potential use in generating an attenuated vaccine. 
GPCMV has also furthered our understanding of the pentameric entry complex. 
Recombinant GPCMV lacking GP129-GP133—the HCMV pentameric complex 
homologue—had impaired cellular entry and failed to spread in vivo [124]. GPCMV 
infection of guinea pigs is the best small animal model to study transplacental 
transmission of CMVs. MCMV and RCMV do not efficiently cross the placenta and 
infect offspring in utero, but GPCMV does. An extensive review of this model and its 
uses for vaccine and drug development can be found in references [125,126]. 
5. Conclusions 
 Dissemination of cytomegaloviruses has two goals: (1) achieve systemic 
dissemination in order to be transmitted to a new host and (2) establish latency within 
the current host. In either case, there are multiple mechanisms to achieve these goals. 
There are key events and cell types that impact dissemination. First, infection occurs in 
the oropharyngeal cavity, resulting in upper respiratory tract infection. These cells then 
release infectious viral progeny, viral chemotactic factors, and induce the innate 
responses. This environment will induce the invasion of innate immune cells into the 
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tissue. These immune cells become infected and traffic the virus throughout the body. 
Figure 1.3 illustrates an alternative mechanism of systemic dissemination and modifies 
Fenner’s original sequential dissemination (i.e., infection site → draining lymph nodes 
→ blood filtering organs) [22,23]. We propose an alternative mechanism for CMV 
dissemination (Figure 1.3) where virally infected cells can directly seed secondary 
organs that lead to secretion in bodily fluids. As we have seen time and time again, 
CMV deviates from the norms of viral infections and, as always, has its own agenda. 
 
 
Figure 1.3. Alternative mechanism of HCMV dissemination generated from animal 
model extrapolation. 
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Abstract 
Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus that can cause 
severe disease following in utero exposure, during primary infection, or latent virus 
reactivation in immunocompromised populations. These complications lead to a 1-2-
billion-dollar economic burden, making vaccine development and/or alternative 
treatments a high priority. Current treatments for HCMV include nucleoside analogues 
such as ganciclovir (GCV), foscarnet, and cidofovir. Recently, letermovir, a terminase 
complex inhibitor, was approved for prophylaxis after stem cell transplantation. These 
treatments have unwanted side effects and HCMV is becoming resistant to them.  
Therefore, we sought to develop an alternative treatment that targets a different stage in 
viral infection. Currently, small antiviral peptides are being investigated as anti-influenza 
and anti-HIV treatments. We have developed heparan sulfate-binding peptides as tools 
for preventing CMV infections. These peptides are highly effective at stopping infection 
of fibroblasts with in vitro derived HCMV and murine cytomegalovirus (MCMV). 
However, they do not prevent MCMV infection in vivo. Interestingly, these peptides 
inhibit infectivity of in vivo-derived CMVs, albeit not as well as tissue culture grown 
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CMVs. We further demonstrate that this class of heparan sulfate-binding peptides is 
incapable of inhibiting MCMV cell-to-cell spread, which is independent of heparan 
sulfate usage. These data indicate that inhibition of CMV infection can be achieved 
using synthetic polybasic peptides, but cell-to-cell spread and in vivo grown CMVs 
require further investigation to design appropriate anti-CMV peptides. 
1. Introduction 
 HCMV is a significant pathogen within immunocompromised groups. Disease in 
these populations can result from primary infection or spontaneous latent virus 
reactivation [1, 2]. As 60-90% of adults are latently infected with HCMV there is a 
substantial population at risk for complications if their immune system becomes 
compromised. [3, 4]. HCMV infection/reactivation in immunocompromised persons can 
result in mononucleosis-like symptoms, interstitial pneumonia, gastroenteritis, retinitis, 
or organ transplant rejection in transplant patients [1, 3]. HCMV is also the leading 
cause of congenital disease [5, 6]. In utero infection may result in fetal abnormalities 
such as microcephaly or severe sequelae that can evolve over time in the form of 
progressive deafness, mental retardation, or learning disabilities [7, 8]. HCMV infections 
impose a yearly 1-2-billion-dollar economic burden; therefore, developing effective 
treatment and preventive strategies is a high priority [5, 9].  Because there is no 
effective vaccine, treatment of infected immune compromised patients primarily consists 
of nucleoside analogs such as ganciclovir (GCV), foscarnet or cidofovir which inhibit 
DNA replication [10-12]. Unfortunately, GCV treatment can be myelosuppressive, while 
foscarnet and cidofovir are nephrotoxic [13]. All DNA polymerase inhibitors select for 
resistant HCMV mutants and cases of GCV-resistant HCMV infections are on the rise 
[1, 14, 15]. This has led to the development of novel treatments such as the recently 
FDA-approved terminase inhibitor, letermovir [16].  
 Antiviral peptides (APs) are an attractive alternative treatment for inhibiting viral 
infections. Indeed, peptide therapeutics are being investigated for respiratory viruses 
and HIV [17-19]. APs have different mechanisms for virus inhibition from inhibiting viral 
attachment, entry, replication, or egress [20]. HCMV attaches to a host cell via heparan 
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sulfate proteoglycans (HSPG) [21]. Viral glycoproteins, gB and gM/gN, initially interact 
with negatively-charged sulfate moieties, which serve to “dock” the HCMV virion to the 
host cell [21]. Docking triggers a signal cascade within the cell allowing for subsequent 
viral entry. HSPG are ubiquitously expressed on most host cells supporting the idea that 
HCMV can infect almost any human cell type [22]. 
 HSPGs have a myriad of functions including binding chemokines and cytokines and 
serving as scaffolds for ligand receptors, growth factors, and other cell adhesion 
molecules [23]. Cell surface HSPGs are also major components of host-mediated 
endocytosis and cell membrane fusion processes. HSPG functions have been exploited 
for malarial and viral infections including HCMV and herpes simplex virus-1 [24-26]. 
Because of their major role in the early stages of HCMV replication, HSs are an 
attractive target for intervention. HS binding peptides effectively inhibit HCMV infection 
[27]. However, these peptides were not tested against the more virulent in vivo- derived 
virus or in an in vivo setting [28].  
 We have previously reported that synthetic heparin-binding peptides bind 
pathologic amyloid deposits in vitro and in vivo [29, 30]. As HCMV attaches to cells via 
HS, we investigated whether these peptides could inhibit virus attachment. In this study, 
we demonstrate that these synthetic polybasic peptides are efficient at inhibiting viral 
entry of tissue culture-derived HCMV and MCMV. We also provide evidence of 
effectively inhibiting a clinical isolate HCMV obtained from infected bodily secretions. 
However, these peptides could not prevent cell-to-cell spread, of MCMV potentially 
explaining the need to further investigate additional antiviral peptides for efficiency in 
vivo.  
2. Results  
Peptide Characteristics 
 Three polybasic peptides, designated p5(coil), p5(coil)D and p5+14(coil), were 
synthesized using a glycine-rich backbone to enhance flexibility of the peptide chain 
(Table 2.1). The p5(coil) peptide is the parental peptide [31, 32] from which the derivative 
p5(coil)D and p5+14(coil) peptides were designed. p5(coil)D is the D-form of p5(coil). Because 
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D-form peptides are more proteolytically stable and are equally effective as L-form 
peptides at inhibiting HCMV entry, we focused on the p5(coil)D for the majority of this 
study [33]. We also utilized the peptide p5+14(coil), which is p5(coil) with an additional 
repeat of the last 14 amino acids. The addition of 14 amino acids has been shown to 
increase the efficacy of peptide-induced HCMV inhibition [27]. At a peptide 
concentration of 50 µM both p5(coil)D and p5+14(coil) inhibited HCMV and MCMV infection 
of fibroblasts (Table 2.1).  We chose 50 µM as the initial concentration for the screening 
the peptides because another polybasic D-form peptide could inhibit MCMV in vivo at 
this dose [33].  All three peptides were predicted to adopt a flexible coil secondary 
structure, which is different from previously published peptides and may increase their 
efficacy  [34, 35]. 
 
Table 2.1. Polybasic peptide descriptions and characteristics.  
Peptide secondary structures were predicted via ITASSER software. Peptide inhibition 
of infection was determined at 50 µM  
 
 As p5(coil) was the peptide from which the others were generated, we tested the 
binding of a biotinylated variant to a panel of HS moieties using a synthetic glycoarray 
(Figure 2.1A). p5(coil) bound significantly more effectively to sulfated glycans (black 
bars) than to unsulfated glycans (red bars) (Figure 2.1A) with the exception of the 5-
sugar HS008 glycan. Statistical analysis showed significantly enhanced binding of 
p5(coil) to almost all sulfated glycans relative to non-sulfated species (Table S2.1). In 
general, no significant difference was observed between peptide binding to the 
structurally different sulfated HS. Figure 2.1B lists the structure of the HS used in the 
glycan array.  These results highlight that p5(coil) preferentially binds sulfated glycans. 
Pep$de	 AA	 Primary	structure	 Property	 Net	Charge	(posi$ve)	
MCMV	Infec$on	
Inhibi$on	
HCMV	Infec$on	
Inhibi$on	
p5(coil)		 31	GGGYS	KGGKG	GGKGG	KGGGK	GGKGG	GKGGK	G	 Flexible	coil	 8			 		
p5(coil)D		 31	
[GGGYS	KGGKG	GGKGG	KGGGK	GGKGG	GKGGK	
G]D	
D	form	of	
p10	 8	 68% 89 %
p5+14(coil)		 45	
GGGYS	KGGKG	GGKGG	KGGGK	GGKGG	GKGGK	
GGGKG	GKGGG	KGGKG	 Flexible	coil	 12	 72% 96%
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Figure 2.1. Binding of peptide p5(coil) to an array of synthetic HS glycans.  
(A) A 0.5mg/ml aliquot of biotinylated p10 peptide was incubated with a heparan sulfate glycan array and the binding was 
visualized using streptavidin-conjugated fluorophore. Non-sulfated glycans are shown in red. Each bar represents the 
mean and SD of 5 replicates. Statistical analyses data are presented in Table S1. (B) Composition of HS glycan’s used in 
A.
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Efficacy of Inhibition of CMV Infection 
         The blockade of HCMV and MCMV attachment to cells was studied in the 
presence of increasing concentrations of peptide p5(coil)D or p5+14(coil) (Figure 2.2). The 
estimated IC50 of p5(coil)D and p5+14(coil) for blocking HCMV (TB40/E) were 9.98µM and 
0.6µM respectively (Figure 2.2A) and 22.6µM and 2.97µM for MCMV (Figure 2.2B). 
These data indicate that our peptides are capable of inhibiting both HCMV and MCMV, 
however MCMV is inhibited to a lesser extent. Peptide inhibition of infection of mice was 
evaluated using the MCMV mouse model (Figure 2.3). BALB/c mice were pretreated 
with 250ug per mouse of p5(coil)D or p5+14(coil) one hour prior to infection.  Evaluation of 
the viral titer in spleens harvested 4 days post infection indicated no significant 
difference in viral burden (Figure 2.3). In order to confirm peptide was present at the 
time of infection and following infection we evaluated peptide biodistribution post 
administration (Table S2.2). Our biodistribution assay confirms that p5(coil)D or p5+14(coil) 
are present within the host at the time of infection and following infection. While there 
are differences in biodistribution between the two peptides, there is no difference in viral 
dissemination to the spleen. We have previously reported the inability of p5RD, another 
anti-viral polybasic peptide, to substantially inhibit infection of any primary dissemination 
organ (e.g spleen, liver, and lung) [33]. The inability of these peptides to reduce viral 
load in vivo could be due in vivo dosage/timing effect, but  an alternative explanation is 
that the peptides differ in their ability to block in vivo-derived virus versus in vitro-derived 
viruses.  Previous studies have reported differences between MCMVs grown in culture 
compared with those harvested in vivo, which was related to their HSPG usage for entry 
[36-40].  
Peptide Inhibition of In Vivo- and In Vitro-Derived MCMV  
 To evaluate the possibility of differential inhibition between in vitro-derived virus 
and in vivo-derived virus, we performed plaque reduction assays using MCMV salivary 
gland isolated virus (SGV) and MCMV passaged on cultured cells (TCV) (Figure 2.4).  
Both p5(coil)D and p5+14(coil) significantly inhibited infection of both murine TCV (Figure 
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Figure 2.2. The p5(coil) family of peptides prevent HCMV and MCMV infection. 
Peptides were serially diluted and assayed in a HCMV (TB40/E UL18Luc) luciferase assay (A) or an MCMV plaque 
reduction assay (B).  IC50 of p5(coil) D= 9.98 µM and p5+14(coil) = 0.6 µM for HCMV and IC50 of p5(coil)D = 22.6 µM and 
p5+14(coil)= 2.97 µM for MCMV were calculated is GraphPad Prizm. Each point represents an average of 3-4 replicates +/- 
SD of 3 experiments.  
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Figure 2.3. Peptide efficacy in vivo.  
BALB/c mice were treated with peptide (250ug/mouse) i.v. and infected with 1x106 PFU 
of MCMV i.p one hour later.  Bars represent the average of 4-5 mice per group from 2 
experiments. One-way ANOVA with a Tukey’s multiple comparison of means was used 
to determine statistical significance. ns= not significant.  
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Figure 2.4. Differential effects of peptide treatment on in vivo- and in vitro-derived 
MCMV 
Peptide at 50 µM concentration was used to inhibit  (A) tissue culture (TCV) or (B) 
salivary gland-derived MCMV (SGV). (C) Data from A and B to compare the efficacy of 
p5+14(coil) inhibition of TCV and SGV. (D) MEF 10.1s were treated with 50mM sodium 
chlorate to remove 2-O and 6-O linked sulfations. Treated cells were infected with ~100 
PFUs of TCV or SGV. Either TCV (E) or SGV (F) was incubated with varying 
concentrations of heparin and used to infect MEF 10.1s (~100 PFU/well). Data was 
normalized to untreated (PBS) controls. Bars represent the average +/- SD from 2 
experiments with 3 replicates per experiment.  Statistical significance was determined 
by one-way ANOVA with a Tukey’s multiple comparison of means. ns= not significant; * 
= p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; **** = p £ 0.0001. 
 
 
 
41 
 
 
Figure 2.4.
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2.4A) and SGV (Figure 2.4B) relative to untreated cells (PBS). Additionally, in both 
cases the p5+14(coil) was significantly more efficacious than p5(coil)D.  When used at 50 
µM, peptide p5+14(coil) inhibited murine TCV (75%) more effectively than SGV (40%) 
(Figure 2.4C). Our data support observations made by Ravindranath and Graves [36] 
and indicate SGV and TCV use different entry strategies.  One entry mechanism is 
inhibited by peptides, (i.e., TCV) and the other is only partially blocked (i.e., SGV). 
 To further investigate the differences in SGV and TCV entry identified by the 
peptide inhibition studies, mouse embryonic fibroblasts (MEF 10.1s) were treated with 
50mM sodium chlorate prior to infection to remove 2-O and 6-O linked HS sulfations 
[41]. We focused on these sulfation patterns based on observations from HCMV, which 
indicated that these O-linked sulfations were important for viral attachment [28]. This 
treatment resulted in inhibition of infection of both SGV and TCV with the latter being 
significantly more impacted (Figure 2.4D).   It is known that incubation of MCMV with 
heparin blocks cellular entry, therefore we studied the effect of increasing heparin 
concentration on infection efficiency  of TCV (Figure 2.4E) and SGV (Figure 2.4F).  
Pretreatment of TCV with heparin resulted in a dose dependent decrease in infection, 
with 50% loss of efficiency in the presence of 40 µg/mL heparin (Figure 2.4E).  In 
contrast, there was no significant decrease in the infectivity of murine SGV following 
pretreatment with up to 40 µg/mL heparin (Figure 2.4F). 
 Because virus derived from different tissues vary in their susceptibility to antibody 
neutralization [37], we speculated that perhaps not all in vivo derived MCMV would be 
resistant to peptide inhibition. Therefore, we infected mice time points were necessary 
to maximize viral load in the given organ.  Once MCMV organ titers were determined, 
whole organ homogenates were plated at ~100 PFU on peptide treated MEF 10.1s 
(Figure 2.5A). As expected there was some inhibition of in vivo grown virus but not to 
the same levels as TCV. Interestingly, there was no difference between the different 
organs in regards to peptide inhibition susceptibility. Since there is no difference 
between viruses isolated from different organs the SGV phenotype is not the result of 
SGV sample preparation. 
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Figure 2.5. Generation of peptide resistant MCMV in vitro. 
(A) Virus was harvested from salivary gland (SGV), spleen (SPV), and footpads (FPV) of 
mice infected with MCMV. MEF10.1s were treated with 50 µM of p5+14(coil) then infected 
with ~100 PFU of each virus. Percent infection inhibition was determined by comparison to 
untreated controls. (B) TCV was grown on RAW 264.7 macrophages and BMDMs. Progeny 
virus was then subjected to a plaque reduction assay. Percent virus inhibition was 
determined by comparison to untreated controls. (C) Comparison of peptide inhibition of 
MEF10.1s infected with TCV, SGV, BMDMV originally from TCV or SGV. Bars represent 
the average +/- SD from 2 experiments with 2-3 replicates per experiment. Statistical 
significance was determined by one-way ANOVA with a Tukey’s multiple comparison of 
means with a two-tailed t test. ns= not significant; * = p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; 
**** = p £ 0.0001. (D) Schematic of method used to generate in vivo-like virus in vitro.   
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 We speculated that the differences in susceptibility to the peptides correlated 
with differences in entry complexes that determine cellular tropism [42]. MCMV grown 
on macrophages contain different entry complexes compared to MCMV grown on 
fibroblasts [42].  Therefore, we tested whether MCMV derived from macrophages in 
vitro would mimic peptide inhibition of SGV or TCV. In vitro-derived MCMV was grown 
on the macrophage cell line, RAW 264.7 or bone marrow derived macrophages 
(BMDMs). The progeny viruses were subjected to a plaque reduction assay (Figure 
2.5B). Peptide treatment of cells blocked RAW 264.7-grown virus (~75% inhibition) but 
only partially BMDM virus (~50% inhibition). Not only are BMDMs capable of generating 
“in vivo like” virus, but when SGV virus was grown on BMDMs the peptide was even 
less efficient in blocking MCMV infection (Figure 2.5C). Regardless of the initial MCMV 
input into BMDMs, they produced “in vivo-like” virus (Figures 2.5B, 2.5C, 2.5D). 
Additionally, these results indicate that the phenotype observed with SGV is not an 
artifact of sample preparation and the salivary gland homogenate itself does not impact 
peptide efficacy.  
Peptide Inhibition of In Vivo-Derived HCMV  
 We sought to determine whether p5+14(coil) could inhibit infection of a clinical 
isolate of HCMV. This virus was used directly from a patient’s urine from  
Johns Hopkins [11].  This is important because the tropism/entry complex can mutate 
after a single passage in vitro [43, 44]. Peptide p5+14(coil) significantly inhibited the entry 
of a clinical isolates of HCMV into human fibroblasts (~70% inhibition, Figure 2.6A), but 
was significantly more effective when tissue culture-grown TB40/E virus was used 
(~90% inhibition). Because these results mimicked MCMV’s peptide inhibition, we 
tested which HS moieties were important for viral entry. MRC-5 fibroblasts were treated 
with 50mM sodium chlorate to remove 2-O and 6-O sulfations (Figure 2.6B). Despite 
the small but significant difference between HCMVs from in vitro or in vivo grown 
viruses, removing the 2-O and 6-O sulfations prevented infection of both HCMVs, albeit 
more inhibition of tissue culture grown HCMVs than the clinical isolate was observed. 
These results corroborate the MCMV data. Both viruses highly rely on sulfated surface  
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Figure 2.6. Peptide and sodium chlorate treatment prevents uCMV infection. 
(A) MCR-5 human fibroblasts were treated with p5+14 (coil) at 50 µM and infected with 
the TB40/E strain or an unpassaged clinical isolate. (B) MRC-5s were treated with 
50mM sodium chlorate to remove 2-O and 6-O linked sulfations. All cells were infected 
with ~100 PFUs of TB40/E or clinically derived HCMV. Percent infection was normalized 
to PBS treated controls. Boxes are the averages of replicate from two experiments +/- 
SD. Statistical significance was determined by unpaired t-test. ns= not significant; * = p 
£ 0.05; ** = p £ 0.01; *** = p £ 0.001; **** = p £ 0.0001. 
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glycans for entry. 
Do Polybasic Peptides Prevent MCMV Cell-to-Cell Spread? 
 Cell-to-cell spread in vivo is important for viral dissemination in the host [11, 45, 
46].  We evaluated the effectiveness of p5(coil)D and p5+14(coil) on cell-to-cell spread. 
Infected peritoneal exudate cells (PECs) were harvested from MCMV-infected mice and 
co-incubated with MEF 10.1s, treated with 100µM p5(coil)D, p5+14(coil), or PBS as control. 
Inhibition of MCMV infection was measured via plaque reduction assay. Peptide 
treatment had no effect on cell-to-cell spread (Figure 2.7A). Because most of the PEC 
population consists of immune cells (data not shown), we tested our peptide’s ability to 
inhibit cell-to-cell spread from infected to uninfected MEF 10.1 fibroblasts in a plaque 
reduction assay. As seen with the PECs, peptide treatment did not inhibit cell-to-cell 
spread regardless of cell type (Figure 2.7B). To evaluate whether or not HS mediates 
cell-to-cell spread, we treated murine fibroblasts with heparinase, sodium chlorate, and 
heparin. Cell associated virus spread was marginally affected in the absence of HS, 
pointing to a different entry mechanism from cell-free MCMV, as heparin treatment was 
ineffective at inhibiting infection (Figure 2.7C). These data highlight the complexity of 
CMV entry whether the virus enters from cell-to-cell spread or cell free virus. 
3.Discussion 
 Decades of investment and innovation have failed to generate a protective 
HCMV vaccine [10, 11]. Without a vaccine, treatment of HCMV relies on drugs that 
target two different stages during HCMV replication. First, nucleoside analogues (e.g., 
GCV, foscarnet and cidofovir) have been the standard treatment  for HCMV disease, 
but these compounds are myelosuppressive and nephrotoxic. The recently approved 
letermovir (trade name Prevymis), which inhibits the terminase complex is not 
myelosuppressive or nephrotoxic  [16].  All of these agents potentially select for 
resistant viruses [47] [15]. Therefore, a multi-faceted approach may be required to 
inhibit additional stages during HCMV replication and this could include APs that block 
viral entry. Other anti-CMV APs inhibit viral entry of in vitro derived CMV, but none have 
been shown to inhibit a clinical isolate of HCMV [27, 28, 33, 48].  We demonstrated that 
 
 
48 
Figure 2.7. Peptide inhibition of MCMV cell-to-cell spread. 
(A) MEF 10.1s were treated with PBS, p5 (coil), p5+14 (coil) at 100 uM one hour prior to 
incubation with 1 x 105 MCMV peritoneal exudate cells.  (B) MEF10.1s were treated with 
p5+14 (coil) at 50 uM  one hour prior to incubation with either cell free MCMV or 300 MEF 
10.1s infected with MCMV. (C) MEF10.1s were treated with 12U/uL of heparinase for 
one hour, 50mM of sodium chlorate overnight, or 40 µg/mL of heparin then infected with 
cell associated MCMV.  Bars represent the average from 2 experiments with 3-4 
replicates per experiment. Statistical significance was determined by an Ordinary one-
way ANOVA with a Tukey’s multiple comparison of means or an unpaired t-test. ns= not 
significant; * = p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; **** = p £ 0.0001. 
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our p5(coil) peptides are capable of inhibiting infection of both HCMV and MCMV and 
that these peptides can partially inhibit infection of in vivo-derived CMVs and more 
completely cell free virus. This is the first report of an effective inhibition HCMV isolated 
directly from urine. Clinical isolates have previously been shown to be resistant to anti-
HCMV antibody neutralization [49]. Although inhibition of in vivo-derived virus was not 
as efficient as the blockade of tissue culture-derived virus, greater than 50% reduction 
in infectivity was achieved, which is comparable to that observed following sodium 
chlorate treatment of cells. These results support previous observations and point to the 
important role of 2-O or 6-O sulfated cell surface glycans in viral entry via HS moieties 
[28].  
  Our data indicate that the p5(coil) peptides, which presumably inhibit the 
interactions of viral attachment proteins with HS, were unable to inhibit cell-to-cell 
spread.  Also, heparin treatment of infected cells did not inhibit cell-to-cell spread. 
These data provide insights into why polyclonal antibodies generated in response to the 
gB vaccine are of limited efficacy [50] (i.e., the mechanism of HCMV cell-to-cell spread 
may be independent of HS interactions involving the surface viral gB protein). The 
studies of peptide-mediated inhibition of viral attachment and infection have elucidated 
several important aspects of CMV infection pathways.  First, these peptides, which bind 
preferentially to sulfated HS, effectively inhibited TCV entry into cultured cells. There 
was one HS exception, HS008, to which the peptide did not bind. This glycan consisted 
of GlcA-GlcNS-ClcA-GlcNS-GlcA while the HS007 is one sugar moiety shorter but binds 
to the peptide very well.   The full set of features that are important for viral entry, (i.e., 
length, number of repeating sugar units, etc.) and whether it depends on in vivo or cell 
culture grown virus remains to be determined.  Interestingly, another AP, p5+14, also 
did not bind to HS008 (data not shown)[27]. Could the lack of binding to HS008 be the 
reason that the peptides cannot block 100% of the infection? Without knowing the 
composition of the HS on the cell surface, we can only speculate that this is an 
explanation (i.e., 5% remaining for HCMV and 30% for MCMV). Entry differences could 
be due to differences in entry complexes, glycosylations of the virion proteins, or other 
factors during replication in vivo. Because we have demonstrated that virus grown on 
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BMDMs recapitulates the “in vivo” virus phenotype it will allow an in-depth investigation 
of these  hypotheses. Our data demonstrate the significant biochemical differences 
between in vivo-grown virus and virus cultured in vitro.  Previously, differences between 
in vivo-derived and tissue culture grown MCMVs were defined as “virulent” for in vivo 
grown virus or “attenuated” when grown in vitro. These differences were not due to 
selection of mutated viruses, but rather differential usage of different sugar moieties for 
entry [36, 39, 40], which could explain why one may be more virulent than the other.  
Interestingly, it appears that all in vivo derived viruses, regardless of the tissue from 
which they were isolated from, utilizes discrete surface HS as compared to cell-culture-
derived virus. These differences in HS usage may explain the lack of peptide-mediated 
inhibition of in vivo grown MCMV. Furthermore, it is noteworthy that cell attachment by 
in vivo grown virus did not depend on 2-O or 6-O glycans as indicated by the differential 
inhibition following sodium chlorate treatment of the cells (Figure 6).   
 Perhaps most notably, we have shown that the HS-binding peptides do not inhibit 
cell-to-cell spread of CMV, which represents the main mechanism of cellular 
transmission in vivo [45, 51-53]. Our data indicate that cell-to-cell spread does not 
require HS.(i.e., heparinase and sodium chlorate treatment of uninfected cells prior to 
being co-cultured with infected fibroblasts only achieved approximately 15% infection 
inhibition). These data indicate that our current understanding of CMV entry remains 
incomplete.  Further understanding of the mechanism of cell-to-cell spread may improve 
treatment strategies for HCMV.  
4. Materials and Methods 
Cells and Viruses:  
All experiments were performed with low (< 20) passage cells. MRC-5 human  lung 
fibroblasts were cultured in MEM (Lonza, Rockland, ME) supplemented with 10% Fetal 
Bovine Serum (FBS) (Atlanta Biologicals, Flowery Branch, GA), 1% 
penicillin/streptomycin, and 1% L-Glutamine. Mouse embryonic fibroblast 10.1 (MEF 
10.1 [54]) were cultured in DMEM (Lonza, Rockland, ME) supplemented with 10% 
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Fetalclone III serum (Hyclone, Logan, UT), 1% penicillin/streptomycin, and 1% L-
Glutamine. RAW 264.7 cells were cultured in DMEM (Lonza, Rockland, ME) with 10% 
Fetalclone III (Hyclone, Logan, UT), 1% penicillin/streptomycin, and 1% L-Glutamine. 
Primary bone marrow derived macrophages (BMDM) were cultured in RPMI 1640 
(Lonza, Rockland, ME) supplemented with 10% Fetalclone III (Hyclone, Logan, UT), 1% 
penicillin/streptomycin, and 1% L-Glutamine. 
 
The HCMV TB40/E and MCMV K181 [55] viruses were used. HCMV TB40/E expressing 
luciferase under the control of the UL18 promoter was a gift from Drs. Christine 
O’Connor and Eain Murphy (University of Buffalo and FORGE Life Science, LLC). 
TB40/E viruses were propagated on HUVECs. MCMV was produced in vitro using 
MEF10.1s. All viruses were stored at  -80 oC until use. Viral titer was assessed by 
plaque assay (described below) on MEF10.1 cells (MCMV) or MRC-5 cells (HCMV). 
The HCMV clinical isolates were collected at Johns Hopkins University without any 
identifiers that can link them to a specific patient. To generate BMDM virus, 
differentiated BMDMs were infected with K181 and virus was harvested after a 100% 
cytopathic effect (CPE) was observed. Salivary-gland derived virus was harvested from 
mouse SGs at 14 dpi with K181 via the i.p. route. Spleen-derived virus was obtained by 
harvesting the organ 5 dpi after i.p. infection while footpad derived virus was obtained 
by harvesting footpads 3 dpi following K181 with footpad inoculation. All organs were 
homogenized and titered via plaque assay.  
BMDM Differentiation:  
Bone marrow from naïve mice was harvested and incubated in RPMI 1640 for 4 hours. 
Media was then changed, and macrophage-colony stimulating factor (M-CSF) 
(PeproTech, Rocky Hill, NJ) was supplemented at 1ng/uL for 7 days. Media was 
changed ever 3 days. Differentiated cells were infected with K181 at an MOI ~0.1. Virus 
was harvested 1 day after cells showed 100% CPE. 
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Treatment of Cells and Viruses: 
Cells were washed with PBS prior to addition of treatment. Heparinase I (NEB, Ipswich, 
MA) was used at 12U/uL in media. Cells were pretreated for 1 hour at 37oC before 
addition of virus or cells. MEF 10.1s or MRC-5s were treated for 1 hour with 50 mM 
sodium chlorate to remove 2-O and 6-O linked HS as previously described [41]. Heparin 
at varying concentrations was pre-incubated with virus or infected fibroblasts for 30 
minutes at 4oC. Following pretreatment, viral infectivity was assayed by plaque assay or 
cell-to-cell transfer assay as described below. 
Peptides:  
Peptides were purchased and purified as previously described [27]. Briefly, peptides 
were purified with high performance liquid chromatography (HPLC) and purity confirmed 
by mass spectrometry (MS). Purified peptides were lyophilized and resuspended in PBS 
prior to use.   
Plaque Reduction Assay:  
Lyophilized peptides were resuspended in PBS and stored at 4 oC until use. Fibroblasts 
were seeded into 24 well dishes. After cells reached ~80% confluency, media was 
removed and cells were washed with PBS. Peptide in PBS + 10% FBS or PBS + 10% 
FBS as the control was added and incubated for 30 minutes at 37 OC. Virus was added 
to treated and untreated control wells (~100 PFU/well) and incubated for an additional 
hour. Following virus incubation, media was removed and overlay was added. Overlays 
consisted of 0.75% carboxymethyl cellulose (CMC) (Sigma Aldrich, St. Louis, MO) for 
MCMV infected wells and 0.5% SeaKem agarose (Lonza, Rockland, ME) in complete 
media for HCMV infected wells. For MCMV assays plates were incubated for 5 days at 
which point they were stained with Coomassie stain and plaques counted using a 
dissecting microscope. Reduction in viral infectivity was expressed as a percent of 
infectivity of PBS treated wells. Data was analyzed using Prism 7 (GraphPad Software, 
La Jolla, CA).  
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Cell-Cell Transfer of Virus: 
To examine fibroblast mediated cell-to-cell spread, MEF 10.1 cells were infected with 
K181 at  MOI of 3. Following 16 hour incubation, cells were trypsinized, washed and 
counted. Approximately 300 potentially infected cells were added to an uninfected 100% 
confluent monolayer of MEF 10.1 cells. The uninfected monolayer was pretreated with 
peptide or PBS. Infected cells were given an hour to transfer infection, media was 
removed and a CMC overlay was added. In order to evaluate immune cell mediated cell 
to cell spread mice were injected i.p. with 3% thioglycollate [56]. After 4 days, animals 
were infected i.p. with MCMV K181 at 1x106 PFU and peritoneal exudate cells (PECs) 
were collected 12 hours post infection. PECs were added to an uninfected monolayer 
either treated with p5+14(coil) or untreated. PECs were incubated for an hour, media was 
removed and a CMC overlay added. Analysis was performed as described for plaque 
reduction assay. 
HCMV Infectivity Assay: 
HCMV TB40/E infectivity was assessed using a luciferase reporter assay as previously 
described [33]. Briefly, MRC-5 fibroblasts were seeded in a 24 well dish. After reaching 
~80% confluency, cells were washed once with PBS and peptide with PBS + 10% FBS 
or PBS + 10% FBS control was incubated at 37 oC for 30 minutes. Virus was added at 
~1000 relative light units (RLU) and incubated at 37oC for one hour. Cells were washed 
and media replaced then incubated at 37 oC for 3 days. On day 3, cells were washed 
with PBS, lysed using passive lysis buffer (Promega, Madison, WI) and the cell lysates 
were pelleted. Luciferase reagent (Gaussian luciferase) was combined 1:1 with cell 
lysate in a clear bottom 96-well plate. Luminescence was measured using a Synergy 2 
plate reader (BioTek, Winooski, VT) and recorded as RLU. The RLU from untreated 
uninfected samples was subtracted as background and results were normalized to 
untreated infected to 100% infection. Data was analyzed using Prism 7 (GraphPad 
Software, La Jolla, CA). Data was expressed as percent of luminescence of untreated 
infected well. 
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Statistical Analysis and IC50 Determination: 
Each experiment represents two or more independent experiments with at least three 
replicates per experimental group unless otherwise indicated. Individual data points are 
shown for all graphs. Error bars represent the standard deviation (SD) of each dataset. 
Statistical significance was determined by one-tailed Student’s t-test or one-way 
ANOVA with Tukey’s multivariance analysis when appropriate. IC50 values were 
calculated using a linear regression sigmoidal dose dependent test. All statistical 
analysis was performed using Prism 7 (GraphPad Software, La Jolla, CA). Statistical 
significance was assigned to p-values < 0.05. Significant values are labeled as ns= not 
significant; * = p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; **** = p £ 0.0001.   
Glycan Array:  
Glycan array was performed by Z-biotech LLC. Briefly, biotinylated peptide was 
incubated with various heparan sulfate derivatives. Following incubation an anti-biotin, 
fluorescently labeled antibody was added and a plate reader determined fluorescence. 
Data represents 6 technical replicates per HS residue.  
Mice: 
Animal use was approved under UTK IACUC protocol. Animals used were housed and 
bred in Walters Life Science Laboratory Animal Facility at The University of Tennessee. 
BALB/c mice (6-12 wks) were purchased from Jackson Laboratory (Bar Harbor, ME) 
and housed under specific pathogen-free conditions. 
In Vivo Analysis of Peptide Efficacy:  
Mice were treated with intravenously via retro-orbital route with 250ug/mouse of 
indicated peptide, 1 hour prior to infection. One hour post treatment animals were 
infected i.p. with 1x106 PFUs of K181. Four days post infection animals were scarified 
and spleens were harvested. Viral burden was determined by plaque assay as descried 
above.  
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Peptide Biodistribution  
To determine the distribution of our APs in vivo, mice were injected i.v. in the lateral tail 
vein, with I125 labeled peptides(<120 μCi, 20 μg of peptide). At 1 and 4 hours post 
injection mice were euthanized with isoflurane inhalation overdose and spleen, liver, 
lung, and nine other tissues were harvested and the tissue radioactivity measured as 
previously described (30)(33). The biodistribution of radiolabeled peptide was 
expressed as percent inject dose per gram of tissue (%ID/g).  
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Table S2.1. Statistical analysis of glycan array.  
Statistical significance was determined by an Ordinary one-way ANOVA with a Tukey’s multiple comparison of means. 
ns= not significant; * = p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; **** = p £ 0.0001  Analysis was carried out using GraphPad 
Prizm.
		 HS001	 HS002	 HS003	 HS004	 HS005	 HS006	 HS007	 HS008	 HS009	 HS010	 HS011	 HS012	 HS013	 HS014	 HS015	 HS016	 HS017	 HS018	 HS019	 HS020	 HS021	 HS022	 HS023	 HS024	
HS001	 		 ns	 ns	 ns	 **** **** **** ns	 **** **** * ns	 **** ns	 **** **** **** *** **** ns	 **** **** **** ****
HS002	 ns	 		 ns	 ns	 **** *** **** ns	 **** **** *** *** **** ** **** **** **** **** **** ** **** **** **** ****
HS003	 ns	 ns	 		 ns	 **** **** **** ns	 **** *** * ns	 **** ns	 **** **** **** ** **** ns	 **** **** **** ****
HS004	 ns	 ns	 ns	 		 **** ** **** ns	 **** **** **** *** **** ** **** **** **** **** **** ** **** **** **** ****
HS005	 **** **** **** **** 		 ns	 **** ns	 **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** ****
HS006	 **** *** **** ** ns	 		 **** ns	 **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** ****
HS007	 **** **** **** **** **** **** 		 **** ns	 ns	 * **** ns	 **** ns	 ns	 ns	 ** ns	 **** ns	 **** ns	 ns	
HS008	 ns	 ns	 ns	 ns	 ns	 ns	 **** 		 **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** ****
HS009	 **** **** **** **** **** **** ns	 **** 		 ns	 ns	 * ns	 *** ns	 ns	 ns	 ns	 ns	 ** ns	 **** ns	 ns	
HS010	 **** **** *** **** **** **** ns	 **** ns	 		 ns	 ns	 ns	 ns	 ns	 * ns	 ns	 **** ns	 ns	 **** ns	 ***
HS011	 * *** * **** **** **** * **** ns	 ns	 		 ns	 ns	 ns	 ns	 ** ns	 ns	 **** ns	 ns	 **** * ****
HS012	 ns	 *** ns	 *** **** **** **** **** * ns	 ns	 		 * ns	 * **** ns	 ns	 **** ns	 ns	 **** *** ****
HS013	 **** **** **** **** **** **** ns	 **** ns	 ns	 ns	 * 		 *** ns	 ns	 ns	 ns	 ns	 ** ns	 **** ns	 ns	
HS014	 ns	 ** ns	 ** **** **** **** **** *** ns	 ns	 ns	 *** 		 ** **** ns	 ns	 **** ns	 * **** **** ****
HS015	 **** **** **** **** **** **** ns	 **** ns	 ns	 ns	 * ns	 ** 		 ns	 ns	 ns	 ns	 ** ns	 **** ns	 ns	
HS016	 **** **** **** **** **** **** ns	 **** ns	 * ** **** ns	 **** ns	 		 ns	 ** ns	 **** ns	 **** ns	 ns	
HS017	 **** **** **** **** **** **** ns	 **** ns	 ns	 ns	 ns	 ns	 ns	 ns	 ns	 		 ns	 ** ns	 ns	 **** ns	 *
HS018	 *** **** ** **** **** **** ** **** ns	 ns	 ns	 ns	 ns	 ns	 ns	 ** ns	 		 **** ns	 ns	 **** * ****
HS019	 **** **** **** **** **** **** ns	 **** ns	 **** **** **** ns	 **** ns	 ns	 ** **** 		 **** * ** ns	 ns	
HS020	 ns	 ** ns	 ** **** **** **** **** ** ns	 ns	 ns	 ** ns	 ** **** ns	 ns	 **** 		 * **** **** ****
HS021	 **** **** **** **** **** **** ns	 **** ns	 ns	 ns	 ns	 ns	 * ns	 ns	 ns	 ns	 * * 		 **** ns	 ns	
HS022	 **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** **** ** **** **** 		 *** ***
HS023	 **** **** **** **** **** **** ns	 **** ns	 ns	 * *** ns	 **** ns	 ns	 ns	 * ns	 **** ns	 **** 		 ns	
HS024	 **** **** **** **** **** **** ns	 **** ns	 *** **** **** ns	 **** ns	 ns	 * **** ns	 **** ns	 *** ns	 		
Key:	 ns	 * ** *** **** 	Unsulfated		HS	
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Table S2.2. p5(coil)D or p5+14(coil) Biodistribution in BALB/c mice.  
Mice were injected with 250ug/mouse of I125 labeled peptide. Mice were euthanized at 1 
and 4 hour post injection (hpi) and the indicated organs were harvested. The amount of 
I125 present in each organ was measured.  Data represents percent-injected dose/gram 
of tissue %(ID/gram tissue) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue	Distribu+on	p5(coil)D	 p5+14(coil)
%ID/gram	+ssue	 1hpi	Average	 SD	 4hpi	Average	 SD	 1hpi	Average	 SD	 4hpi	Average		SD	
Muscle	 0.42	 0.02	 0.13	 0.04	 1.3	 0.21	 0.17	 0.01	
Liver	 3.27	 0.41	 3.17	 0.47	 7.23	 1.06	 0.82	 0.07	
Pancreas	 0.67	 0.11	 0.2	 0.05	 2.79	 0.17	 0.44	 0.04	
Spleen	 1.21	 0.24	 0.64	 0.08	 3.72	 0.31	 0.65	 0.1	
Le<	kidney	 189.23	 42.96	 189.75	 48.81	 16.25	 0.72	 1.93	 0.62	
Right	kidney	 161.54	 33.66	 234.86	 53.72	 16.58	 1.05	 1.93	 0.09	
Stomach	 3.36	 1.25	 1.01	 0.28	 14.4	 1.26	 3.08	 0.7	
Upper	intes+ne	 1.15	 0.18	 0.44	 0.16	 3.91	 0.43	 0.88	 0.06	
Lower	intes+ne	 1.18	 0.08	 0.37	 0.04	 3.53	 0.33	 0.58	 0.03	
Heart	 0.69	 0.08	 0.24	 0.11	 2.03	 0.38	 0.29	 0.01	
Lung	 2.08	 0.17	 0.94	 0.29	 5.15	 0.27	 0.9	 0.13	
Blood	 1.3	 0.07	 0.22	 0.09	 3.53	 0.18	 0.53	 0.05	
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CHAPTER III: A LITTLE COOPERATION HELPS MURINE 
CYTOMEGALOVIRUS GO A LONG WAY – MCMV CO-INFECTION 
RESCUES A CHEMOKINE SALIVARY GLAND DEFECT 
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Abstract  
Cytomegaloviruses (CMVs) produce chemokines (vCXCLs) that have both sequence 
and functional homology to host chemokines. Assessment of vCXCL-1’s role in CMV 
infection is limited to in vitro and in silico analysis due to CMV’s species specificity.  In 
this study, we used the murine CMV (MCMV) mouse model to evaluate the function of 
vCXCL-1 in vivo. Recombinant MCMVs expressing chimpanzee CMV vCXCL-1 
(vCXCL-1CCMV) or host chemokine, mCXCL1, underwent primary dissemination to the 
popliteal lymph node, spleen, and lung similar to the parental MCMV.  However, neither 
of the recombinants expressing chemokines was recovered from the salivary gland 
(SG) at any time post infection although viral DNA was detected.  This implies that the 
virus does not grow in the SG or the overexpressd chemokine induces an immune 
response that leads to suppressed growth.  Pointing to immune suppression of virus 
replication, recombinant viruses were isolated from the SG following infection of 
immune ablated mice (i.e., SCID, NSG, or cyclophosphamide treated).  Depletion of 
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neutrophils or NK cells does not rescue the recovery of chemokine expressing 
recombinants in the SG.  Surprisingly we found that co-infection of parental virus and 
chemokine expressing virus leads to the recovery of the recombinants in the SG.  We 
suggest that parental virus reduces the levels of chemokine expression leading to a 
decrease in inflammatory monocytes and subsequent SG growth. Therefore, aberrant 
expression of the chemokines induces cells of the innate and adaptive immune system 
that curtail the growth and dissemination of the recombinants in the SG.  
1. Introduction 
 Human Cytomegalovirus (HCMV) is a ubiquitous b-herpesvirus that is an 
important pathogen in immune compromised individuals and newborns [1-3]. It infects 
between 50% and 90% of the population resulting in largely asymptomatic infections [1]. 
However, primary or reactivated HCMV is a frequent cause of retinitis in AIDS patients 
[4] and increases the incidence of organ rejection and graft versus host disease in 
transplant recipients [5, 6]. Central nervous system damage due to congenital HCMV 
infection affects 5,000-8,000 newborns in the U.S. each year [7]. As a result, HCMV is 
the leading cause of infectious hearing loss and non-hereditary mental retardation [1]. 
Understanding HCMV pathogenesis is important for the development of an effective 
vaccine or potential therapeutics.  
  CMVs encode numerous proteins that modulate the host immune system. HMCV 
infection alters the expression of host chemokines [8], but also encodes viral homologs 
of host chemokines and their receptors [9-12]. The virulent strain of HCMV, Toledo [13], 
produces a functional CXC chemokine, vCXCL-1Tol, which binds the chemokine 
receptors CXCR1 and CXCR2 inducing chemotaxis and calcium flux in freshly isolated 
human peripheral blood neutrophils (PBNs) [14, 15]. In our previous studies, we have 
shown that the viral chemokine from chimpanzee cytomegalovirus (vCXCL-1CCMV), 
which is 22% identical and 52% similar to the vCXCL-1Tol protein, triggers calcium 
release and chemotaxis of PBNs [16]. Both viral chemokines were shown to upregulate 
the expression of adhesion molecules on PBNs and downregulate neutrophil apoptosis, 
albeit with different potencies [16]. These findings provide circumstantial evidence for a 
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role of vCXCL-1 in activating and recruiting neutrophils to facilitate CMV dissemination. 
Clinical evidence, including the recovery of HCMV from neutrophils of 
immunocompromised patients [17-19] and the presence of neutrophilic infiltrates in 
CMV associated retinitis [20], supports the role of neutrophils, as well as monocytes 
[21-23], in HCMV dissemination. While the species specificity of CMVs limits the direct 
evaluation of vCXCL-1 in HCMV dissemination, the function of vCXCL-1CCMV was used 
as surrogate for the HCMV vCXCL-1 homolog.  We chose vCXCL-1CCMV for our 
experiments because it is more conserved in CCMV isolates unlike vCXCL-1 from 
HCMV, which is one of the most variable genes in the HCMV genome [24-26].  In 
addition, we wanted to extend our previous in vitro vCXCL-1CCMV findings into an in vivo 
system.  
MCMV is a well-established animal model of CMV infection and has similar 
cellular tropism and disease manifestations to HCMV [27]. MCMV expresses a 
chemokine homolog, MCK2, which increases the inflammatory response in mice and 
enhances dissemination of MCMV to the SG [28, 29]. Therefore, MCMV was chosen to 
characterize the role of vCXCL-1CCMV in vivo. To test this in the mouse system, we 
generated recombinant MCMVs expressing vCXCL-1CCMV and host chemokine, 
mCXCL1 (i.e., KC) under the control of the HCMV immediate early promoter, which will 
express the protein at relatively high levels. Our results show that expression of both the 
host and viral chemokines is detrimental to the recombinants in the SG. We show that 
there is an increase in inflammatory monocytes that contributes to a blockade of viremia 
and growth in the SG. Surprisingly, co-infection with a non-chemokine-expressing strain 
of MCMV restored growth of the chemokine expressing recombinants in the SG by 
tipping the immune response to a more favorable environment for normal growth of the 
recombinants.  
2. Results 
Construction of the Chemokine Expressing MCMVs 
 Strict species specificity of CMVs requires the generation of a recombinant 
MCMV to assess the function of viral chemokines in the mouse model. Therefore, we 
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generated a recombinant MCMV expressing vCXCL-1CCMV (RMvCXCL-1CCMV) to study 
the role of this chimpanzee CMV viral chemokine in viral dissemination in vivo. MCMV 
expressing mCXCL1 was also generated as a control to evaluate the specific effects of 
the viral chemokine on dissemination.  mCXCL1 is the murine equivalent of human 
CXCL-1 (Gro-α) with a high affinity for CXCR2. MCMV RM4511 was chosen as the 
parental strain of these recombinants because RM4511 lacks a functional MCMV viral 
CC chemokine, MCK2. This allows us to analyze the contribution of vCXCL-1CCMV and 
mCXCL1 in the dissemination of MCMV in the absence of the endogenously encoded 
chemokine, MCK2 (Supplemental Figure S3.1A). 
Recombinant plasmid, L120.1, was modified to contain either the vCXCL-1CCMV 
or mCXCL1 coding sequence under the control of HCMV IE promoter (Figure S3.1B). 
This promoter has been used to drive expression of other genes inserted into the 
MCMV genome and was chosen to ensure high levels of chemokine expression. We 
chose to insert the chemokine cassette into the ie2 region as it is dispensable for growth 
of MCMV in vivo [30].  The chemokine cassette displaces the puromycin-GFP segment 
present in RM4511, such that loss of GFP expression allowed visual selection of 
recombinant viruses. 
Following transfection of NIH3T3 cells with Drd-linearized L120.1+vCXCL-1CCMV 
or L120.1+mCXCL1 and subsequent infection with RM4511, recombinant viruses were 
passaged twice in medium containing mycophenolic acid and xanthine to select for 
recombinant viruses expressing gpt. The loss of GFP expression identified recombinant 
viruses and each virus was plaque purified three times. Recombination and correct 
insertion of the chemokine cassette was confirmed using PCR (Figure S3.1C). 
Recombinant MCMVs have Similar In Vitro Growth Kinetics and Chemokine Expression  
 To determine whether insertion of the vCXCL-1CCMV or mCXCL1 cassette 
affected replication or spread of the recombinant viruses in cell culture, we setup both 
single (MOI=5) and multi (MOI=0.05) step growth curves. RMvCXCL-1CCMV and 
RMmCXCL1 replicated as well as RM4511 in both assays (Figure S3.1D), indicating no 
deleterious effects of the insertion on growth of the viruses in cell culture. 
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Immunoblotting Ni-NTA-concentrated supernatants from each time point of the single 
step growth curve was used to detect the temporal expression of the chemokines in the 
supernatants of virally infected cells. Both RMvCXCL-1CCMV and RMmCXCL1 proteins 
were detected in the supernatants beginning at the second day post infection (p.i.) and 
continuing for the duration of the experiment (Figure S3.1E). 
Dissemination of Chemokine Expressing Viruses In Vivo 
 The contribution of vCXCL1 to the replication and dissemination of recombinant 
viruses in vivo was evaluated after infecting mice with RM4511, RMmCXCL1, and 
RMvCXCL1CCMV in the foot pad (FP) and measuring virus in the organs with a plaque 
assay. Recombinants reached similar titers as parental virus in FP and in organs of 
primary dissemination (i.e., lymph node, lung, and spleen) (Figure 3.1A). However, no 
recombinant virus was detected in SG at day 7 and 14 p.i. when the parental virus 
usually reaches peak titers (Figure 3.1A). To exclude the possibility that the 
dissemination of the recombinant virus to the SG was only delayed, viral load in the SG 
was also measured at day 21 p.i. No recombinant virus was detected even at this later 
time point (data not shown). Similar experiments were performed using i.p. infection to 
determine if the route of infection had any effect on viral dissemination. Mice infected 
i.p. also had no chemokine expressing recombinants in the SG (data not shown). The 
lack of dissemination of these recombinants to the SG was accompanied by an absence  
of detectable viremia during secondary dissemination at day 4 p.i. (Figure 3.1B).  
Surprisingly, we found equivalent amounts of viral DNA in the SG at day 7 in spite of the 
differences in viremia, but less viral DNA for the recombinants only at day 14 p.i. 
(Figure 3.1C).  These data point to a viremia defect that still allows for enough 
recombinant virus to disseminate to the SG early after infection but the recombinant 
viruses can not continue to grow in the SG. 
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Figure 3.1 Overexpression of host or viral chemokine prevents MCMV 
dissemination/growth in the SG.  
(A) hCXCR2 transgenic mice were inoculated in the FP with 106 PFU of either 
RMmCXCL1 (▼), RMvCXCL-1CCMV (▲), RM4511 (□). Organs were harvested at the 
indicated days p.i. and virus titers were determined via plaque assay.  Each symbol 
represents the mean virus titer of 5-10 mice (+/- SD). Data is representative of 2 
experiments. (B) Viremia as measured via leukocyte infectious centers assay was 
carried out on PBLs isolated from infected hCXCR2 transgenic mice at day 4 p.i. Data 
points represent % infected PBLs from individual mice and the horizontal line represents 
the mean from at least 3 mice for each experiment. The dashed line indicates the 
detection limit (DL) of the assay. (C) DNA was isolated from SG of infected mice at 7 
and 14 days p.i.  The amount of relative viral DNA to host DNA was quantified via SYBR 
green qPCR. Each bar is the average of 4 mice +/- SD. 
 
 
 
 
 
 
 
 
 
 
71 
 
 
 
Figure 3.1. 
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NK, T, and B Cell Mediated Blockade of SG Growth of the Chemokine Expressing 
Recombinants 
 Both vCXCL-1CCMV and mCXCL1 bind and activate neutrophils via CXCR2 [16, 
31]. The recruitment and activation of CXCR2+ cells could lead to an inflammatory 
environment that prevents normal SG growth.  Although there was a slight increase in 
the number of neutrophils recruited to the site of inoculation at day 3 p.i., in mice 
infected with the chemokine expressing recombinants compared to RM4511, it was not 
statistically significant (Figure 3.2A). In addition, we observed more NK cells early (day 
5) in both the spleen and the lung for the mCXCL1 expressing virus, but only the lung at 
day 7 continued with significant increases in both recombinants (Figure 3.2B). Early in 
infection (day 5 p.i.), there was a 2-3 fold increase in inflammatory and patrolling 
monocytes in the lungs of chemokine expressing recombinant viruses compared with 
RM4511 infected mice (Figure 3.2B). There was no difference in the CD4/CD8 ratios in 
the sites of primary dissemination or in the SG (Figure 3.2B, 3.2C).   
 These data show that the chemokine expressing recombinants induce differential 
recruitment of inflammatory monocytes and NK cells suggesting an immune mediated 
blockade of the dissemination/growth of the recombinants in the SG. To investigate the 
extent of this blockade, mice were administered cyclophosphamide (cyclo) to deplete 
immune cells prior to infection [32-34] and. dissemination of the recombinants was 
measured in the different organs. We observed no difference in the primary 
dissemination between the chemokine expressing recombinants and the parental virus 
in untreated and cyclo treated mice in spite of a significant decrease in cells in the 
spleen and lung (Figure SF2). However, the chemokine expressing recombinants were 
recovered from the SG of cyclo treated mice albeit at a much lower titer compared with 
the parental (Figure 2D), with detectable viremia measured at day 4 p.i (Figure 2I left 
panel) compared with the parental (Figure 3.2D), with detectable viremia measured at 
day 4 p.i (Figure 2I left panel). 
 Data from the above experiment provide further evidence for an immune 
mediated blockade of recombinant virus dissemination/growth in the SG. Activated 
neutrophils or NK cells could trigger an inflammatory response capable of clearing 
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Figure 3.2 Absence of cellular subsets permits dissemination/growth of 
chemokine expressing recombinants to the SG. 
hCXCR2KI mice were infected in the FP with 1 x 106 PFU RM4511, RMmCXCL1, or 
RMvCXCL1. Flowcytometry was used to measure the number neutrophils (CD11b+, 
Ly6G+) infiltrating the FP at day 3 p.i. (A) and NK cells (CD3- CD49b+), patrolling 
(CD11b+, Gr1lo, CD11c+) and inflammatory monocytes  (CD11b+, Gr1hi, CD11c-) 
recruited (B) into the spleen and the lung at day 5 and 7 p.i. (C) CD4+ (CD3+ CD4+) and 
CD8+ (CD3+ CD8+) cells from 14 day p.i. mice (D) Mice were treated with 
cyclophosphamide for systemic immune ablation prior to infection with the parental and 
recombinant viruses alone. Viral titers in the SG were measured at days 3, 7, 14 and 18 
p.i. Mice were depleted of neutrophils using anti-Ly6G antibody (E) or NK cells with anti-
asialo GM1 (F) or control treated on days -1, 0 prior to i.p. infection with parental and 
recombinant viruses alone. (G) NSG mice, which lack T, B, and NK cells or (H) SCID 
mice were inoculated with parental or recombinant viruses i.p. For experiments in panel 
C-G the SG from the mice were harvested at day 14 p.i. and the virus titered. (I) Viremia 
as measured via leukocyte infectious centers assay was carried out on PBLs isolated 
from cyclophosphamide (Cyclo) treated BALB/c mice (left) or NSG mice (right). Data 
points represent the % infected PBLs and the horizontal line represents the mean of at 
least 3 mice for each experiment. The dashed line indicates the DL of the assay.  
Panels A-H: Results are from 5-10 mice per infection and are representative of 2 or 
more experiments. Bars represent the mean virus titer (+/- SD). One Way ANOVA 
followed by Tukey's multiple comparison test was used to compare the data. *** = P < 
0.001, ** = P < 0.01, * = P < 0.05.   
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Figure 3.2. 
 
 
75 
recombinant viruses from the SG or suppressing their ability to grow.  Both can express 
CXCR2 and can respond to both of the CXC chemokines overexpressed in these 
viruses [35] and NK cells form an important arm of the innate immune response to 
MCMV infection [36-38].  To parse out the contribution of these immune cell subsets in 
this blockade, we depleted neutrophils or NK cells. Virus was measured in the SG at 
day 14 p.i. Despite a slight enhancement of neutrophils to the site of infection and 
increases in NK cells (Figure 3.2A, 3.2B), depletion of either cell type did not restore 
MCMV recombinants in the SG (Figure 3.2E, 3.2F). These results show that neither 
neutrophils nor NK cells are responsible for decreased viremia of the recombinants or 
growth defect in the SG observed in vivo. 
Another approach to map the immune response responsible for the phenotype of 
the chemokine expressing recombinants in vivo, is to use mice that have genetic 
defects that alter their immune capabilities. First, we utilized the NSG mouse model, 
which lacks NK cells, T and B lymphocytes [39, 40]. NSG mice were infected with the 
recombinant or parental viruses and the viral load in the SG at day 14 p.i. was 
measured.  We recovered recombinant virus from the SG of NSG mice at day 14 p.i., 
albeit much less than the parental virus (~3 logs) (Figure 3.2G). Note that these viral 
titers are similar to those in the cyclo treated mice (Figure 3.2D) and that BALB/c mice 
show the same SG defect as our transgenic or knock in mice (Figure S3.3A). In 
addition we observed viremia for the chemokine expressing recombinants as well as 
parental virus in NSG mice (Figure 3.2I right panel). Data from this experiment 
suggests that NK and/or T and B cells play a partial role in preventing the dissemination 
of the recombinant S3.2). However, the chemokine expressing recombinants were 
recovered from the SG of cyclo treated mice albeit at a much lower titer virus to the SG, 
but in light of results of the NK depletion experiment (Figure 3.2F), T or B cells are 
more likely. 
To address the role of the T and B cells in the lack of dissemination of chemokine 
expressing recombinants, we used SCID mice, which lack both T and B cells. In 
particular, T cells play an important role in controlling MCMV infection. While CD8+ T 
cells effectively clear MCMV from organs in the periphery [41], viral clearance from the 
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SG is dependent on CD4+ T cells [42, 43]. To determine if the adaptive immune 
response could be clearing RMvCXCL-1CCMV and RMmCXCL1 from the SG, SCID mice 
were infected with recombinant or parental virus and viral load was measured in the SG 
at day 14 p.i. Here again, the chemokine expressing recombinants were recovered from 
the SG of SCID mice as seen in the NSG mice, although not to the same levels as 
parental virus (Figure 3.2H). This data suggests that the absence of RMvCXCL-1CCMV 
and RMmCXCL1 from the SG may be a result of an amplified adaptive immune 
response to the recombinants as a well as a dissemination defect. Together, data from 
these experiments suggests that the chemokine expressing recombinants aberrant 
production of the chemokines induces an innate (i.e., IM mediated) and adaptive (i.e., 
T/B cell mediated) immune response that is responsible for the lack of viremia and/or 
clearance from the SG. 
Co-Infection Rescues Dissemination of Chemokine Expressing Recombinants  
 If this chemokine mediated response leads to an increased immune response 
that masks normal growth, a simple co-infection experiment could revel its function is 
trans. We hypothesized that during co-infection (i.e., parental + recombinant), the 
dissemination/growth defect would dominate, leading to an inhibition or reduction in the 
dissemination/growth of parental virus in the SG.  To test this hypothesis, mice were 
infected in the same FP with a mixed inoculum at a 1:1 ratio of the parental and 
chemokine expressing recombinant virus. SGs from these mice were harvested 14 days 
p.i. and the viral load determined. Surprisingly, chemokine expressing recombinant 
viruses were recovered from the SG of mice infected with the mixed inoculum albeit at 
reduced titers (Figure 3.3A).  Because there was no difference between vCXCL-1CCMV 
and mCXCL1 in these co infection experiments and the chemokine receptors for 
mCXCL1 are well characterized, we carried out the remaining coinfection experiments 
only with mCXCL1 expressing virus.  Dissemination of the chemokine-expressing 
recombinants to the SG was also rescued in mice that were co-infected i.p. 
demonstrating that the route of infection was not critical (Supplemental Figure S3B).  
This rescue is also independent of MCMV’s expression of its endogenous CC  
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Figure 3.3 Rescue of the chemokine expressing recombinant virus dissemination 
to the SG upon co-infection with parental viruses requires interaction at the site 
of infection.  
hCXCR2KI mice were infected with 5 x 105 PFU of either parental (RM4511) or 
chemokine-expressing recombinant viruses (RMmCXCL1 or RMvCxCL1CCMV) alone or 
in the same FP with a 1:1 mixed inoculum (5 x 105 PFU of each). Viral titer was 
measured in the SG at day 14 p.i. (B-C) Mice were infected with 5 x 105 PFU of either 
RM4511 or RMmCXCL1 virus alone, in different FPs (B) with 5 x 105 PFU of RM4511 
and RMmCXCL1 or in the same FP.  (C) FP were infected with 1:1 ratio with a low 
inoculum (100 PFU) each of RM4511 and RMmCXCL1. Viral titer in the SG was 
measured at day 14 p.i. The * indicates viral titers in the SG from mice infected with a 
co-infection with GFP+ 4511 or GFP- RMmCXCL1. The horizontal line is the median titer 
from the experiment. Each symbol represents the titer from an individual mouse. 
Dashed line indicates the DL of the plaque assay. (D) Schematic representation of the 
infectious centers assay performed on plastic adherent leukocytes isolated from the FP 
of mice infected with a 1:1 mixed inoculum (5 x 105 PFU of each) at day 3 p.i. (E) GFP 
positive viruses were plaque purified from D and subjected to a round of amplification to 
ascertain the presence of GFP negative viruses within these plaques. Data is expressed 
as % co-infected plaques from total GFP positive plaques purified.  Bar represents 
mean from 9 mice + SD.  
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Figure 3.3. 
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chemokine (MCK2), as both the CC expressing RM4503 and mutated RM4511 (MCK2-) 
rescue the dissemination of the recombinants to the SG (Figure S3.3C). Higher 
replication of the virus in the FP, spleen, or lung post co-infection (Figure S3.3D) does 
not explain the increase in virus in the SG during co-infections.   In addition, the timing 
of the infections was critical.  For example, no recombinants were recovered in the SG 
when the infection of the two viruses was separated by 2 or 7 days (Figure S3.2E). 
Taken together, these data indicate that the adverse effects of aberrant chemokine 
expression are nullified during co-infection and the SG phenotype rescue is temporally 
restricted requiring the viruses to interact early during infection. 
The Requirement for Interaction at the Site of Infection During Co-Infection Rescue 
 To explore how co-infection rescues the dissemination of recombinant viruses to 
the SG, mice were infected with the two viruses in separate footpads the site of 
infection, but still allow them interact at the sites of primary dissemination (i.e., spleen 
and lung). Both the viruses grew to similar levels in the footpad and primary 
dissemination sites (Figure S3.3D). However, no chemokine expressing recombinant 
viruses were recovered from the SG of these mice at 14 days p.i. (Figure 3.3B).   
The requirement of the close proximity of the two viruses to mediate the rescue 
phenotype suggests that the viruses may co-infect the same cell at the site of infection.  
To test this possibility we infected mice with a low PFU mixed inoculum (1:1 ratio of 100 
PFU each of RM4511 and RMmCXCL1).  Infection with a low PFU inoculum reduces 
the probability of co-infection by greater than 1000 fold and subsequently reduces the 
dissemination rescue (Figure 3.3C). In order to directly address whether the viruses co-
infect cells at the site of infection, we performed infectious centers assay with plastic 
adherent leukocytes isolated from the FP at day 3 p.i. Mice were infected with high 
titered mixed inoculum at a 1:1 mix of parental and recombinant, which is schematically 
described in Figure 3D. During the amplification step, we were able to detect GFP 
positive and negative plaques from ~ 49% of purified GFP positive plaques (Figure 
3.3E). All purified GFP negative plaques yield all GFP negative plaques during the 
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amplification step. These results indicate that the two viruses need to co-infect the same 
cell at the site of infection. 
Live Parental Virus is Required to Rescue the Isolation of Chemokine Expressing 
Recombinant Virus from the SG 
 A possible contribution to the rescue of dissemination of the recombinants to the 
SG during co-infection is that the presence of the parental virus particles stimulates an 
immune response that overcomes the blockade of dissemination. To explore this 
possibility, we infected mice in the same FP with a mixed inoculum containing a 1:1 
mixture of viable RMmCXCL1 or RM4511 and either UV inactivated RM4511 or 
RMmCXCL1, respectively. Infection of mice with an inoculum containing UV inactivated 
RMmCXCL1 + Rm4511 did not alter the dissemination of RM4511 to the SG (Figure 
3.4). However, UV inactivation of RM4511 completely abolished the rescue of the 
dissemination of RMmCXCL1 to the SG. These data demonstrate that live-replicating 
parental virus is necessary to mediate the rescue of the chemokine expressing 
recombinants to the SG. 
The need for recombinant and live parental virus to co-infect the same cells 
suggests that the chemokine expressing viruses might have undergone DNA 
recombination with the parental virus. This could lead to the loss of expression of the 
chemokine gene and allow for subsequent dissemination/growth. PCR amplification and 
subsequent DNA sequencing of the chemokine gene from recombinants isolated from 
the SG following co-infection shows that they all carry an unmutated chemokine gene 
(Figure S3.4A). Additionally, RFLP analysis of these isolates showed no overt 
recombination (Figure S3.4B).   According to this data, there is no alteration of the 
chemokine expressing recombinants, but a genuine rescue of the SG phenotype. 
Co-Infection Alters the Immune Response to Chemokine Expressing Recombinant 
Viruses  
 To see how the immune response profile changes following co-infection, immune 
cells were characterized from co-infected mice from the different organs.  The major 
reduction between RMmCXCL1 and the co-infected mice is the inflammatory  
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Figure 3.4 The rescue of the dissemination phenotype requires live virus.  
hCXCR2KI mice were infected with 5 x 105 PFU of either RM4511 or RMmCXCL1 virus 
alone, or a mixed inoculum (1:1 mix) of UV inactivated (UV ia) RMmCXCL1: live 
RM4511 or UV ia RM4511: live RMmCXCL1. Viral titer was measured in the SG at day 
14 p.i.  Each symbol indicates the titer from individual mice. The * indicates viral titers in 
the SG from mice infected with a mixed inoculum. The horizontal line represents the 
mean titer from the experiment. The dashed line indicates the DL of the assay.  
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monocytes found in the lung (Figure 3.5).  These cell types may interfere with the 
normal secondary dissemination/growth of the chemokine expressing recombinants to 
the SG. During co-infection, the reduction in their recruitment to sites of infection would 
allow for increased dissemination to the SG of the chemokine expressing recombinants. 
Co-Infection Reduces mCXCL1 Production In Vitro 
 In the absence of any recombination or mutation of the chemokine gene, a 
reduction in chemokine production during co-infection could lead to the SG recovery of 
the recombinants. To test this possibility, we carried out an in vitro co-infection assay. 
Cells in culture were infected with recombinant or parental virus alone or with a mixed 
inoculum. Supernatants were harvested every 24 hrs. and silver stained to measure 
chemokine protein levels.  We observed a reduction in the relative expression of the 
chemokine during co-infection in vitro compared with recombinants alone (Figure 3.6A). 
In spite of these differences in chemokine expression, there was no difference in the 
viral titers (Figure 3.6B). These data suggest that during co-infection, less chemokine is 
produced, without an effect on viral load. This reduction could be sufficient for 
dissemination of the recombinants to the SG. 
3. Discussion 
 In our previous study we characterized the CCMV chemokine homolog, vCXCL-
1CCMV, and demonstrated that it is a functional chemokine, activating and recruiting 
human neutrophils similar to the HCMV chemokine vCXCL-1Tol [16].  Due to the species 
specificity of CMV, the in vivo function of vCXCL-1CCMV is unknown. We have gained 
significant knowledge about HCMV dissemination using the MCMV mouse model [1, 
12]. MCMV has similar tropism to HCMV and both viruses demonstrate a cell-
associated viremia in myelomonocytic lineage cells such as neutrophils, monocytes, 
and their precursors [1, 12, 17, 27, 44-46]. Although the mechanism and relative 
contribution of each of these cell types to MCMV dissemination in vivo has been studied 
in some detail, the role of host and viral chemokines on this dissemination remains 
unclear [1, 12, 46, 47]. In this study, we used MCMV RM4511, which does not express 
functional MCK2, to generate recombinant MCMVs expressing viral and host CXC 
 
 
83 
 
 
 
 
 
 
Figure 3.5. Co-infection alters the cellular infiltrate at the site of infection to favor 
dissemination. 
 hCXCR2KI mice were infected either singly or at 1:1 of each and analyzed with 
flowcytometry. Bars represent the average of the data from 6-9 mice per experiment +/- 
SEM. One Way ANOVA followed by Tukey's multiple comparison test was used to 
compare the data. *** = P < 0.001, ** = P < 0.01, * = P < 0.05, NS= non significant. 
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Figure 3.6. Co-infection in vitro reduces the recombinant MCMV chemokine levels 
without affecting viral growth.   
MEF cells were co-infected at an MOI of 5 of RMmCXCL1 and RM4511 or each one 
individually.  The supernatant was collected at different time points p.i. After 6xHis-
tagged chemokine enrichment, proteins were visualized on a silver stained SDS PAGE 
gel.  Graph represents the relative concentration of chemokine to the loading control + 
SD from two experiments. One Way ANOVA followed by Bonferroni's multiple 
comparison test was used to compare the data. *** = P < 0.001, ** = P < 0.01, * = P < 
0.05 (B) Viral titers were measured in the supernatant collected from the in vitro co-
infection assays.  Mixed infection (Mxd) was carried out at a MOI of 10 (i.e., MOI 5 of 
RM4511 + MOI 5 of RMmCXCL1). The data is representative from 3 experiments. 
Symbols represent the average titer +/- SD. 
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chemokines in order to evaluate the impact of vCXCL-1CCMV on viral dissemination 
The primary dissemination pattern of RMvCXCL-1CCMV and RMmCXCL1 was similar to 
RM4511 (Figure 3.1A).  However, the chemokine expressing recombinant viruses were 
not recovered from the SG (i.e., secondary dissemination) (Figure 3.1A). There was no 
difference in viral growth of the recombinants compared to the parental virus at the site 
of inoculation in the FP or the primary dissemination organs (i.e., popliteal lymph node, 
spleen, and lung (Figure 3.1A)).  However, viral DNA was detected in the SG from our 
recombinants (Figure 3.1C). It is possible that our recombinants are unable to 
replicate in the SG and carry a mutation in the sgg1 gene, which has been shown for 
other MCMV recombinants with a SG growth defect [48, 49].  However, this is unlikely 
for several reasons.  First, the independently generated recombinants show a similar 
SG phenotype (data not shown). Moreover, when the recombinants reach the SG, as is 
the case of SCID mice, NSG mice, cyclo treatment or co-infected mice, they are able to 
replicate in the SG (Figure 3.2D, 3.2G, 3.2H).  Therefore, the recombinants are capable 
of SG replication when immune cells are depleted. However, we did observe defective 
viremia for the recombinants pointing to at least a partial dissemination defect (Figure 
3.1B).   
It is possible that overexpression of the chemokine leads to an over active 
immune response against the recombinants, which results in their increased clearance 
from the SG. Viral clearance from the SG is CD4+ T cell mediated [42, 43].  Chemokine 
expressing recombinants were found in the SG of SCID mice, lacking B and T 
lymphocytes, supporting this possibility (Figure 3.2H). Chemokine expressing 
recombinant viruses were also found in the SG in NSG mice and after systemic immune 
ablation with cyclophosphamide treatment, implicating both the innate/adaptive immune 
system for the SG dissemination defect/clearance (Figure 3.2D and 3.2G).  
Interestingly, the restored viremia for the recombinants in both cases paralleled an 
increase in viremia still implicating a dissemination defect (Figure 3.2E).  Thus, 
although the recombinants may be susceptible to adaptive immune mediated clearance 
or growth suppression in the SG, they also show an innate immune-mediated defect in 
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SG dissemination. This points to a multifunctional defect: cells in the blood carrying 
MCMV and immune clearance in the SG. 
While exploring the effects of chemokine expression in trans in the co-infection 
model (i.e., parental + chemokine expressing recombinants), we made the 
serendipitous discovery that the recombinants were able to disseminate to the SG even 
in immune-competent mice (Figure 3.3A).  The rescue of dissemination required the 
two viruses to infect simultaneously and at the same site, as separating the infection 
spatially or temporally does not rescue the dissemination to the SG (Figure 3.3B and 
Figure S3.3).  This localization is required for the two viruses to infect the same cell, 
most likely a monocyte/macrophage population at the site of infection (Figure 3.3C, D 
and E). We show that these viruses do not undergo recombination, mutation, or 
deletion of the chemokine gene while replicating within parental virally infected cells 
(Figure S3.4).  Our data points to the parental virus reducing the production of the 
chemokine from the recombinant during co-infection without affecting viral growth 
(Figure 3.6, Figure S3.6).  Therefore, the reduced chemokine level seen during mixed 
infection is not due to less virus production, but to potentially intracellular resource 
competition among other possibilities [50-56].  Unfortunately we were unable to show 
this reduction in the chemokine levels in vivo due to the limits of chemokine protein 
detection. How could parental virus interfere with the HCMV IE promoter?  Intracellular 
resource competition or gene expression suppression like that seen with HCMV IE 
proteins on the MIEP [57] within the infected cells could be responsible for the  reduced 
chemokine levels in vivo and subsequent rescue of SG virus.   Currently these are just 
several possible explanations that are being explored. 
In order to have a decrease in chemokine production, there needs to be co-
infection at the site of infection (Figure 3.3A, B).  Surprisingly, MCMV coinfection in vivo 
is more common than one would expect [58].  Using both an attenuated virus and a 
clever Cre/Lox system, Cicin-Sain et al. were able to show functional 
transcomplemetation but also co-dissemination to distant organs.   They estimate that 
1:22 of the virally infected cells are co-infected in vivo.   Many of our findings 
recapitulate their findings: in order to get complementation, viruses must be infected at 
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the same footpad and at the same time.   Although their attenuated viruses did have 
reduced primary growth/dissemination while our did not.  Our findings point to a co-
infection requirement implying that this is an internal effect.  Otherwise the secreted 
chemokine effect would dominate over the parental virus (i.e., no SG 
growth/dissemination of following co-infection).  This internal “competition” suggests a 
possible resource competition scenario instead of “chemokine masking” that acts in 
trans.   Although we were unable to show a true titration of virus and chemokine 
production to support resource competition (Figure S3.6),  this assay is limited  by its 
sensitivity and the fact that we are using viruses instead of plasmids, which would allow 
for tighter controls on entry and copy number of our chemokine genes.  Additional tightly 
controlled experiments will be needed to ascertain how or whether this competition 
occurs. 
Our data shows that over-produced chemokines may recruit or activate cells of 
innate or adaptive immune system that are detrimental for the dissemination/growth of 
the recombinants in the SG.  A more physiological level of expression of the viral 
chemokine could allow for evaluation of the viral chemokine in vivo such as expression 
under the control of the MCK2 promoter, which expresses with late kinetics.  These data 
also bring up the interesting observation that the immune system mediated blockade of 
dissemination of the chemokine expressing recombinants to the SG is not very stringent 
and a little reduction in chemokine levels seems to be sufficient to tip the scales in favor 
of normal dissemination/growth to the SG. 
Surprisingly, neutrophil or NK cell depletion did not restore dissemination to the 
SG (Figure 3.2E, F). Therefore another innate cell type that expresses CXCR2 could be 
responsible for this phenotype.  For example, dendritic cells or a subset of monocytes 
can be induced to express CXCR2 and CXCR1 [59-62] and may be involved in this 
process. Although an exhaustive analysis of vCXCL1CCMV receptor usage is lacking, 
mCXCL1 receptor usage is well-characterized [63].  As both have the same phenotype 
in our experiments, this SG dissemination defect does not seem to be exclusively a 
vCXCL1CCMV phenomenon. NK cells play a major role in the antiviral response against 
MCMV and mCXCL1 increases their presence during primary dissemination (Figure 
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3.2B) [36-38]. BALB/c mice, which do not induce NK cell activation via the m157-Ly49H 
axis, are susceptible to MCMV infection and show much higher viral titers in peripheral 
organs [64, 65]. In spite of this, depletion of NK cells did not alter isolation of 
recombinant viruses in the SG.    
Recently, Farrell et al. showed that FP infected MCMVs spread via the 
lymphatics and that this infection/spread is multi-layered[66]. They show that the 
subcapsular sinus macrophages act to dampen MCMV growth and without them more 
fibroblasts are infected resulting in higher titers and increased spread.  In our 
experiments, we hypothesize that an increase in inflammatory cells blocks the normal 
dissemination of MCMV to the SG.  In mice infected with the chemokine expressing 
recombinants, we observed more inflammatory monocytes in the lungs compared to 
mice infected with the parental virus (Figure 3.2B). Co-infection reduced the number of 
inflammatory monocytes in the lung, while not affecting the number of patrolling 
monocytes (Figure 3.5).  This data supports our hypothesis that the monocytes at the 
site of infection or around the foci of infection are the wrong type when the chemokine is 
expressed during MCMV infection (i.e., more inflammatory rather than patrolling). 
Although this might not affect viral growth at the site of infection, it would adversely 
affect the dissemination of the virus during viremia.  Preliminary experiments adoptively 
transferring leukocytes isolated at day 3 p.i. from the FP of mice infected with parental, 
recombinant, or a mixed inoculum show that we can recover virus from the SG of mice 
receiving cells from mice infected with parental or a mixed inoculum.  However, no virus 
was recovered from the SG of mice that received cells from chemokine expressing 
recombinants (Figure S3.5). 
Therefore we propose a model where the virus is carried out of the FP to the 
organs of primary dissemination initially by patrolling monocytes. During infection with 
the chemokine expressing recombinants alone, the over expression of the chemokine in 
the organs of primary dissemination (i.e., spleen, liver, lung) causes an enhanced 
inflammatory state. This inflammatory state supports the differentiation of inflammatory 
monocytes to M1 macrophages at the site, which do not disseminate the virus to the 
SG.  The increased number of inflammatory monocytes may also interfere with the 
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ability of patrolling monocytes to gain access to virally infected cells.  During co-
infection, there is a reduction in chemokine levels. The reduced chemokine levels leads 
to less IM cells at the site of infection and a reduction in the inflammatory environment 
granting patrolling monocyte access to the foci of infection, allowing for increased 
dissemination. This model is summarized in (Figure S3.7). 
Although our results may seem to contradict our original hypothesis (i.e., the 
expression of HCMV CXC chemokines aids dissemination), we have to consider the 
caveat that our chemokine expressing recombinants over express the chemokines.  In 
reality, the expression of the vCXCL-1 gene in HCMV is tightly regulated and expressed 
with late expression kinetics [14, 67], and not constitutively, as in the case of our 
recombinants. Because monocytes play an important role in HCMV dissemination in 
vivo [68-70], it is conceivable that HCMV has evolved to express vCXCL-1 at the stage 
when the virus is budding from the infected cell.  The chemokine-induced monocyte is 
at the right place at the right time to pick up the budding virus and once the infected the 
monocyte/neutrophil re-circulates, it carries the virus to distal sites spreading infection 
within the host. 
4. Materials and Methods 
Cells and Viruses   
Murine NIH3T3 and M210B4 cells (ATCC) were propagated in DMEM supplemented 
with 10% Fetal clone III (FCIII) (Hyclone), 1% penicillin/streptomycin (Hyclone), 1X 
NEAA, 1% sodium pyruvate (100mM), and 0.5 % HEPES (1M). MEF 10.1 cells (ATCC) 
were propagated in DMEM supplemented with 10% FCIII and 1% P/S and L-Gln.  The 
parental MCMV strain used in this study was MCMV RM4511, [29] which has a 1.7 kb 
puromycin-green fluorescent protein (GFP) cassette inserted into the ie2 region and a 
double point mutation in the m131 gene resulting in a nonfunctional MCK2 protein 
(Supplemental Figure S1A).  RM4503 is similar to 4511 except with wild-type mck2.  
These virusese were obtained from Dr. Edward Mocarski, Emory University. For UV 
inactivation of the virus, 50µl of the stock virus were exposed to UV light in a UV 
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crosslinker (Stratagene Stratalinker) at a setting of 1200 for 8 minutes. Complete 
inactivation was confirmed via a plaque assay. 
Mice  
Initially, mice that over express human CXCR2 (hCXCR2) or replace the murine CXCR2 
(mCXCR2) gene with the human CXCR2 (hCXCR2) gene were used. There was 
concern that vCXCL-1CCMV might not stimulate mCXCR2 as seen with vCXCL-1Tol [71].  
The hCXCR2 transgenic BALB/c mice express the hCXCR2 gene under the control of 
the neutrophil-specific, human myeloid related protein-8 promoter [71].  These are 
named hCXCR2 transgenics.  In the co-infection experiments, mice that knockin the 
hCXCR2 gene with the mCXCR2 gene were used (i.e., hCXCR2KI)[72]. These mice 
have normal expression levels of hCXCR2 in all the appropriate murine cell types. We 
have subsequently shown that vCXCL-1CCMV can function in normal mice (data not 
shown), which allowed us to use SCID and NSG mice with the appropriate parental 
controls (i.e., BALB/c). 3-4 week old BALB/c, NOD-NSG (NSG) mice were originally 
purchased from Jackson Laboratory (Bar Harbor, ME) and SCID/NCr were purchased 
from Taconic Labs.  All mice were housed under specific pathogen free conditions at 
the University of Tennessee or the University of Cincinnati Medical School.  The IACUC 
committees at the University of Tennessee or the University of Cincinnati approved all 
procedures on animals.   
Plasmid Constructs  
An EcoRI/PstI digested fragment containing the coding region for vCXCL-1CCMV or host 
mCXCL1 (KC) was cloned into the EcoRI/PstI digested plasmid pcDNA3.1/Zeo 
immediately downstream of the HCMV immediate early promoter (HCMV IE). The 1.2kb 
HCMV IE-chemokine fragment was PCR amplified adding the flanking restriction sites 
and a C-terminal 6-His tag using the primers: MluI HCMV IE                         (5’-
CGACGCGTCGATGTACGGGCCAGATATACGCCTTGACATTGATTAT-3’) and SalI 6 
His (5’ACGCGTCGACTGGTGGTGGTGGTGGTGACCTCCTCC-3’).  After sequence 
verification, the HCMV IE-chemokine cassette was digested with MluI and SalI and 
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cloned into the plasmid L120.1. L120.1 has 5’ and 3’ sequences from MCMV IE2 for 
homologous recombination and a gpt expression cassette used for selection of 
recombinant viruses (C. Meiering, unpublished data). 
Generation of Recombinant Viruses 
Recombinant viruses were generated using a transfection/infection strategy with 
subsequent selection for the loss of GFP along with gpt expression.  NIH3T3 cells were 
transfected with Drd-linearized L120.1+vCXCL-1CCMV or L120.1+mCXCL1 using 
Lipofectamine 2000 (Invitrogen). Three hours post-transfection, the cells were infected 
with MCMV RM4511 at an MOI=3. Transfectants were harvested and passaged twice 
under selection (mycophenolic acid (12.5 µg/ml) and xanthine (100 µg/ml)). 
Recombinant viruses were identified by the loss of GFP fluorescence and subjected to 
three rounds of plaque purification. For PCR verification, viral DNA was isolated by 
phenol-chloroform extraction and used for diagnostic PCR. The primers used were: 
RM4511 For (5’-CATTGACGTCAATGGTGGGAAAGTACATGGCG-3’), RM4511 GFP 
Rev (5’-CCCGACGCGCGTGAGGAAGAGTTCTTGCAG-3’), and HCMV IE Rev (5’-
GAACTCCATATATGGGCTATGAACTAATGACC). 
In Vitro Growth Assay 
NIH3T3 or MEF 10.1 cells were plated in triplicate in a 6-well dish and infected with 
RM4511, RMvCXCL-1CCMV, or RMmCXCL1 for either a multi-step (MOI=0.5) or single-
step (MOI=5) growth analysis.  Supernatants were collected at the indicated times post 
infection sonicated prior to tittering. Viruses were titered via plaque assay. 
MCMV Quantitation by qPCR 
SYBR green real-time qPCR was performed to measure viral load in SG using primers 
designed to detect MCMV IE1 [73]: IE1 Fwd 5′-AGCCACCAACATTGACCACGCAC-3′ 
and IE1 Rev 5′-GCCCCAACCAGGACACACAACTC-3′.  Primers against murine β-actin 
were used for loading normalization: β-actin Fwd 5′-GCT GTA TTC CCC TCC ATC 
GTG -3′ and β-actin Rev 5′-CAC GGT TGG CCT TAG GGT TCA-3′. For setting up the 
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qPCR reaction, 100ng of DNA extracted from infected SG tissue at indicated time points 
was mixed with primers (0.5 μM), and 12.5 μL of Power SYBR Green PCR Master Mix 
(Applied Biosystems, Life Technologies), and adjusted to 25 μL with nuclease-free 
water. The PCR was performed using a 7900HT Fast Real-Time PCR System (Applied 
Biosystems) using the following PCR conditions: initial incubation at 95 °C for 10 min, 
and subsequent 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Relative 
quantification (RQ) of viral DNA (IE1) was carried out using SDS software package v2.3 
(Applied Biosystems) following normalizing the Ct values of β-actin for the same 
sample. 
In Vitro Protein Expression 
Aliquots from the single-step growth assay or coinfection assays were removed and 
used to verify chemokine expression. Ni-NTA agarose beads were used to isolated 
vCXCL-1CCMV and mCXCL1 proteins from 100 µg of total protein. The eluted protein 
samples were subjected to Western blot analysis using the primary anti-6-His antibody 
(Qiagen) diluted 1:200 and secondary anti-mouse HRP antibody diluted 1:2000. Silver 
staining for the proteins in the supernatant was carried out using Pierce Silver Staining 
Kit (ThermoFisher Scientific) per manufacturer’s instructions. Relative concentration of 
the protein was calculated using ImageJ on the captured images (NIH). 
In Vivo Growth of Parental and Recombinant Viruses 
106 PFUs of parental or recombinant viruses were inoculated in the FP or 
intraperitoneally of hCXCR2 transgenic, hCXCR2KI, BALB/c, NSG or SCID mice.  At 
different times post infection, mice were euthanized and their footpads, spleens, liver, 
lungs, popliteal lymph node, and salivary glands were removed. Organs were 
individually weighed, homogenized, and clarified.  Supernatants were titered. 
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Leukocyte Infectious Centers Assay 
Assay was performed as described in [74].  Briefly, peripheral blood was harvested and 
red blood cells lysed. Leukocytes were plated onto NIH3T3 monolayers.  After 6 hrs. 
cells were overlayed with CMC media.  Plaques were counted after 7 days. 
Plaque Formation Assay 
Plaque formation assay on MEF 10.1 cells was used to determine viral titers in the 
organs. Briefly MEF 10.1 cells were plated in a 6 well dish.  Organs were harvested and 
homogenized. The homogenate was serially diluted and added the MEF 10.1 cells and 
incubated for 1 hr. After incubation the diluted virus was removed and cells were 
overlayed with carboxy methyl cellulose (CMC) media and incubated for 7 days. At the 
end of the incubation period, CMC was removed and plates were stained with 
Coomassie blue and plaques counted. 
Co-Infection Experiments 
Mice were infected (either in the same foot pad or separate foot pads) or 
intraperitoneally with 5 x 105 PFU each of chemokine expressing recombinants 
(RMmCXCL1/RMvCXCL1) and RM4511 or RM4503 for high titer inoculum experiments 
or with 100 PFU of each virus for the low titer inoculum experiments. Mice infected 
separately with chemokine expressing recombinants or RM4511/RM4503 served as 
controls for these experiments. Salivary glands were harvested at 14 days p.i. from 
these mice and virus was titered. Initially the GFP+ plaques (i.e., parental virus) were 
visualized under an inverted fluorescence microscope and counted. Following fixation 
and Coomassie blue staining all plaques were counted and the number of GFP+ 
plaques were subtracted from the total to give the number of GFP- plaques (i.e., 
chemokine expressing recombinants) 
Depletion of Cellular Subsets 
In vivo depletion of cellular subsets was performed using antibodies one day prior to 
MCMV infection and then every three days until harvest. Neutrophils were depleted 
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using 1A8 (anti-Ly6G) or RB6C (anti-Ly6G/C) antibody (1mg/ inoculation) (BioXcell, 
West Lebanon, NH). For NK cell depletions, mice were injected i.p. with 100 ul of anti-
asialo GM1 or PBS (Wako Chemicals, USA) diluted 1:10 in PBS on the days indicated 
in the figure legend.  Flow cytometry was used to confirm depletion of GR-1hi, CD11bhi 
neutrophils and CD3-, DX5+ NK cells.   
Flow Cytometry 
Feet (cut at ankles), lung, and SG tissues were minced into small pieces (~3mm) and 
incubated on a rotatory shaker at 37°C for one hour in a 0.5% W/V solution of type I 
collagenase (Worthington, NJ). Following collagenase digestion, single cell suspensions 
where obtained by passing the feet, lungs, SG, and spleens through 40um cell strainers 
(Fisher Scientific). Red blood cells were lysed with ACK (ammonium-chloride-
potassium) lysis buffer.  Cells were stained for FACS analysis with the following 
fluorochrome-conjugated antibodies to analyze the cellular subsets: anti-CD3 (17A2) 
anti-CD4 (GK1.5), anti-CD8 (SK1) anti-CD45.2 (104), anti-CD11c (N418), anti-Ly6G 
(1A8), anti-Ly6C (HK1.4) (all from Biolegend); anti-CD49b (DX5) from eBiosciences; 
and anti-CD11b (M1/70) from BD Pharmigen. Cells were analyzed on BD LSR II flow 
cytometer (BD Biosciences) and evaluated using FlowJo Mac software, version 10.1.  
Statistical Analysis 
Statistical significance was calculated using one tailed Student’s t test or 1 way ANOVA 
followed by Tukey's or Bonferroni’s Multiple Comparison Test in Prism5 (GraphPad) 
following the recommendations of Vaux et al. [75, 76]. A p value < 0.05 was considered 
statistically significant. 
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Supplementary Figures  
 
Figure S3.1. Construction and characterization of wild type (WT) MCMV, parental 
MCMV (RM4511), RMmCXCL1, and RMvCXCL1CCMV viruses. 
 (A) The RM4511 recombinant MCMV contains a double point mutation resulting in a 
missense mutation that converts amino acids CC to GR in MCK2. This in effect creates 
an MCK2 negative strain. RM4511 also has a puromycin/green fluorescent protein 
expression cassette (puro-GFP) cassette in the ie2 locus. The mCXCL1 or vCXCL-
1CCMV expression cassette containing a gpt selectable marker was used for selection 
and replaces the puro-GFP cassette. (B) Schematic representation of the puro-GFP and 
chemokine expression cassettes. The sizes of the diagnostic PCR products produced 
using the MCMV/GFP primers (2.5kb) and MCMV F/HCMV IE primers (3.0 kb) 
are shown. (C) Three PCR reactions were performed using viral DNA as the template. 
(i) Amplification of either the mCXCL1 or vCXCL-1CCMV gene using HCMV IE and 6 
His primers. This generates a ~325 bp product (mCXCL1) and a ~425bp (vCXCL-
1CCMV). (ii) Verification of the loss of the puromycin-GFP expression cassette using a 
primer flanking the 5’ MCMV IE2 homologous region and a primer within the puromycin-
GFP cassette (MCMV GFP). This generates a 2.3kb product. (iii) Verification of the 
correct insertion site of the mCXCL1 or vCXCL-1CCMV expression cassette using a 
primer flanking the 5’ MCMV IE2 homologous region and a primer within the expression 
cassette (HCMV IE). This generates a 3kb PCR product. (D) NIH3T3 cells were infected 
in triplicate with RM4511, RMmCXCL1 or RMvCXCL1CCMV at a MOI of 0.05 (multi-
step) or 5 (single-step). Supernatants were harvested daily for five days p.i. and 
assayed via a plaque assay. (D) Western blot analysis was used to confirm the 
expression of mCXCL1 and vCXCL1CCMV proteins. NIH3T3 cells were infected with 
RM4511, RMmCXCL1, or RMvCXCL1CCMV at a MOI of 5. Supernatants were 
harvested at the indicated times post infection. Recombinant proteins were enriched 
using Ni-NTA agarose beads from 100 mg of total protein. The eluted protein samples 
were subjected to Western blot analysis using anti-6-His antibody to detect the 6-His 
tagged chemokines.  
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Figure S3.1. 
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Figure S3.2. Cyclophosphamide treatment of mice leads to a reduction in NK cell 
numbers but does not affect primary dissemination of virus.  
Mice were treated with cyclophosphamide to deplete the immune cells prior to being 
infected in the foot pad with 1 x 106 PFU of the parental (RM4511) or chemokine 
expressing recombinant (RMvCXCL1CCMV or RMmCXCL1) virus. 
Untreated mice were use as control. (A) Organs (popliteal lymph node, spleen and lung) 
were harvested at days 3, 7, 14, 18 post infection, homogenized and viral titer 
measured. Bars represent virus titer from at least 5 mice per time point + SEM. Dashed 
line represents the detection limit (DL) for the plaque assay. (B) Spleen and lung were 
harvested at day 4 p.i.. Single cell suspension prepared as described in materials and 
methods and stained for flow cytometric analysis. The graph shows the number of NK 
(CD3-CD49b+) cells in the spleen and lung of infected untreated and cyclo-treated 
mice. (C) Mice were infected in the FP with 1 x 106 PFU of the parental (RM4511) or 
chemokine expressing recombinant (RMvCXCL1CCMV or RMmCXCL1) virus. Feet 
were cut and processed as descried in materials and methods at days 3 and 5 post 
infection and the stained for flow cytometric analysis. The graphs show number of CD4 
(CD3+ CD4+) and CD8 (CD3+ CD8+) T cells in the FP of the mice. Bars represent the 
average number of cells from 4-5 mice per group +/- SEM. 
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Figure S3.2. 
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Figure S3.3. Rescue of dissemination of recombinant viruses upon co-infection is 
not affected by route of infection and MCK2 chemokine expression.  
(A) BALB/c mice were infected in the FP with 1 x 106 PFU of the parental (RM4511) or 
chemokine expressing recombinant (RMvCXCL1CCMV or RMmCXCL1) virus. SG was 
harvested at days 10 and 14 p.i. and viral load measured using plaque assay. (B) Mice 
were infected i.p. with either the parental virus (RM4511) or recombinant virus alone, or 
a mixed inoculum (1:1 mix of 5 x 105 PFU each of parental and recombinant virus). 
Viral titer was measured in the SG at day 14 p.i. (C) Mice were infected with either 
RM4503 (i.e., MCK2+) or recombinant RMmCXCL1 virus alone or mixed inoculum (1:1 
mix of 5 x 105 PFU of each Rm4503 and RmMCXCL1) in the FP. Viral titer was 
measured in the SG at day 14 p.i. by plaque assay. (D) Mice were infected with a mixed 
inoculum(1:1 mix of 5 x 105 PFU each of parental and recombinant virus) in the FP 
(Mixed) or in different FPs with 5 x 105 PFU each of RM4511 and RMmCXCL1 (Diff). 
FP, popliteal lymph node, spleen and lungs were harvested at days 3 and 5 days p.i., 
and viral titer measured by plaque assay. Bars represent mean titer from 5 mice per 
group + SEM. (D) Mice were infected with 1 x 106 PFU of RM4511 and RMmCXCL1 in 
the same FP but delayed by 2 or 7 days. Viral titer was measured in the SG of these 
mice at day 14 p.i. after the second infection. RMmCXCL1- >RM4511 = first infection 
RMmCXCL1 and second infection with RM4511, RM45111->RMmCXCL1 = first 
infection RM4511 and second infection with RMmCXCL1. For figures A, B, C and E the 
symbols represent viral titer in each individual mouse and the horizontal line represents 
the median viral titer in each of the experimental groups. Dashed line represents the 
detection limit (DL) for the plaque assay. The * indicates viral titers in the SG of mice 
infected with a mixed inoculum. 
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Figure S3.3.
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Figure S3.4. Recombinant virus isolated from the salivary gland after co-infection 
with parental virus does not undergo recombination or mutation of the 
chemokine gene.  
RMmCXCL1 plaques were isolated from the SG of co-infected mice at day 14 p.i 
and grown in large scale cultures. (A) Phenol-chloroform extraction was used to isolate 
viral DNA and sequenced using HCMV IE and 6His primers described in materials and 
methods. The protein sequence generated from the resulting DNA sequence and 
aligned using Web based ClustalW (1, 2). Green is the signal peptide sequence, red is 
the CXC motif, blue is the His tag, * = 100% identity of the amino acid at the position 
among the sequences analyzed. (B) RFLP analysis was performed on viral DNA 
isolated from the RMmCXCL1 virus 
(RMmCXCL1 parental) and SG isolated virus following coinfection. Viral DNA was cut 
using BstZ17I, HpaI and HindIII restriction endonucleases. Predicted restriction 
fragment sizes of the digested viral DNA are indicated on right hand side of each gel. 
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Figure S3.4. 
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Figure S3.5. Dissemination of virus after adoptive transfer of infected leukocytes.  
Mice were infected with 1x105 PFU of RM4511, RMmCXCL1, or a mixed inoculum 
consisting of a 1:1 mixture 1x105 PFU each of RM4511 and RMmCXCL1. Leukocytes 
were isolated from the FP at day 3 p.i. and adoptively transferred to mice via tail vein 
injection. SG from these mice was harvested at 
day 14 post transfer, homogenized, and virus titered. Bars represent average virus titer 
from 3 mice per 
group +/- SEM. 
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Figure S3.6. Effect of dose of parental virus on production of mCXCL1 during co-
infection in vitro.  
To test the dose dependence of co-infection on the production of the chemokine, we 
reduced the parental (RM4511) to recombinant (RMmCXCL1) ratio from 1 to 0.2, and 
0.02 in an in vitro co-infection assay. Supernatant was collected at the indicated 
timepoints. The chemokine was enriched using anti His beads and silver stained as 
described in Materials and Methods. Adjusted relative concentration (Adj. relative 
concentration) for the chemokine was calculated using ImageJ as in Figure 6 of the 
chapter. 
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Figure S3.7. A model of how co-infection rescues the chemokine expressing 
recombinant virus dissemination.  
(A) During single infection, the overproduction of the chemokine at the site of infection in 
the primary organs of dissemination recruits inflammatory cells (NK and IM) to the site 
and interferes with normal secondary viraemia and subsequent SG dissemination. (B) 
During co-infection, the reduction in chemokine levels in the primary organs reduces the 
number of inflammatory cells (i.e., IM) to the site and allows PMs to gain access to the 
virus. The infected PMs then disseminate the virus to the SG. Figure 10 Key: IM = 
Inflammatory monocyte, PM = Patrolling monocyte, NK = Natural killer cells, FP = Foot 
pad, SP = Spleen, LN = Popliteal lymph node, Lu = Lung and Sg = Salivary gland, 
=Chemokine; Viruses:  = RMmCXCL1/RMvCXCL1CCMV,  = RM4511. 
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Abstract  
 Human cytomegalovirus (HCMV) is a β-herpes virus that is a significant 
pathogen within immune compromised populations. Morbidity associated with HCMV 
infection is the consequence of viral dissemination and inflammation. HCMV has 
evolved to manipulate the host immune system to enhance viral dissemination and 
ensure long-term survival within the host. The immunomodulatory protein vCXCL-1, a 
viral chemokine, is hypothesized to attract neutrophils to the infection site, which aids 
viral dissemination during infection. Neutrophils harbor HCMV in vivo, however the 
interaction between vCXCL-1 and the neutrophil has not been evaluated in vivo. Using 
the mouse model of MCMV infection, we show that murine neutrophils harbor and 
transfer infectious MCMV and virus replication initiates within this cell type. Utilizing 
recombinant MCMVs expressing vCXCL-1 from the HCMV strain Toledo, we 
demonstrate that vCXCL-1 significantly enhances MCMV dissemination kinetics. 
Through cellular depletion experiments, we demonstrate that vCXCL-1 relies slightly on 
neutrophils for increased dissemination. However, vCXCL-1's major contribution to 
MCMV dissemination is neutrophil independent. This work adds neutrophils to the list of 
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innate cells (i.e., dendritic and macrophages) that contribute to MCMV dissemination, 
but refutes the hypothesis that neutrophils are the primary target cell responding to 
vCXCL-1.  
1. Introduction 
Human cytomegalovirus (HCMV) contributes to morbidity and mortality in 
immunocomprimised populations [1, 2]. It is also the leading cause of infectious 
congenital disease [3, 4], which can result in microcephaly or other sequela (e.g. 
progressive deafness and learning disabilities) following in utero or neonatal infections 
[5, 6]. Primary infection or latent viral reactivation in an immunocopromised adult [7, 8], 
such as cancer therapy patients, organ transplant recipients, or HIV/AIDS patients can 
cause gastroenteritis, retinitis, organ transplant rejection and other ailments [2, 9]. 
Regardless of the host, disease due to viral infection is the result of inflammation and 
viral dissemination [10]. Interestingly, HCMV has evolved numerous immunomodulatory 
proteins that blunt normal protective immune responses and restructure the 
inflammatory environment [11-13]. The viral chemokine, vCXCL-1 is an HCMV protein 
that preferentially recruits neutrophils, which are CXCR2+ over other innate immune 
cells in vitro [14-16].  
vCXCL-1 engages the chemokine receptor CXCR2 [14, 15],  but also functions 
through CXCR1 and CX3CR1 chemokine receptors [15, 16]. CX3CR1+/CXCR1+ natural 
killer (NK) cells functionally respond to vCXCL-1 albeit at a significantly reduced level 
compared to CXCR2+/CXCR1+ neutrophils [16]. Unfortunately, an adequate in vivo 
evaluation of vCXCL-1’s interaction with the immune system and its contribution to CMV 
pathogenesis is lacking. Because cytomegaloviruses can only effectively replicative 
within their respective species host [17-19], vCXCL-1’s evaluation in vivo has been 
limited.  
Mouse cytomegalovirus (MCMV) infection of mice is frequently used to study 
CMV dissemination. MCMV has similar pathogenesis to HCMV, contains many 
homologues and orthologous to HCMV genes, and disseminates via innate immune 
cells [20, 21]. One limitation of the MCMV model is that it does not encode vCXCL-1. 
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MCMV does encode a C-C chemokine, MCK2 [22-24], which is hypothesized to function 
through the CX3CR1 receptor [25]. Without a true homologue, the impact of vCXCL-1 
and the neutrophil's role in dissemination has been largely neglected in the mouse 
model. We have previously expressed vCXCL-1 under the control the HCMV IE 
promoter in MCMV and found a decrease in salivary gland dissemination [26, 27].  We 
suspected that this was due to inappropriate timing and levels of vCXCL-1 expression.  
Here, we engineered a recombinant MCMV expressing human vCXCL-1 from the 
HCMV Toledo strain (vCXCL-1Tol) with a 2A peptide linked to the MCK2 chemokine. 
This ensures that vCXCL-1 is being expressed at the correct physiological time and 
level. We demonstrate that the murine neutrophils are capable of harboring, 
transferring, initiating viral replication, that CXCR2 stimulation is sufficient to alter 
normal MCMV dissemination kinetics. Additionally, we show that infection with 
recombinant MCMVs expressing vCXCL-1 increases viral dissemination and virulence.  
2. Results 
Murine Neutrophils Harbor, Transfer, and Initiate MCMV Replication  
The neutrophil’s capacity to impact viral dissemination is an area of contention. In 
human blood, neutrophils harbor the largest viral burden [28, 29], transfer infectious 
HCMV ex vivo and in vitro, but are unable to support productive viral replication [30, 31]. 
In the MCMV mouse model, the interaction between murine neutrophils and MCMV has 
not been evaluated. Here we couple a thioglycollate inflammation model [32] with 
MCMV infection to study the relationship between MCMV and murine neutrophils 
(Figure 4.1A).  The neutrophil population purified out of peritoneal exudate isolated 
from MCMV infected mice using aLy6G microbeads (Figure S4.1A) and the remaining 
population of peritoneal exudate cells (termed Flowthrough) were both assayed for viral 
genome via qPCR (Figure 4.1B). We did not observe any significant difference in the 
viral genome content between the two populations indicating that neutrophils are a 
substantial reservoir for CMV immediately following infection at the infection site. As 
neutrophils are a substantial reservoir for CMV immediately following infection at the  
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Figure 4.1. Neutrophils harbor and transfer MCMV ex vivo and in vivo.    
(A) Experimental design (B) Total DNA was extracted from 1 x 106 purified neutrophils 
or flow through cells. qPCR was performed to evaluate the number of MCMV genomes 
present. (C) Infectious centers assay for determining the number of infected neutrophils. 
1 x 106 purified neutrophils where incubated with an uninfected fibroblast monolayer for 
5 days and the number of plaques evaluated. (D) MCMV genomes were quantified from 
whole blood isolated from mice that were adoptively transferred neutrophils from 
infected mice. (E) PECs were evaluated for the presence of GFP virus. GFP cells were 
gated on and neutrophil (Ly6G+, CD11b+) and macrophage populations 
(F4/80+,CD11b+) were evaluated.  Statistical significance was determined by student’s t- 
test. Bars represent the average titers +/- SD. ns= not significant; * = p £ 0.05; ** = p £ 
0.01; *** = p £ 0.001. 
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infection site. As neutrophils are phagocytes, the genome found within the neutrophil 
population could represent non-infectious MCMV, therefore an infectious centers assay 
was carried out to measure infectious genome. Figure 4.1C demonstrates that while 
there is no difference between genomic copy number between the two populations, the 
neutrophil population did have a reduced amount of infectious MCMV. In order to 
determine whether or not this purified neutrophil population was capable of infecting a 
new host, purified neutrophils were adoptively transferred to uninfected mice. Three 
days post neutrophil transfer, blood was harvested and assayed for MCMV genome via 
qPCR. Transferring the infected purified neutrophil population was sufficient to 
productively infect a new host (Figure 4.1D).  
 In order to investigate whether neutrophils can support MCMV replication, mice 
were infected with a MCMV that encodes GFP under the CMV immediate early 
promoter (i.e., 4503) [22] and analyzed with flowcytometry.  Peritoneal exudate cells 
(PECs) in which the virus has entered, uncoated, and began replication will express 
GFP.  All GFP+cells were initially gated and these cells were further analyzed (Figure 
4.1E). GFP+ neutrophils (Ly6G+, CD11b+) and macrophages (F4/80+,CD11b+) were 
identified. Other GFP+ immune cells are present, however the identify of these cells was 
not determined. The gating strategy used to obtain these results been outlined (Figure 
S4.1B). This demonstrates that neutrophils can be infected with MCMV and begin the 
infectious cycle. 
CXCR2 Stimulation Alters Normal MCMV Dissemination Kinetics 
Because vCXCL-1Tol functions primarily through CXCR2 (14, 15, 33), we sought 
to understand whether a targeted CXCR2 response could alter normal MCMV 
dissemination kinetics. When mice are injected i.p. with IL-17A, mesothelial cells 
release host CXCL-1 (i.e., Groa), which elicits primarily a neutrophilic CXCR2 mediated 
response (34). We exploited this experimental setup to mimic the viral chemokine's 
function in vivo and evaluated the contribution of CXCL-1/CXCR2 axis on viral 
dissemination (Figure 4.2A). Mice treated with IL-17A prior to i.p. infection with MCMV 
had a significantly greater viral burden in the spleen and lungs five days post infection  
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Figure 4.2. CXCR2 stimulation increases MCMV dissemination.  
(A) MCMV was administered i.p. during peak neutrophil response induced with IL-17A 
or vehicle control (NT). Viral titers of whole organ homogenates were determined in the 
spleen (B) and lungs (C) of mice treated with IL-17A five d.p.i.. n=3 with 4-5 mice per 
group. (D) SG of mice were harvested 5 d.p.i. Total DNA was harvested and subjected 
to qPCR for total MCMV burden in the SG. (E) Depletion of neutrophils reduces IL-17A 
enhanced MCMV dissemination to the spleen. Plaque assays of spleens of mice 5 d. 
p.i. that received PBS, IL-17A alone, 1A8 depleting antibody coupled with IL-17A 
treatment (IL-17A & 1A8), or 1A8 neutrophil depleting antibody alone prior to infection 
with MCMV. Data is the combination of two pooled experiments. Data is normalized to 
the mean PFU/gram of tissue of the PBS control for each experiment . Statistical 
significance was determined by student’s t-test or one-way ANOVA with Tukey’s 
multiple comparison of means. Bars represent the average titers +/- SD. ns= not 
significant; * = p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; **** = p £ 0.0001. 
 
 
121 
Figure 4.2. 
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(d.p.i.) compared to vehicle control treated animals (Figures 4.2B and 4.2C). IL-17A 
treated animals also had a greater seeding of the salivary gland (SG) at five d.p.i. 
(Figure 4.2D). While there was faster SG seeding, IL-17A treated animals did not have 
a significant difference in viral burden within this organ at 14 d.p.i. compared to control 
animals (data not shown).  
Neutrophils were depleted to test the importance of neutrophils in IL17A 
enhanced MCMV dissemination (Figure S2). Animals were treated with either neutrophil 
depleting antibody or vehicle control for two days prior to IL-17A administration then 
every other day until euthanization. Spleens were titered at 5 d.p.i. (Figure 4.2E).  
Neutrophil depletion of IL-17A treated animals resulted in a significant decrease of viral 
burden in the spleen (p<0.05 IL17A vs IL17A neutrophil depleted).  However, neutrophil 
depletion did not completely revert to untreated IL-17A viral titer levels. These data 
indicate another cell type is responding to CXCR2 or other ligands, which aids viral 
dissemination.  
Generation of Recombinant MCMV Expressing vCXCL-1   
 We previously generated recombinant MCMVs that over express vCXCL-1. 
These viruses had unaltered primary dissemination kinetics, but secondary 
dissemination was undetectable (26). We hypothesized that chemokine over expression 
resulted in the lack of dissemination to the SG. Therefore, we engineered a recombinant 
MCMV in which vCXCL-1 from the HCMV Toledo strain is expressed in tandem with the 
MCMV chemokine, MCK2. These two genes were connected via a 2A-peptide self-
cleaving peptide to allow co-expression of the two chemokines (35) (Figure 4.3A). The 
recombinant MCMV was generated by coupling classical bacterial recombineering (36) 
with CRISPR/Cas9 technology. SW105 E.coli harboring the wild type (WT) Smith strain 
bacterial artificial chromosome (BAC) pSM3fr-MCK2-2fl were induced to recombine a 
functional galactokinase (GalK) into the MCK2 locus. Figure 4.3B, HindIII RFLP 
analysis confirmed GalK insertion into (WT) pSM3fr-MCK2-2fl resulting in a 1.5kb size 
increase of the 7.1kb band into the top of the triplet band (boxed in red).  Because the 
SW105 strain is DrecA it is unable to repair double stranded (ds) breaks, we used 
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Figure 4.3. Generation of recombinant MCMV expressing vCXCL-1 
(A) Bacterial artificial chromosome schematic of vCXCL-1 insertion into the MCK2 
locus.  (B) HindIII RFLP analysis of the BACs. The triplet banding patterns are boxed in 
red. (C) Western blot analysis of the viral supernatant of MCK2-2A-vCXCL-1 MCMV. 
(D) Single step growth curve (MOI= 5.0). (E) Multistep growth curves (MOI=0.05). Bars 
represent the average titers +/- SD.  
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CRISPR/Cas9 to create a ds break in the GalK insertion allowing for insertion of MCK2-
2A-vCXCL-1 into the BAC and increasing recombinant selection efficiency. The 500bp 
addition of vCXCL-1 into the 7.1kb band resulted in the creation of a doublet in middle 
band of the HindIII banding triplet (Figure 4.3B). A 6 HIS-tag was added to the vCXCL-
1 gene and a FLAG-tag to the MCK2 gene allowing us to perform western blot analysis 
of the MCK2-2A-vCXCL-1 gene product to ensure the expression and cleavage of two 
proteins (Figure 4.3C). Glycosylated MCK2 and vCXCL-1 are slightly larger than 37 kD 
(37, 38) and 10kD respectively (27). These data indicate that the self-cleaving 2A-
peptide efficiently generates two independent proteins. In order evaluate whether the 
insertion of the vCXCL-1 gene alters replication in vitro both single step and multistep 
growth curves were conducted (Figure 4.3D and E). These analyses reveal that the 
insertion of the vCXCL-1 gene does not alter viral replication in vitro. 
vCXCL-1 Expressing MCMV Alters Normal Viral Dissemination Kinetics  
 In order to test the hypothesis that vCXCL-1Tol alters normal dissemination 
kinetics, we infected BALB/c mice with either MCMV expressing vCXCL-1Tol, Smith 
(WT), or vCXCL-1Tol RQ. vCXCL-1Tol RQ has the reintegrated WT MCK2 locus into the 
recombinant vCXCL-1Tol and serves as a control for adventitious mutations that could 
have occurred during the recombineering of recombinant vCXCL-1Tol MCMV. Mice 
infected subcutaneously in the f.p. had no difference in viral burden at the site of 
inoculation 3 d.p.i. (Figure 4.4A). However, MCMV expressing vCXCL-1Tol had a larger 
viral burden in the draining popliteal lymph node 3 d.p.i. when compared to the WT or 
vCXCL-1Tol RQ infected mice (Figure 4.4B). This indicates that vCXCL-1 does not alter 
growth at the infection site, but the protein alters the rate of viral dissemination within 
the mouse. To evaluate whether vCXCL-1 expression alters secondary dissemination 
mice were infected with WT and recombinant MCMVs and SG were harvested 14 d.p.i. 
Plaque assays of whole organ homogenates revealed that MCMV expressing vCXCL-
1Tol had a greater SG viral burden at 14 d.p.i. than either WT or RQ viruses (Figure 
4.4C). These data indicate that vCXCL-1Tol significantly alters the normal dissemination 
kinetics of MCMV.  
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Figure 4.4. Infection of mice with vCXCL-1 expressing MCMVs increases primary 
and secondary dissemination.  
Mice were infected via footpad (FP) with 1 x 106 PFU of either WT or vCXCL-1Tol. 
Plaque assays were preformed on FP (A), lymph nodes (LN) (B), and salivary glands 
(SG) (C) harvested 3 (FP & LN) and 14 (SG) days post infection. n=3-5 experiments 
with at least 3 mice per group. Statistical significance was determined by one-way 
ANOVA with Tukey’s multiple comparison of means. (D) Mice were infected either 
intranasally (D) or intraperitoneally (E) and plaque assays were performed on SG 
harvested 14 d.p.i.  Two independent experiments with 3-4 mice per group are 
presented. Statistical significance was determined by student’s t-test. Bars represent 
the average titers +/- SD.  ns= not significant; * = p £ 0.05; ** = p £ 0.01; *** = p £ 0.001; 
**** = p £ 0.0001.  
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 Because inoculation routes produce different dissemination results (25), mice 
were infected intranasally (i.n.) (Figure 4.4D) or i.p. (Figure 4.4E) with the vCXCL-1Tol 
expressing MCMV or WT MCMV. 14 d.p.i. SG were harvested, and viral burden was 
determined as described above. Regardless, the route of inoculation vCXCL-1 
enhances MCMV dissemination kinetics.     
Analysis of Cellular Subsets Responding to vCXCL-1 In Vivo Early During Infection 
 As vCXCL-1Tol significantly increases dissemination from the FP but the viral load 
in the FP is unchanged compared to WT MCMV, we evaluated the inflammatory cellular 
profile in organs early during infection. Mice were infected as in Figure 4 and FP, LN, 
and blood from infected animals were analyzed by flow cytometry.  In the FP (Figure 
4.5A), vCXCL-1Tol induces a neutrophilic influx compared with WT MCMV, but there is 
no significant difference in either inflammatory monocytes or patrolling monocytes (25). 
In the LN, all three of these populations are significantly increased compared to WT 
MCMV (Figure 4.5B) while blood showed no difference compared to WT (Figure 4.5C). 
Additionally, there was no difference in total cellular influx in any of these tissues (data 
not shown). The increase in neutrophils at both the infection site and the draining lymph 
node led us to speculate that these cells could be responsible for the increased viral 
dissemination to the LN and SG.  
Removal of Specific Cellular Subsets Reveals Insights to vCXCL-1 Function 
 Using depleting antibodies, the importance of different cell types was tested. 
When neutrophils are depleted with anti-Ly6G antibody prior to MCMV infection (Figure 
4.6A), vCXCL-1 induced inflammation in the FP decreases to WT MCMV swelling levels 
without depletion (Figure 4.6B), but is not decreased to the level of WT MCMV infected 
and neutrophil depleted. This indicates that vCXCL-1 induced inflammation is not totally 
dependent on neutrophils. To examine whether neutrophil depletion alters viral burden 
in different tissues, LNs were harvested from MCMV infected mice that were neutrophil 
depleted or not and viral titers in tissues were determined (Figure 4.6C). When 
neutrophils were depleted in mice prior to infection with vCXCL-1Tol, viral load was  
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Figure 4.5. vCXCL-1 alters cellular infiltrate in primary dissemination organs.  
Mice were infected via the FP as in figure 4. (A) FP, (B) LN, and (C) peripheral blood 
were harvested 3 d.p.i. and evaluated with flowcytometry. Neutrophils were 
characterized as Ly6G+, CD11b+ Inflammatory monocytes: Ly6G-, Ly6Chi, CD11b+, 
CD11c- patrolling monocytes: Ly6G-, Ly6Clo, CD11b+, CD11c+. Statistical significance 
was determined by students t-test. Bars represent the average titers +/- SD. ns= not 
significant; * = p £ 0.05; ** = p £ 0.01. 
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Figure 4.6. Neutrophils are partially responsible for vCXCL-1-Tol induced 
inflammation and dissemination.  
(A) Neutrophil depletion experimental design. (B) FP swelling, measured by digital 
caliper, of infected up to 3 d.p.i. normalized to uninfected footpads (C) Plaque assays 
were preformed on LN harvested from depleted or control mice at 3 d.p.i. Bars 
represent the average of two experiments with 3 mice per group. Statistical significance 
was determined by one way ANOVA with Tukey’s multiple comparison of means. Bars 
represent the average titers +/- SD. *** = p £ 0.001; **** = p £ 0.0001.  
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slightly less in the LN than non-depleted, but viral titers did not return to WT MCMV 
levels.  These data indicate that neutrophils are partially responsible for vCXCL-1 
mediated dissemination, but they are not the major target of vCXCL-1. 
vCXCL-1Tol Increases Virulence 
 Because there is no effective method for depleting monocytes without depleting 
other cellular subsets (39), we infected Nod-Scid-IL2-gamma chain (NSG) deficient 
mice.  These mice lack T, B, and NK cells and also have defective macrophages and 
dendritic cells (40). Although these mice are highly immune deficient, monocytes and 
neutrophils remain functional. The number of mice surviving daily was recorded and 
plotted as a Kaplan-Meier survival curve (Figure 4.7A). Interestingly, many of the mice 
infected with the vCXCL-1Tol  virus died on or before 10 d.p.i, while all mice infected with 
the WT survived out to 12 d.p.i.. These data indicate that vCXCL-1 is a virulence factor 
as 58% of mice infected with recombinant MCMVs expressing vCXCL-1Tol died, but 
mice infected with WT MCMV survived. We also observed significantly increased viral 
titer in spleens of mice infected with recombinant virus compared to WT virus (Figure 
4.7B). However, there was no difference in the SG viral titer for mice in both these 
groups (Figure 4.7C). These data point to either the significance of viral load in the 
spleen for mouse survival or another unknown effect of vCXCL-1Tol, which increases 
mortality in NSG mice. 
3. Discussion 
Because most HCMV infections are asymptomatic studying, its dissemination 
from primary infection to the establishment of latency in humans has been limited to in 
vitro and ex vivo analysis (1, 2). These studies revealed that innate immune cells are 
major reservoirs of HCMV in the blood and contribute to viral dissemination (29). 
HCMV's reliance on innate immune cells has resulted in the evolution of 
immunmodulatory proteins such as chemokines, capable of activating and recruiting 
innate immune cells (13). The discovery of the HCMV chemokine, vCXCL-1, led to the 
hypothesis vCXCL-1 recruits innate immune cells to the infection site and these  
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Figure 4.7. vCXCL-1 increases virulence of MCMV which correlates with increased 
viral loads in the spleen.   
A) Kaplan-Meier survival curve comparing NSG mice infected with either vCXCL-1Tol or 
WT MCMV.  At the termination of the experiment, MCMV titers in the spleen (B) or 
salivary gland (C) were determined. Statistical significance was ascertained using the 
student’s t-test. Bars represent the average titers +/- SD.  Each point is the viral titer 
from each mouse.  Data is from three separate experiments with 4-6 mice per group for 
each virus.  
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recruited cells are major contributors to viral dissemination (30, 41, 42). As β-herpes 
viruses are species specific, an in vivo analysis of vCXCL-1 function is lacking. Here we 
employ the mouse model using recombinant MCMV expressing the HCMV vCXCL-1 
from the Toledo stain to study vCXCL-1 function in vivo. A major limitation of the MCMV 
model and the reason recombinant MCMVs were used is the immunomodulatory 
proteins of MCMV and HCMV differ. MCMV encodes one known C-C chemokine MCK2 
(22), which is hypothesized to function through the CX3CR1 chemokine receptor  (25) 
and aids viral entry (24). However, HCMV encodes both C-C and C-X-C  
chemokines (13), which have been shown to attract monocytes, neutrophils, and NK 
cells in vitro (15, 16, 43). vCXCL-1 attracts neutrophils and to a lesser extent NK cells 
(15, 16). These observations suggest the neutrophil is a major player in HCMV 
dissemination. Many innate immune cell types have been evaluated in the MCMV 
model, but not neutrophils. 
In order to establish this model, we needed to understand the MCMV-neutrophil 
interactions and how/whether they have a role in MCMV dissemination.  This is 
important because neutrophils can transfer HCMV (30) and vCXCL-1 alters human 
neutrophil function (15). We show that in a thioglycollate induced model, murine 
neutrophils can transfer MCMV to new cells and viral transcription/translation begins in 
neutrophils and macrophages (i.e., GFP expression) (Figure 4.1). To the best of our 
knowledge, this is the first report demonstrating murine neutrophils are able to harbor 
and transfer MCMV ex vivo and in vivo.  
 As vCXCL-1 is expressed late in the HCMV life cycle (1), it is likely that infectious 
viral particles are being released simultaneously with chemokine expression. Therefore, 
we sought to mimic this environment. IL-17A, when injected i.p. into mice, induces 
CXCL-1 (aka Groa) expression (34). Groa is a chemokine that uses the CXCR2 
receptor to enact its function (44). This induces primarily a neutrophil influx into the 
peritoneal cavity. Stimulating the CXCR2 signaling axis during infection increased viral 
burden in primary dissemination organs (i.e. spleen and lungs) and resulted in an 
increased SG seeding. However, IL-17A treatment prior to infection did not lead to 
increased viral burden in the SG 14 d.p.i. This could potentially be explained by 
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inconsistent CXCR2 stimulation. As the IL-17A treatment is transient there is no 
continual Groa release. Therefore, it is not surprising that this treatment only impacted 
primary dissemination. Interestingly, when neutrophils were depleted from the IL-17A 
inflammation model, there was only a slight decrease in viral burden compared to non-
depleted animals, indicating that there is another CXCR2+cell responding to IL-17A. 
While neutrophils are the only statistically significant population that changes in 
response to IL-17A (34) (data not shown), there could be a biologically relevant small 
subset of CXCR2+ cells (i.e. inflammatory monocytes) (45-47) responding to Groa and 
aiding viral dissemination. 
Previously, we demonstrated that over expressing vCXCL-1 in the context of 
MCMV infection did not change primary dissemination, but secondary dissemination 
was inhibited (26). We speculated that the timing and quantity of viral chemokine 
expression induced an abnormal inflammatory environment, resulting in expedited or 
premature viral clearance. To alleviate this concern, we generated a recombinant 
MCMV that expresses vCXCL-1 at relatively normal physiological times and levels by 
linking it to the natural MCMV chemokine, MCK-2. When mice were infected with the 
recombinant MCMV vCXCL-1Tol, there was a significant difference in viral dissemination 
kinetics for both primary and secondary dissemination when compared to wild type 
MCMV infection. Because different inoculation routes have different dissemination 
mechanisms, it was important to determine if the phenotype observed was inoculation 
route dependent (25, 48). We show the vCXCL-1Tol dissemination phenotype was still 
present whether mice were inoculated by the more natural inoculation route (i.e., 
intranasal (48)) or the more common intraperitoneal route. Since our previous studies 
revealed vCXCL-1Tol - neutrophil interactions, we depleted murine neutrophils to dissect 
this relationship in vivo. As with the IL-17A neutrophil depletion, neutrophil depletion 
coupled with recombinant viral infection significantly reduced viral dissemination, but 
this depletion did not return viral burden to WT levels. indicating there is another target 
cell through which vCXCL-1Tol is functioning.  
As monocytes also express CXCR2 under certain conditions (45, 49), the next 
logical experiment would be to deplete monocytes. Unfortunately, specific depletion of 
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monocytes is not possible (39).  Instead we chose to utilize the NSG mouse model. 
These mice are highly immunocompromised and lack mature B, T and NK cells (40), 
and also have defective macrophages and dendritic cells, which could participate in 
MCMV dissemination (48, 50) (25). However, the NSG mouse does have functional 
monocytes. Since neutrophils were not the major cell type aiding dissemination (Figure 
4.6), we hypothesized if viral dissemination of the recombinant MCMV compared to WT 
MCMV was still increased in NSG mice, it would point toward the monocyte responding 
to vCXCL-1Tol. Surprisingly, infection of NSG mice with vCXCL-1Tol  MCMV and not WT 
MCMV resulted in death (Figure 4.7). This was not expected, but these results support 
the claim that vCXCL-1Tol is a virulence factor (12, 15, 27, 51). 
 While neutrophils are not the major cell type aiding dissemination, our results 
provide the first evidence that murine neutrophils contribute to MCMV dissemination. 
We also report that vCXCL-1 significantly enhances CMV dissemination and 
pathogenesis.  However the hypothesis that the neutrophil is the sole responder to 
vCXCL-1Tol  is incorrect and needs to be expanded to include another cell type(s). 
CXCR2+ positive monocytes (45, 49) and myeloid derived suppressor cells (52, 53) 
have been reported and these could be vCXCL-1Tol's target. Our hypothesis supports 
previous findings in which monocytes are the major drivers CMV dissemination (1, 2, 
54) (25). Interestingly, the deaths of NSG mice when infected with vCXCL-1Tol provided 
evidence supporting this protein being a virulence factor. We have previously shown 
that vCXCL-1 from different HCMV strains vary in their ability to active and induce 
neutrophil recruitment, (15) but we now have a system to test their virulence in vivo. In 
conclusion, vCXCL-1 directly influences CMV dissemination kinetics and virulence 
through neutrophils and potentially monocytes. 
4. Materials and Methods 
 
Plasmids  
pCas9 was a gift from Luciano Marraffini (Addgene plasmid #42876) (55). The 
selectable marker of this plasmid was altered to kanamycin using Gibson Assembly. 
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p2A-Tol ORF was synthesized (Genscript) after adding the P2A sequence (Addgene). 
This plasmid contains 250bp of MCK2 that is FLAG-tagged followed by the 2A-peptide 
then vCXCL-1 from the HCMV Toledo strain, which has a 6 HIS tag. pcDNA-MCMV IE1 
was generated as a standard for qPCR.  
 
Cells and Mice   
All experiments were performed with low (< 20) passage cells. Mouse embryonic 
fibroblast 10.1 (MEF 10.1) (56) were cultured in DMEM (Lonza, Rockland, ME) 
supplemented with 10% Fetalclone III serum (Hyclone, Logan, UT), 1% 
penicillin/streptomycin, and 1% L-Glutamine.  
BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, ME) and housed 
under specific pathogen-free conditions. 4-5 -week-old nonobese diabetic severe 
combined immunodeficient, IL-2 common γ chain null (NSG) mice were purchased from 
Jackson Laboratory (Bar Harbor, ME). All mice were housed under specific pathogen 
free conditions at the University of Tennessee or the University of Cincinnati College of 
Medicine. The Institutional Animal Care and Use Committees (IACUCs) at the 
University of Tennessee or the University of Cincinnati approved all procedures on 
animals. 
 
Viruses, BAC Mutagenesis, and Recombinant Virus Generation  
The RM4503 virus was gift from Dr. Ed Mocarski, Emory University (22) and the MCMV 
Smith strain virus derived from the pSM3fr-MCK2-2fl BAC was a gift from Dr. Chris 
Benedict  (57). MCMV was produced in vitro using MEF10.1s. All viruses were stored at 
-80oC until use. Viral titer was assessed by plaque assay (described below) on MEF 
10.1 cells.  
BAC mutagenesis was preformed on the pSM3fr-MCK2-2fl BAC by coupling Galk 
recombineering (36) with CRISPR/Cas9 technology. Briefly, SW105 E.coli housing 
pSM3fr-MCK2-2fl were induced to express the lambda red recombinase and GalK was 
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inserted into the MCK2 locus resulting in pSM3fr-MCK2-2fl-GalK. The SW105s housing 
pSM3fr-MCK2-2fl-GalK were heat induced and pCas9 with a gRNA targeting the GalK 
gene along with the PCR product from the p2A-Tol were transformed in. The 
transformants were plated on chloramphenicol and kanamycin to select for BAC and 
CRISPR plasmid. The following day colonies were streaked onto MacConkey Agar 
Base (Difico) containing 1% galactose. Colonies that retained the GalK gene were pink 
while transformants with the desired recombination were white. SW105s containing 
recombinant BACs were further assessed via HindIII RFLP analysis and the 2A-Tol 
insert was sequenced via Sanger sequencing after PCR amplification.  
2A Tol and control BACs were transfected into MEF 10.1s using LT1 transfection 
reagent (Mirus). BAC origin excision was achieved through serial passage as previously 
described (58) with the evaluation of viral DNA slightly altered. MCMV DNA was 
harvested from purified viral particles instead of DNA being isolated form infected cells. 
BAC excision was confirmed via PCR. Approximately 10 serial passaged were needed 
to effectively excise the BAC. 
 
Western Blotting 
Roller bottle  (850 cm2) (Coring) supernatant was harvested at 100% CPE. Ni-NTA 
beads were used to purify 6xHis proteins and anti-FLAG agarose beads were used to 
purify FLAG tagged proteins from approximately 60mL of supernatant. Purified proteins 
were combined 1:1 6 His and FLAG. Proteins were run on a 15% SDS-PAGE and 
blotted on to an AZURE biosystems membrane. Subsequently, using the anti-His and 
anti-FLAG AZURE western kit were used. Membranes were developed using an 
Odyssey Clx Li-Cor. Blots were analyzed using Image studio v4.0.   
 
 
qPCR. MCMV Quantification 
SYBR Green real-time quantitative PCR (qPCR) was performed to measure the viral 
load using primers designed to detect MCMV IE1 (59) :IE1 Forward 5’-
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AGCCACCAACATTGACCACGCAC-3’ and IE1 Reverse 5’-
GCCCCAACCAGGACACACAACTC-3. Copy number was standardized using pcDNA-
MCMV IE1. For setting up the qPCR reaction, 100 ng of DNA extracted from infected 
SG tissue at indicated time points was mixed with primers (0.5 µM), and 12.5 µL of 
Power SYBR Green PCR Master Mix (Applied Biosystems, Life Technologies), and 
adjusted to 25 µL with nuclease-free water. The PCR was performed using a Chromo4 
DNA engine PCR system (BioRad) using the following PCR conditions: initial incubation 
at 95 °C for 10 min, and subsequent 40 cycles of 95°C for 15 s and 60°C for 1 min. 
Quantification of viral DNA (IE1) was carried out using MJ OpticonMonitor analysis 
software version 3.1. 
 
Peritoneal Inflammation Models and Neutrophil Purification 
Thiglycollate induced peritoneal inflammation was carried out as previously described 
(32). Briefly, mice were injected with 3% Brewer’s thioglycollate (BD). 4 hours post 
injection mice were infected with 1x106 pfu of MCMV then 3 hours later mice were 
sacrificed and peritoneal exudate cells were harvested. IL-17A (Shenadoah 
biotechnology INC.) induced inflammation was preformed as previously described (34).  
 
Neutrophil purification was conducted using an aLy6G microbead purification kit 
(Miltenyi Biotec). Briefly, 9-10 mice were administered 3% thioglycollate as previously 
described. The peritoneal exudate was pooled from all mice and the resulting single cell 
suspension was subjected to microbead purification. Purity was determined by flow 
cytometry.   
 
Flow Cytometry  
Feet (cut at the ankles) were minced into small pieces (~3 mm) and incubated on a 
rotatory shaker at 37 ° C for 1 h in a 0.5% w/v solution of type I collagenase 
(Worthington). The suspension of cells, lymph nodes, or peritoneal exudate cells were 
passed through a 40 μm cell strainer (Fisher Scientific). Red blood cells were lysed with 
ACK (i.e., ammoniumchloride-potassium) lysis buffer. Cells were stained for FACS 
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analysis with the following fluorochrome-conjugated antibodies for cellular subsets: anti-
Ly6G (1A8), anti-Ly6C (HK1.4) anti-F4/80 (BM8) anti-CD11c (N418) (all from 
BioLegend); anti-CD49b (DX5) from eBiosciences and anti-CD11b (M1/70) from BD 
Pharmingen. Data was acquired on BD LSR II flow cytometer (BD Biosciences) and 
analyzed using FlowJo software, version 10.1. 
 
Neutrophil Depletion 
In vivo depletion of neutrophils was preformed as previously described (60). Briefly, 
depleting antibodies were administered every day for 2 days prior to MCMV infection or 
IL-17A treatment and then every other day until harvest. Neutrophils were depleted 
using 1A8 (anti-Ly6G) (0.25 mg inoculation) (BioXcell). Flowcytometry was used to 
confirm depletion. 
 
Plaque Assay  
Plaque formation assay on MEF 10.1 cells was used to determine viral titers in the 
organs. Briefly, MEF 10.1 cells were plated in a six-well dish. Organs were harvested 
and homogenized. The homogenate was serially diluted and added to the MEF 10.1 
cells and incubated for 1 h. After incubation, the diluted virus was removed and cells 
were overlaid with carboxy methyl cellulose (CMC) media and incubated for 5 days. At 
the end of the incubation period, CMC was removed and plates were stained with 
Coomassie blue and plaques counted. 
 
Adoptive Transfer of Neutrophils 
4 hrs after i.p. thioglycollate injection, 9-10 mice were infected i.p. with MCMV 
(RM4503) (22). 4 hrs post infection, mice were euthanized and PECs isolated.  
Neutrophils were purified using MACs beads as described above.  1x106 neutrophils 
were injected into the footpad of naive mice and the amount of MCMV in the blood was 
quantified from 250ul of whole blood via qPCR at 3 days post transfer.  
 
 
 
 
138 
In Vitro Growth Assay.  
MEF 10.1 cells were plated in triplicate in a six-well dish and infected with Smith (WT) or 
vCXCL-1Tol for either a multi-step (MOI=0.05) or single-step (MOI=5) growth analysis. 
Supernatants were collected at the indicated times p.i. and sonicated prior to assessing 
the titer. Viruses were titered via plaque assay. 
 
Infectious Center Assay 
The infectious centers assay was performed as previous described (61). Briefly, PECs 
were harvested and red blood cells were lysed with ammoniumchloride-potassium 
(ACK) lysis buffer. 1x106 PECs or purified neutrophils were incubated for 12 hours on 
an uninfected monolayer and overlaid with CMC media. Plaques were counted after 5 
days. 
 
Virulence studies: 
 NSG mice (4-6 animals per virus strain per experiment) were infected i.p. with 5x105 
PFU of either vCXCL-1Tol or WT MCMV.  Mice were monitored daily for weight loss and 
administered supportive care if necessary.  Mice were euthanized at day 12, SG and 
spleens were removed and virus titers in the organs determined by plaque assay as 
describe above.   
 
Statistical analysis 
Statistical significance was determined using Student t-test or one way ANOVA with 
Tukey’s multiple comparison of means. ns= not significant; *  p £ 0.05; **  p £ 0.01; ***  
p £ 0.001; ****  p £ 0.0001 using Prism 7.  
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Supplemental Figures 
 
 
Figure S4.1. Gating strategy used to identify GFP positive cells. 
(A) Neutrophils (Ly6G+, CD11b+) purity following microbead isolation was evaluated 
with flowcytometry. Data is representative of 2 experiments with 6-7 mice per 
experiment.  Live cells were gated on. (B) Following identification of live cells, single 
cells were analyzed for GFP expression. Gates were set on unstained infected 
peritoneal exudate cells.   
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Figure S4.2. Conformation of neutrophil depletion. 
Neutrophil depletion was evaluated with flow cytometry. Four-hour post IL-17A 
treatment animals were euthanized and peritoneal exudate was harvested. The exudate 
was assayed for the presence of neutrophils (Ly6G+ CD11b+). Data is representative of 
two experiments with 3 animals per group.  
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CHAPTER V: CONCLUSIONS AND FUTURE DIRECTIONS 
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1.Conclusions 
 The work conducted in this dissertation seeks to further our understanding of 
human cytomegalovirus's (HCMV) mechanism of spread throughout the host. Chapter 
one extensively reviews the process of CMV dissemination and highlights important 
aspects viral spread in humans and various animal models. The two goals of this 
research were to first probe facets of CMV entry using antiviral peptides and second to 
effectively evaluate the impact of HCMV's immunomodulatory protein, vCXCL-1, on the 
dissemination process in vivo.  
 Previously, we used antiviral peptides (APs) as just that, antivirals. CMV attaches 
to permissive cells by engaging heparan sulfate [1]. Therefore, inhibiting this interaction 
is an attractive antiviral target. The heparan sulfate binding peptides previously 
described [2, 3] are highly effective at inhibiting CMV infection in vitro, but these 
antivirals lack efficacy in vivo. In chapter two, we demonstrate ineffectiveness of a new 
AP family in vivo. However, instead of shelving these APs as we have done with 
previous peptides, we repurposed them as tools to probe CMV entry. Our initial results 
supported previous findings by Ravindranath et al, indicating that mouse 
cytomegalovirus (MCMV) derived in vivo and MCMV derived in vitro differ in entry 
mechanisms. We were able to confirm that this phenotype holds true for HCMV. 
Additionally, we demonstrate that in vivo derived CMVs have a decreased reliance on 
heparan sulfates for viral attachment to host cells. In order to study in vivo derived virus, 
the virus must come directly from infected hosts. Generating in vivo derived virus is 
laborious and not economically friendly. Therefore, we sought to generate virus in vitro 
that phenotypically mimics in vivo virus. By infecting murine bone marrow derived 
macrophages (BMDMs) with MCMV, we were able to devise a mechanism to produce 
virus in vitro that was phenotypically similar to in vivo MCMV. Perhaps the most 
important finding from this work is the knowledge gained in regards to viral cell-to-cell 
spread. CMV does not typically spread in a cell free manner in vivo [4, 5]. Therefore, 
inhibiting entry of cell free virus is potentially inconsequential in context of CMV 
infection. By using our APs and other methods, we were able to demonstrate that cell-
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to-cell spread takes place independent of heparan sulfate usage. These data highlight 
the need to further understand CMV entry in order to effectively treat HCMV disease.  
 Following viral entry, an active area of CMV research is viral dissemination. As 
stated above, HCMV encodes numerous immunomodulatory proteins [6]. These 
proteins enhance viral dissemination and ensure long-term survival within the host [7, 
8]. One protein of interest is the viral chemokine vCXCL-1 [9]. This chemokine is 
capable of inducing innate immune cell migration and activation. Therefore, it is 
hypothesized that vCXCL-1 plays a significant role in viral dissemination. As innate 
immune cells are major dissemination vehicles, it is thought that HCMV uses vCXCL-1 
to get innate immune cells to the infection site. Then the virus subsequently infects 
these cells and uses them to transport virus throughout the host. In chapters three and 
four we investigate the impact of vCXCL-1 on viral dissemination using the mouse 
infection model with MCMV.  
 In chapter three we used a recombinant MCMV (rMCMV) that expressed vCXCL-
1 under the HCMV immediate early promoter (IE1).  This virus will be termed  
rMCMVIE1-vCXCL-1 [10] to distinguish it from the 2A vCXCL-1 recombinant MCMV. The 
IE1 promoter expresses at immediate early time points at high levels. rMCMVIE1-vCXCL-1 
had normal primary dissemination kinetics, however secondary dissemination to the 
salivary gland was impeded. After various cellular depletions (NK, T cells, etc) in 
attempts to identify the salivary gland dissemination deficiency, no single immune cell 
was shown to be responsible for this defect. Interestingly, when co-infection 
experiments were conducted with the rMCMVIE1-vCXCL-1 and a rMCMV expressing GFP 
[11], both viruses were able to disseminate to the salivary gland. In order for the 
rMCMVIE1-vCXCL-1 to reach the salivary gland, co-infection had to take place at the same 
time and at the same location. From these data, we hypothesized that a single cell was 
being infected with both viruses with a silencing IE1 expression enabling productive 
dissemination. This showed that coinfection happens more frequently than expected 
and that there is “cross talk” between viruses that controls their gene expression. 
 While co-infection was able to rescue rMCMVIE1-vCXCL-1 salivary gland deficit, it 
was unable to disseminate to the salivary gland by itself. We speculated that vCXCL-1 
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was being expressed at an inappropriate time during the viral lifecycle and/or the 
chemokine was not being expressed at physiological levels (i.e., too high). This resulted 
in an abnormal inflammatory environment masking the normal cell type for 
dissemination to the SG. Therefore, in order to address the role of vCXCL-1 in MCMV 
pathogenesis, we sought to design a recombinant MCMV that had relevant vCXCL-1 
expression. To accomplish this, we linked the murine chemokine, MCK2, to the human 
vCXCL-1. This MCMV was created using a modification of bacterial recombination 
using CRISPR/CAS technology. The two proteins were linked with a 2A self-cleaving 
peptide. Upon translation the 2A peptide self cleaves resulting in two independent 
proteins, MCK2 and vCXCL-1. When mice were infected with rMCMV expressing 
vCXCL-1 at the same levels of MCK2 (hereafter referred to as rMCMV2A-vCXCL-1), there 
was a significant difference in the rate of primary and secondary dissemination. We 
speculated that neutrophils were responsible for the increased dissemination kinetics 
because our previous data showed effects of vCXCL-1 on neutrophils [12, 13] 
 One caveat to this hypothesis is that murine neutrophils have not been shown to 
be important in MCMV dissemination. Until our work, there was no evidence that MCMV 
interacted with the neutrophil. We demonstrate that the murine neutrophil is capable of 
harboring, transferring MCMV in vitro and in vivo, and initiating viral replication. To 
demonstrate that vCXCL-1 works via neutrophils to increase MCMV dissemination, 
neutrophils were depleted prior to infection with rMCMV2A-vCXCL-1 and the levels of 
MCMV in the organs was tittered. These experiments revealed that neutrophils 
responding to vCXCL-1 aid MCMV dissemination. However, this cell type is not the only 
cell type responding because neutrophil depletion did not return rMCMV2A-vCXCL-1 titers 
to WT MCMV levels.  As monocytes are major players in CMV dissemination [14-16] 
and could potentially respond to vCXCL-1 via CXCR2 [17, 18], the next logical step 
would be to deplete monocytes. Unfortunately, there is no efficient method to deplete 
monocytes [19]. Therefore, we used the highly immune deficient mouse line, NSG mice. 
NSG mice lack functional T cell, B cell, and natural killer cells. These mice also have 
defective macrophages and dendritic cells but still have functional monocytes. If 
neutrophils were not the major cell type responding to vCXCL-1, we hypothesized that if 
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viral dissemination of rMCMV2A-vCXCL-1 was still increased in NSG mice, it would point 
towards the monocyte responding to vCXCL-1. Surprisingly, when NSG mice were 
infected with rMCMV2A-vCXCL-1, 58% of the population died by day 12 post infection. All 
mice infected with rMCMVIE1-vCXCL-1 or WT MCMV survived. These results were not 
expected, but support the claim that vCXCL-1 is a virulence factor [20-22]. Interestingly, 
the salivary gland viral burden of NSG mice did not differ between the viruses. However, 
the viral burden within the primary dissemination organ, the spleen, was much greater 
for animals infected with rMCMV2A-vCXCL-1.  
 In conclusion, this work speaks to the need to reevaluate our approach when 
developing HCMV treatments. Currently, there is no effective vaccine for HCMV 
meaning there is a reliance on treatments. The current vaccines (i.e., soluble gB) seek 
primarily to inhibit viral entry. However, we demonstrate in chapter two that we are still 
in the dark about the mechanisms of viral entry in vivo.  Additionally, without an effective 
vaccine other antiviral targets need to be considered. In chapters three and four we 
show the impact vCXCL-1 has on viral dissemination and as virulence factor. We 
propose that vCXCL-1 should be targeted with vaccines or antivirals because reducing 
the rate of viral dissemination is always a win for the host.  
2. Future Directions 
Chapter 2 
I n this chapter we used heparan sulfate binding peptides to probe entry 
differences between in vivo-derived and in vitro-derived CMVs. While we identified 
novel differences between the two viruses, as well as a new appreciation of cell-to-cell 
spread, there are many questions that need to be answered moving forward.  
 
1. Now that we have developed a mechanism to produce large quantities of MCMV in 
vitro that mimics in vivo virus, we can analyze “in vivo” MCMVs that were previously 
impossible. One question remains as to whether these differences hold true for HCMV. 
There are a few ways this can be accomplished. First, we have large quantities of 
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supernatants from experiments where we infected human stem cells with HCMV. We 
believe that these supernatants contain virus that will have an in vivo phenotype 
because these are a primary cell line that produce them. The basis for this assumption 
is that BMDMs, a primary cell line, produced in vivo MCMV in vitro. A second avenue to 
obtain large quantities of in vivo like HCMV is using our collaborator’s protocol (Dr. 
Andrew Yurochko at LSU) to harvest human monocytes and subsequently differentiate 
them into macrophages. This approach is an attempt to mimic the experiment 
preformed with MCMV.  
2. The second aspect of in vivo vs in vitro derived virus differences is the ratios of 
glycoproteins found of the virion. The glycoprotein ratio affects the cellular tropism for 
HCMV [23]. We hypothesize that the ratio of glycoproteins differs between the two viral 
sources. We would approach our colleague, Dr. Josh Munger, who specializes in HCMV 
virion mass spectrometry to help us answer this question.  
3. As we discovered that cell-to-cell spread occurs independently of heparan sulfate 
usage, we question whether this event could progress independent of the viral 
glycoproteins present in the virion. Because we have developed a system to create 
mutant viruses, we can systematically knockout various MCMV glycoproteins following 
the direction of previously conducted research [24] and evaluate whether or not cell-to-
cell spread takes place independently of specific viral glycoproteins. This information 
will be of the upmost importance when designing future CMV treatments.  
4. An alternative hypothesis to explain the differences between in vitro- and in vivo-
derived viruses, is that there is a difference between the way the viruses are packaged 
upon exit. Recently, HSV-1 was shown to be able to spread via microvesicles (MVs) 
[25]. Additionally, HCMV infected cells release MVs that carry glycoproteins [26]. These 
are small vacuole like particles that are normally secreted from healthy cells. MVs carry 
proteins and other information between cells. Therefore, it is possible that CMVs are 
being packed into MVs and hijacking this normal process in vivo. While many cells, 
even tissue culture cells, secrete MVs, our hypothesis is that primary cell lines have not 
lost the ability to secrete the right kind of MVs in which CMVs could be packaged. This 
hypothesis can be tested with differential centrifugation. The isolated MVs could then be 
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plated on an uninfected monolayer to determine whether or not they carry infectious 
virus. Additionally, transmission electron microscopy could be carried out on isolated 
MVs to observe virons inside of MVs as conducted previously with HSV-1 [25].  
Chapter 3  
In chapter three we began evaluating the in vivo function of vCXCL-1. Many of the 
future directions for chapter three were accomplished in chapter four or will be 
discussed there, but there are still interesting questions deserving answers from this 
work.  
1. First, are the rMCMVs expressing vCXCL-1 under the control of the HCMV IE1 
promoter not disseminating to the salivary gland or are the viruses being cleared from 
the organ more quickly than normal? It appears from data that these viruses at least 
make it to the salivary gland, however they disappear by day 14, when salivary gland 
viral burden is at its peak. This likely indicates that the virus is being cleared 
prematurely. The premature clearance is more likely due to the abnormal chemokine 
expression, which is recruiting a cell type that is competent at viral clearance (e.g. 
natural killer cell). We have preliminary data indicating a large influx of natural killer cells 
into the salivary gland 7 days post infection. However, this experiment was only 
conducted once. Biological replicates are needed to determine if this phenotype holds 
true.  
2. Viral burden and persistence within the host impact the virus's ability to enter latency 
[15]. Therefore it will be interesting to evaluate whether these viruses are capable of 
entering latency and whether they can reactivate.  
Chapter 4 
In chapter four we developed a new method to generate recombinant MCMVs. With this 
technology we were able to generate rMCMVs, which expressed HCMV's vCXCL-1 in 
tandem with MCMVs chemokine MCK2.  
1.Our viral genetic system works, but it is not highly efficient. We propose two ways to 
increase its efficiency. 1)  Increase recombination efficiency by plating the transformants 
 
 
154 
on MacConkey agar that contains 1% galactose (not lactose) plus kanamycin and 
chloramphenicol. We use a forward and back selection recombination strategy.  The 
forward selection on galatose and a CRISPR/CAS system targeting the GalK gene for 
back selection. By plating the backwards selection on MacConkey agar containing 
galactose, kanamycin (for the cas9 plasmid) and chloramphenicol (for the bacterial 
artificial chromosome), colonies that ferment galactose turn pink. The colonies that have 
undergone recombination will remain translucent (GalK-). This process should expedite 
the screening process. 2)  Plating the back selection on M63 media containing 0.2% 2-
deoxy-galactose (DOG), 0.2% glycerol, kanamycin and chloramphenicol should also 
help with selection of the rMCMV. The DOG generates a toxic intermediate when GalK 
is present. This is the normal protocol for back selection, however it has not worked for 
us. The inclusion of the kanamycin in the DOG media ensures the Cas9 plasmid 
targeting the GalK gene is maintained. This further puts pressure on the bacteria to 
under go recombinantion as this bacterial cell is recA- and cannot repair double 
stranded breaks.  
2. We show that neutrohpils can harbor and initiate MCMV replication, so it will be 
interesting to identify whether or not this cell type is capable of productive viral 
replication. Studies looking at HCMV and the neutrophil indicate that this cell type in not 
capable of productive replication [27, 28], but this has not been evaluated in the mouse. 
Additionally these studies have all been conducted ex vivo. We hypothesize that the 
neutrophil can productively replicate CMV in vivo. We propose two experiments to test 
this hypothesis. First, using our previously described thioglycollate model, at 20 hours 
post infection the peritoneal exudate should be harvested and neutrophils purified with 
aLy6G microbeads. Total RNA will need to be extracted from the purified neutrophil 
population and RT-qPCR should be conducted on the late gene pp65. The second 
method to evaluate this hypothesis is to harvest spleens from infected animals 5 days 
post infection, purify neutrophils from spleens, and harvest total RNA. The drawback of 
both these experiments is that there are low neutrophil counts at the harvest locations at 
time of harvest. This means that more than fifteen mice should be used for each 
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experiment. Elucidating the murine neutrophil's capacity for productive MCMV 
replication is an important question that needs an answer. 
3. We generated a rMCMV that expresses vCXCL-1 from the virulent Toledo strain. 
Previously we have demonstrated that vCXCL-1s from different HCMV strains vary in 
the ability to activate and attract immune cells [12]. Therefore, it will be interesting to 
make MCMVs that express vCXCL-1s from other strains (e.g. Towne and Texas 15). 
These new rMCMVs should then be introduced into mice and dissemination kinetics 
and virulence in the NSG model should be analyzed. Because vCXCL-1 is variable [12] 
and thought to be a virulence factor [20, 22], it will be important to compare these 
different vCXCL-1s in our experimental setups.  
4. We were not able to identify the cellular culprit behind the increased viral 
dissemination of these recombinant MCMVs. Data indicates that the monocyte might be 
the cell type responding to vCXCL-1 and increasing dissemination, but there is no 
concrete evidence supporting this claim. It will be interesting to further study the 
interaction between vCXCL-1 and the monocyte. These analyses could lead to 
importance of CMV infections in diseases such as atherosclerosis. Monocytes 
stimulated via CXCR2 in the blood stream differentiate into macrophages [17]. 
Macrophages contribute to atherosclerotic plaque formation. The analysis of the 
interaction between monocytes and vCXCL-1 could open the door to many of other 
research avenues.  
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Appendix I: Where The Story Started: Thioglycollate Administration 
Prior To MCMV Infection Increase Viral Dissemination  
 
Abstract 
Innate immune cells (i.e. macrophages, dendritic cells, and neutrophils) are essential for 
systemic cytomegalovirus dissemination. Human cytomegalovirus (HCMV) encodes a 
viral chemokine, vCXCL-1, which preferentially attracts neutrophils, leading to the 
hypothesis that neutrophils aid HCMV dissemination. Neutrophils harbor and transfer 
infectious HCMV. Unfortunately, murine cytomegalovirus (MCMV) does not naturally 
encode vCXCL-1 thereby limiting the effectiveness of the murine model for studying 
vCXCL-1 in vivo. Using MCMV infection of mice a surrogate for HCMV infection, we 
demonstrate that artificially inducing a neutrophil response at the site of infection is 
sufficient to enhance MCMV dissemination.   
1. Introduction 
Neutrophils are a vital antimicrobial innate immune cell. They mature in the bone 
marrow and upon stimulation of CXCR2, egress from the bone marrow [1]. After 
entering into the blood stream, neutrophils patrol for pathogens. While neutrophils are 
generally thought to be simple, short lived phagocytes, there is growing evidence 
suggesting that neutrophils are more complex than initially thought. For example, 
neutrophils can transport antigen to the bone marrow and stimulate a memory CD8+ T 
cell response [2].  Also, despite its antimicrobial functions, neutrophils can serve as 
“Trojan horses” during leshmania infection and West Nile virus infection [3, 4]. Based in 
these findings and the production of a neutrophil attracting chemokine, our hypothesis is 
that HCMV uses the neutrophil for viral dissemination. 
HCMV causes disease in immunocompromised persons. This can be due to 
primary infection or spontaneous latent virus reactivation [5, 6]. HCMV disease in the 
immunocompromised population can manifest as mononucleosis-like symptoms, 
interstitial pneumonia, gastroenteritis, retinitis, or organ transplant rejection [7-9]. HCMV 
is also a leading cause of congenital disease [10, 11]. After in utero infection, newborns 
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can present with microcephaly or more long term sequelae including progressive 
deafness, mental retardation and learning disabilities later in life [10, 12]. Regardless of 
the circumstances, HCMV disease is due to dissemination and inflammation.  
With millions of years of host/pathogen coevolution HCMV has developed 
numerous strategies to modulate the host’s adaptive and innate immune responses. It 
has evolved to not only quell inflammation but also to induce inflammation [5, 13, 14]. 
HCMV produces a viral chemokine, vCXCL-1, that is capable of inducing an innate 
immune response through activation of the chemokine receptors, CXCR1 and CXCR2 
[15, 16]. Chemokines, are small chemoattracting and activating proteins that initiate 
signalling cascades and induce migration of immune cells into lymphoid tissues and 
areas of inflammation or infection [17]. Both natural killer (NK) cells and neutrophils 
functionally respond to vCXCL-1. However, our lab as well and others have shown that 
vCXCL-1 preferentially attracts CXCR2+ neutrophils over CXCR1+ NK cells [15, 16]. This 
information, coupled with in vitro observations indicating neutrophils are capable of 
harboring infectious HCMV, begs the question as to whether or not neutrophils function 
as viral dissemination vehicles in vivo [18, 19].  
Studies evaluating the interaction between HCMV and neutrophils have been 
limited to in vitro analysis. CMVs are highly species specific, thus not all CMVs have 
evolved to produce the same immunomodulatory proteins [5]. For example, HCMV 
produces a viral chemokine, vCXCL-1, which targets CXCR2, however MCMV has 
evolved a CC viral chemokine, MCK2, which is hypothesized to function through the 
chemokine receptor, CX3CR1 [15, 20]. MCMV elicits dendritic cells, macrophages, and 
inflammatory monocytes through this receptor [20-22]. Once the innate immune cells 
arrive at the MCMV infection site, the virus hijacks the innate cell and uses it as a 
dissemination vehicle [20-22]. We hypothesize that HCMV uses a similar mechanism to 
achieve systemic dissemination. We have developed an in vivo model to test this 
hypothesis. Using an inflammation model targeting neutrophilic inflammation, we 
demonstrate that an innate immune response at the infection site is sufficient to alter 
normal dissemination kinetics.  
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2. Results and Discussion 
 As MCMV does not encode a neutrophil specific chemokine we sought to mimic 
the function of vCXCL-1. We accomplished this by implementing the thioglycollate 
inflammation model. We speculated that eliciting a neutrophil response at a specific 
location followed by MCMV infection, would alter MCMV dissemination kinetics 
compared to non-thioglycollate treated animals. Thioglycollate is typically used for 
murine macrophage induction [23] but it can also be used to obtain large quantities of 
neutrophils [24].  At peak neutrophil response (4 hours) as well as peak macrophage 
response (4 days) (data not shown) mice were infected i.p. with MCMV. Five days post 
infection, viral burden in primary dissemination organs (i.e., spleen and lung) was 
measured via plaque assay (Figure A1.1). Typically, between days four and five post 
infection is when viral titers in primary dissemination organs peak. Infecting animals 
during peak neutrophil response (4 hr Thio) resulted in a log difference in viral burden in 
both the spleen (Figure A1.1A) and the lung (Figure A1.1B). However, when infection 
was given during peak macrophage (4 day Thio) the viral titers in both organs were 
comparable to non-thioglycollate treated(NT) controls. This data suggests that 
neutrophils or another innate immune cell responding quickly to an inflammatory 
stimulus to promote primary dissemination. Thioglycollate treatment did not alter 
secondary dissemination kinetics (Figure A1.1C).  Also as a control, mice were infected 
with MCMV and two hours later administered thioglycollate (Figure A1.2). When mice 
were infected prior to thioglycollate treatment there was no difference in primary 
dissemination. This data indicates that there must be an active inflammatory response 
at the time of viral release or infection in order alter normal dissemination kinetics. This 
work laid the foundation for chapter four of the dissertation and was the first indication 
that neutrophils are capable of aiding MCMV dissemination. 
 Since there was an increase in MCMV primary dissemination when mice were 
treated with thioglycollate prior to infection we hypothesized that the presence of a 
functional MCK2 chemokine would not enhance the effect observed in (Figure A1.1). 
We used previously generated recombinant MCMVs to investigate the impact of MCK2  
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 Figure A1.1. Early thioglycollate administration increases MCMV primary 
dissemination . 
MCMV was administered during peak neutrophil response (4 Hr Thio.), peak 
macrophage response (4 Day Thio.), and in an unperturbed system (NT).  Primary 
dissemination organs spleen (A) and lung (B) were harvested 5 days post infection. (C) 
Secondary dissemination was kinetics were determined by harvesting salivary glands of 
infected mice at indicated time points. Viral burden was determined by plaque assay of 
whole organ homogenates. Data is a representation of n=3 with 4-5 mice per 
experimental group. Each data point is an individual mouse.  Horizontal bars respresent 
the average of the mice in the group +/- SD.  Statistical significance was determined by 
tukey's one-way ANOVA and multiple comparison of means. ****: p=<0.0001. DL= 
Detection limit. PFU= plaque forming unit. 
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Figure A1.2 Infection prior to thioglycollate treatment does not impact viral 
dissemination.  
Recombinant RM4511 was administered 2 hours prior to treatment with thioglycollate. 
Five days post infection spleens were harvested from infected animals and assayed for 
viral burden via plaque assay. Statistical significance was determined by unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
Th
io NT
1×101
1×102
1×103
1×104
Treatment
vi
ru
s 
tit
er
 
(p
fu
/g
ra
m
 o
f t
is
su
e)
ns
 
 
165 
in the context of our thioglycollate inflammation model [25]. The recombinant MCMV 
RM4503 has a functional MCK2 protein, while RM411 has a mutation in the CC domain 
of the MCK2 chemokine. These two viruses were used to infect mice treated with 
thioglycollate during the peak neutrophil response. Figure 1.3 demonstrates that when 
MCK2's CC domain is intact there is a significant difference in primary MCMV 
dissemination kinetics in our thioglycollate inflammation model. This is the first 
observation that MCK2 contributes to primary MCMV dissemination.  
The results generated in this small study indicate that infection of the recruited 
neutrophil population increases the rate of dissemination to primary dissemination 
organs. Also the data generated from the RM4503/RM4511 experiment serve as an 
unexpected experimental control. Thioglycollate treatment enhances the permeability of 
the peritoneal endothelium. Therefore it is possible that the increase in viral 
dissemination could be due to virus leaking out of the peritoneal cavity. If this were the 
reason there was an increase in viral dissemination there would not be a difference 
between the animals treated with thioglycollate then infected with either RM4503 or 
RM4511. Lastly, the data indicating that there is a difference between dissemination 
kinetics of RM4503 and RM4511 opens a new door for CMV research. As there is not 
typically a difference in primary dissemination of these two viruses it will be interesting 
to elucidate why there is a difference when infection is introduced in a highly 
inflammatory environment.  
 
 
 
 
 
 
 
166 
 
 
Figure A1.3. MCK2 impacts primary dissemination when paired with the 
thioglycollate inflammation model.  
Recombinant MCMVs , 4503 and 4511 were administered during peak neutrophil 
response (4 Hr) and in an unperturbed system (NT).  Primary dissemination organs 
spleen (A) and lung (B) were harvested 5 days post infection. Viral burden was 
determined with a plaque assay of whole organ homogenates. Data is a representation 
of n=1 with 5 mice per experimental group. Statistical significance was determined by 
tukey's one-way ANOVA and multiple comparison of means. ****: p=<0.0001 ** = p £ 
0.01. PFU= plaque forming unit. 
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3. Materials and Methods  
Cells and Viruses   
MEF 10.1 cells (ATCC) were propagated in DMEM supplemented with 10% FCIII and 
1% P/S and L-Gln.  The parental MCMV strain used in this study was MCMV RM4511, 
[25] which has a 1.7 kb puromycin-green fluorescent protein (GFP) cassette inserted 
into the ie2 region and a double point mutation in the m131 gene resulting in a 
nonfunctional MCK2 protein [25]. RM4503 is similar to 4511 except with wild-type mck2 
[25].  These virusese were obtained from Dr. Edward Mocarski, Emory University.  
 
Mice  
Initially, mice that over express human CXCR2 (hCXCR2) or replace the murine CXCR2 
(mCXCR2) gene with the human CXCR2 (hCXCR2) gene were used [26]. There was 
concern that vCXCL-1CCMV might not stimulate mCXCR2 as seen with vCXCL-1Tol.  The 
hCXCR2 transgenic BALB/c mice express the hCXCR2 gene under the control of the 
neutrophil-specific, human myeloid related protein-8 promoter.  These are named 
hCXCR2 transgenics. Additionally mice that have normal expression levels of hCXCR2 
[27] in all the appropriate murine cell types were used and the same phenotype was 
observed. 
 
Plaque formation assay  
MEF 10.1 cells were used to determine viral titers in the organs. Briefly MEF 10.1 cells 
were plated in a 6 well dish.  Organs were harvested and homogenized. The 
homogenate was serially diluted and added the MEF 10.1 cells and incubated for 1 hr. 
After incubation the diluted virus was removed and cells were overlayed with carboxy 
methyl cellulose (CMC) media and incubated for 7 days. At the end of the incubation 
period, CMC was removed and plates were stained with Coomassie blue and plaques 
counted. 
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Thioglycollate inflammation model 
Thiglycollate induced peritoneal inflammation was carried out as previously described 
[23]. Briefly, mice were injected with 3% Brewer’s thioglycollate (BD). 4 hours or 4 days 
post injection mice were infected with 1x106 PFU of MCMV.  
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Appendix II: Defining "Wild Type"  
 
Abstract  
Human cytomegalovirus (HCMV) is a ubiquitous beta-herpes that is a significant 
pathogen within immune compromised populations. In order to study the virus more in 
depth without passage induced mutations, the entire CMV genome was inserted into a 
bacterial artificial chromosome (BAC). Once in a BAC, elegant mutations within the 
CMV genome can be generated relatively efficiently to study CMV infection. BACs, in 
theory, are highly stable plasmids with exceptionally low mutation rates. In this study, 
we provide a cautionary tale highlighting the limitations of using BACs for CMV 
generation.. 
 
1. Introduction  
Cytomegaloviruses are a species-specific herpes virus. In immune deficient 
human adults the virus can cause gastroenteritis, retinitis, and transplant rejection [1-3]. 
HCMV is also the leading cause of infectious congenital disease. Infection in utero can 
lead to microcephaly and sequelae (e.g. progressive deafness and mental disabilities) 
[4-7]. Due to the afore mentioned species specificity, it is not possible to study HCMV in 
an animal model. This has led to the use of model systems such as chimpanzee CMV, 
guinea pig CMV, and mouse CMV to study viral characteristics and extrapolate them to 
HCMV.  
A common model used to study CMV dissemination is mouse CMV (MCMV) 
infection of mice. The mouse is an attractive model as it has a well characterized 
immune system, and there are numerous tools available to investigate specific immune 
cell contributions to viral dissemination [8]. MCMV was also the first CMV virus to be 
cloned into an artificial chromosome [9]. After the initial cloning into the BAC there have 
been numerous issues with the BAC itself. The first MCMV BAC was missing 10kB of 
the 233kB genome. This large deletion was reinserted in 1999 [10]. However for an 
unknown reason the portion of the genome used for the reinsertion was not from the 
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parental MCMV stain. For over a decade this first BAC created was less virulent than 
other CMV stains and no one knew the reason. However, In 2011 a point mutation 
introducing a premature stop codon was found in the MCK2 coding region [11]. MCK2 is 
important for CMV dissemination and entry [12, 13]. Finding this needle in the haystack 
of MCMVs 233kB genome was a phenomenal discovery. This is even more impressive 
because the point mutation was found using classical sanger sequencing.  
We report unexpected results generated during BAC/MCMV generation. Other 
MCMV BACs have been made which would allow a comparison with original Messerle 
BAC. Our lab has previously used an MCMV BAC called the "Redwood BAC" which is a 
different strain from the Smith BAC [14]. However, we switched to the original Messerle 
BAC for chapter four of this dissertation which we refer to as SmithBAC here. We 
created the recombinants used in chapter four on this BAC. However, the wild type 
MCMVs produced from the BACs were attenuated compared to published literature [15-
18]. Because of this we asked our collaborator to resend us the SmithBac. The second 
SmithBac sent produced MCMVs that phenotypically matched published results. So the 
question remained, “What happened during propagation?” 
2. Results and Discussion  
 In order to find out what has happened between the first shipment of Smith BAC 
and the second version sent to us (V2SmithBAC), mice were infected with the different 
viruses and the titers in the lymph nodes measured (figure A2.1A). These two viruses 
should be identical. However V2SmithBAC, reaches a three log higher titer in the lymph 
node when compared with the original BAC (SmithBAC). This “attenuated” BAC (i.e., 
SmithBAC) was used to generate all of the recombinants in chapter four of this 
dissertation. This raised concerns for the data generated for this paper.    
Because we preformed the appropriate controls by reintegrating the native gene into the 
mutant virus (i.e., ‘rescued’ viruses), we were able to use the data for publication. Figure 
4.4 in the previous chapter indicates that virus with the reintegrated native gene 
matches the wild-type (SmithBAC) virus for all aspects of viral dissemination. Therefore 
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Figure A2.1. Lymph node viral burden of different wild-type MCMVs.  
Mice were infected via footpad (FP) with 1x106 PFU of either SmithBac (SB), 
V2SmithBac, and recombinant MCMVs. Plaque assays were performed on lymph 
nodes harvested 3 days post infection. (A) Comparison of SmithBac and V2SmithBac 
lymph node  titers. (B) Lymph node burden of recombinant viruses made on 
V2SmithBac and the parental V2SmithBac. 
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the phenotype observed is due to the expression of vCXCL-1 from the recombinants we 
created.  
 Although this information allowed for publication, these two versions of these 
viruses differ. In order to find out the differences, we performed whole genome 
sequencing on viral DNA from SmithBAC and V2 SmithBAC. Using Illumina 
NextSeq500 platform per Illumina’s standard protocol for a1.7 megabase genome at 
100x coverage. Therefore, we should have had over 500x genome coverage. 
Unfortunately, the results obtained from sequencing were inconclusive. The viral 
preparations were contaminated with genomic mouse DNA so out of the 2 million reads 
that were generated, only approximately 300,000 reads mapped to the reference MCMV 
genome. This results in roughly 100x coverage. With this read depth, we should have 
been able to identify SNPs. However, technical replicates did not contain identical SNPs 
meaning that the SNPs were due to inadequate coverage and not real differences in 
their genomes. We concluded that we are unable to identify a genetic reason for the 
dramatic difference between SmithBAC and V2SmithBAC dissemination.  
 Because of the defect in SmithBAC, we remade all recombinants on 
V2SmithBac. In examining the recombinants and rescued MCMVs dissemination, we 
found that all viruses generated on V2SmithBAC (SB labels) do not match the original 
wild-type (i.e., V2SmithBAC) (Figure A2.1B). It appears that the recombinants now 
match the titers of SmithBAC and NOT V2SmithBAC.  These results point to some 
modification during a step in our protocol which in induces these changes.  
 The virus generated from the V2SmithBac was directly isolated from a strain of 
e.coli our collaborator used to house the BAC. All other viruses were harvested from the 
SW105 strain of e. coli. Meaning that the BACs had to be transformed into the SW105 
strain. This process could have induced mutations in the BAC, however the likelihood 
that the same mutation occurred in both situations by random is low. We are trouble 
shooting our protocols to identify potential reasons for the observed phenotype.   
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3. Materials and Methods  
Cells and Viruses   
MEF 10.1 cells (ATCC) were propagated in DMEM supplemented with 10% FCIII and 
1% P/S and L-Gln. The Smith stain MCMV was used for these studies. The virus was 
derived from the pSM3fr-MCK2-2fl [11] [10]. This BAC was a generous gift from Dr. 
Chris Benedict. The mutant viruses created in this study were engineered in the same 
way as the viruses in chapter four. These viruses contain the UL146 genes from the 
HCMV strains Toledo and Towne.  
 
Mice  
Initially, mice that over express human CXCR2 (hCXCR2) or replace the murine CXCR2 
(mCXCR2) gene with the human CXCR2 (hCXCR2) gene were used [19]. There was 
concern that vCXCL-1CCMV might not stimulate mCXCR2 as seen with vCXCL-1Tol.  The 
hCXCR2 transgenic BALB/c mice express the hCXCR2 gene under the control of the 
neutrophil-specific, human myeloid related protein-8 promoter.  These are named 
hCXCR2 transgenics. Additionally mice that have normal expression levels of hCXCR2 
[20] in all the appropriate murine cell types were used and the same phenotype was 
observed. 
 
Plaque formation assay  
MEF 10.1 cells was used to determine viral titers in the organs. Briefly MEF 10.1 cells 
were plated in a 6 well dish.  Organs were harvested and homogenized. The 
homogenate was serially diluted and added the MEF 10.1 cells and incubated for 1 hr. 
After incubation the diluted virus was removed and cells were overlayed with carboxy 
methyl cellulose (CMC) media and incubated for 7 days. At the end of the incubation 
period, CMC was removed and plates were stained with Coomassie blue and plaques 
counted. 
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Sequencing and Genome Assembly 
Sequencing was conducted as previously described [21]. Genome assembly was 
conducted with Geneious ver 11.1.5. Briefly, 150x150 paired end Illumina sequencing 
reads were mapped to the C5X reference genome (SmithBAC). SNPs and other 
mutations were identified using the Geneious software.  
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Appendix III:  Understanding the Difference Between In Vivo and In 
Vitro-Derived MCMV 
 
Abstract  
Murine cytomegalovirus (MCMV) is a useful model to study human cytomegalovirus 
(HCMV) processes such as viral entry and dissemination. Here we use MCMV to study 
the differences between entry mechanisms of in vivo and in vitro-derived virus. By using 
carbohydrate binding lectins we confirm previous findings that these two viruses utilize 
different entry processes. Second we show that these two types of viruses have 
different carbohydrate specificities. Last, using murine knockout cell lines lacking the 
ability to produce certain heparan sulfates we have begun the process of mapping 
MCMVs heparan sulfate usage. This work helped to lay the foundation for chapter two 
as well as a springboard for our lab to launch into a new research area.  
 
1. Introduction  
HCMV is a ubiquitious b-herpes virus that infects roughly 70-90% of individuals 
by adulthood [1]. The virus is typically asymptomatic in healthy immune competent 
individuals [2]. However, immuncompromised persons are more like to be subjected to 
the morbidity associated with viral infection. Disease can manifest itself as 
mononucleosis-like symptoms, interstitial pneumonia, gastroenteritis, retinitis, or organ 
transplant rejection [3-5] and be the consequence of a primary infection or spontaneous 
latent virus reactivation [6]. HCMV is also the leading cause of infectious congenital 
disease [7, 8].  During in utero infection, fetal abnormalities such as microcephaly can 
emerge and sequelae like progressive deafness, mental retardation and learning 
disabilities [7, 9].  Regardless of adult or fetal HCMV disease, it all begins with entry into 
a susceptible cell and subsequent dissemination [10].  
Cytomegaloviruses are species specific [2]. This means that they only replicate 
within their respective host (e.g. mouse, equine, chimpanzee) [11-13]. Since many 
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HCMV infections are asymptomatic [1],   research on HCMVs isolated directly from 
infected persons is limited. This is due to the inability to harvest large amounts of virus 
directly from the host. Most research requires either in vitro growth of the clinical 
isolates or an animal model.  The MCMV infection of mice was actively used to 
demonstrat the differences between in vivo and in vitro derived virus until about 1990 
[14-17]. Since then, there has been very little published work on this aspect. Here we 
revisit the last work conducted by Ravindranth and Graves and expand on it to evaluate 
the differences between in vitro and in vivo-derived MCMV.  
2. Results and Discussion  
  Antiviral peptides showed differences between in vitro and in vivo-derived 
MCMVs. These phenotypes are similar to differences found using lectins [17].   Figure 
A3.1 confirms previous reports in which salivary gland virus (SGV)  (Figure A3.1B) is 
largely resistant the effects of lectin inhibition. However, (Figure A3.1A) numerous 
different lectins inhibit in vitro or tissue culture virus (TCV) . The one exception is wheat 
germ agglutinin (WGA).  It can potently inhibit both SGV and TCV.  
 Because WGA's primary sugar specificity is N-acetylgucosamine (GlcNAc) and it 
blocked both viruses, we incubated both TCV and SGV with 1 uM GlcNAc (Figure 
A3.2). Viral treatment with this sugar did not substantial decrease viral infectivity of 
either virus. These data contradict what has been reported in [17] and also what was 
expected based on Figure A3.1.  GlcNAc treatment of these viruses induced a 10% 
inhibition of infection of SGV and a 30% inhibition of TCV. Our results using GlcNAc 
prompted us to try to inhibit MCMV infection using other carbohydrates. We chose 
sorbitol and sucrose because sorbitol gradients are commonly used to purify CMV. Also 
we have previously used a sorbitol gradient to purify SGV and the SGV phenotype was 
albated (data not shown).  In this case, the SGV functioned identically to TCV in regards 
to antiviral peptide inhibition as described in chapter two. We hypothesized that the 
sucrose and sorbitol used to purify the virus was binding to glycoproteins on the virion 
and inhibiting viral infection. To test this, TCV or SGV was incubated with sorbitol or  
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Figure A3.1. Lectin inhibition of TCV-and SGV-derived MCMV  
Lectin inhibition of TCV-(A) and SGV-derived MCMV (B) infection. Data represents 1-2 
experiments with three replicates per experimental condition. Data is normalized to PBS 
treated controls.  
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Figure A3.2. N-acetylgucosamine inhibition of MCMV TCV and SGV 
Data represents one experiment with three replicates for each virus type. Data is 
normalized to PBS treated controls (not shown).  
 
sucrose and inhibition of infection was measured.  Figure A3.3A indicates that TCV is 
slight inhibited with sucrose, while treatment with sorbitol was less so.  Curiously 
treatment with both sugars together increases infectivity compared with sucrose alone 
implying “interference” with sucrose inhibition. Surprisingly, SGV responded almost the 
exact opposite, SGV is not inhibited with sucrose but is inhibited by sorbitol and both 
sugars together (Figure A3.3B).  This points to differences in viral entry, which is similar 
to our findings with anti-CMV peptides. 
 From these data we speculated that the MCMVs were using different heparan 
sulfates for viral entry depending on the source of the virus (i.e., salivary gland vs tissue 
culture grown). Virion docking to heparan sulfates begins CMV’s viral entry process 
[18]. In order to investigate the specificity of this step, we generated heparan sulfate 
knockout lines. We made two MEF 10.1 lines, which lack either the enzyme NDST2 or 
HS2ST using CRISPR technology. The NDST2 mutants will have a decreased sulfation 
pattern and are unable to synthesize heparan [19]. However NDST1 is able to 
compensate for NSDT2's function making this line less specific [19].  The other line that 
knockouts out HS2ST, lacks 2-O sulfations and has a corresponding increase in N-
linked and 6-O sulfations [19]. Figure A3.4 demonstrates TCV is substantially inhibited 
in its ability to infect these knockout cell lines. The next step is to repeat these  
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Figure A3.3. Sucrose and sorbitol inhibition of MCMV TCV and SGV.  
MCMV (TCV (A) and SGV (B))was incubated for one hour with indicated carbohydrate 
and the % infection calculated based on PBS treatment. Data represents one 
experiment with three replicates per experimental condition. Statistical significance was 
determined by one way ANOVA with Tukey’s multiple comparison of means. Bars 
represent the average titers +/- STD. . * = p £ 0.05; **** = p £ 0.0001.  ns = not 
significant.  
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Figure A3.4. Knockout cell line susceptibility to MCMV TCV infection.  
Indicated cells lines were infected with ~100 PFU MCMV TCMV. Infection was 
normalized to wild type cell line (MEF 10.1). Date represents 3-5 experiments with 3 
replicates per experimental group. Statistical significance was determined by one way 
ANOVA with Tukey’s multiple comparison of means. Bars represent the average titers 
+/- STD. . *** = p £ 0.001; **** = p £ 0.0001.  
 
 
 
 
 
 
 
 
ME
F 1
0.1
ΔN
DS
T2
ΔH
S2
ST
0
50
100
150
Cell Line
%
 In
fe
ct
io
n 
N
or
m
al
iz
ed
 
to
 W
ild
 T
yp
e 
C
el
l L
in
e
***
****
 
 
185 
experiments with SGV. Additionally, further knockouts in the heparin sulfate pathways 
(as well as combinatorial knockouts) would allow us to further map which pathways are 
important for TCV vs. SGV infectivity.  
 In this appendix we focus on entry of MCMVs either derived in vitro or in vivo. We 
highlight that there are different entry mechanism between these two  
TCV's capacity to efficiently entry susceptible cell types. It will be interesting to repeat 
these assays and evaluate whether or not SGV produces the same phenotype 
 
3. Materials and Methods  
Cells and Viruses   
MEF 10.1 cells (ATCC) were propagated in DMEM supplemented with 10% FCIII and 
1% P/S and L-Gln.  The parental MCMV strain RM4503, [20] which has a 1.7 kb 
puromycin-green fluorescent protein (GFP) cassette inserted into the ie2 region This 
virusese were obtained from Dr. Edward Mocarski, Emory University.  
 
 
Plaque formation assay  
MEF 10.1 cells was used to determine viral titers in the organs. Briefly MEF 10.1 cells 
were plated in a 6 well dish.  Organs were harvested and homogenized. The 
homogenate was serially diluted and added the MEF 10.1 cells and incubated for 1 hr. 
After incubation the diluted virus was removed and cells were overlaid with carboxy 
methyl cellulose (CMC) media and incubated for 7 days. At the end of the incubation 
period, CMC was removed and plates were stained with Coomassie blue and plaques 
counted. 
 
Lectin plaque reduction assay 
An uninfected monolayer of MEF 10.1 cells were incubated with various lectins at 
20ug/mL for one hour at 4°C. The lectins were diluted in phosphate buffered saline 
(PBS) with 10% FBS and 0.05% BSA. Following this incubation, lectins were removed 
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and cells washed with PBS. The lectin treated monolayer was then infected with ~100 
plaque forming units of MCMV. The remaining experiments follows the plaque formation 
assay as described above.  
 
Lectin panel 
Lectins were purchased from Vector Laboratories: Conconavalin A(ConA), Dolichos 
biflorus agglutinin (DBA), Peanut agglutinin (PNA), Soybean agglutinin (SBA), Ulec 
Europaeus agglutinin I (UEA), Wheat germ agglutinin (WGA). Lectins purchased from 
EY Laboratories: Trichosanthes kirilowii (TKA), Wisteria floribunda (WFA), Amaranthus 
caudatus (ACA), Cancer antennarius (CAC).   
 
Carbohydrate mediated viral inhibition assay 
Concentrated TCV or SGV MCMV was incubated with the indicated carbohydrate 
concentrations for one hour. The virus was then diluted to ~100 PFU and a plaque 
assay was performed.  
 
CRISPR/Cas9 mediated knockout of heparan sulfates  
Guide RNAs were inserted into the lentiCRISPRv2 plasmid (Addgene) via standard 
protocol (see addgene website). gRNAs were deigned using the AUTM gRNA tool. 
Following sequence verification by Sanger sequencing, the lentiCRISPRv2 was 
transfected into MEF 10.1s via Turbofect (Thermofisher). MEFs were kept under 
puromycin selection (Sigma). Genomic DNA was isolated from the cell lines and gene 
knockout was confirmed via PCR.  
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Appendix IV: Identifying Unmasking of C. albicans with 
Flowcytometry in Collaboration with Dr. Todd Reynolds     
 
This appendix is the result of two publications by the titles:  
 
1) Candida albicans Cannot Acquire Sufficient Ethanolamine from the Host To Support 
Virulence in the Absence of De Novo Phosphatidylethanolamine Synthesis. published in the 
journal Infection and Immunity in 2018 by Sarah E. Davis, Robert N. Tams, Norma V. 
Solis, Andrew S. Wagner,  Tian Chen,  Joseph W. Jackson,  Sahar Hasim,  Anthony E. 
Montedonico,  Justin Dinsmore, Timothy E. Sparer, Scott G. Filler, and Todd B. 
Reynolds. 
 
Davis SE, Tams RN, Solis N, Wagner AS, Chen T, Jackson JW, Hasim S, 
Montedonico AE, Dinsmore J, Sparer TE, Filler SG, Reynolds TB. Candida albicans 
cannot acquire sufficient ethanolamine from the host to support virulence in the absence 
of de novo phosphatidylethanolamine synthesis. Infect Immun. 2018. doi: 
10.1128/IAI.00815-17. PubMed PMID: 29866908. 
 
2) Exposure of Candida albicans β (1,3)-glucan 1 is promoted by activation of the Cek1 
pathway. Published in the journal PloS Genetics by Tian Chen, Joseph W. Jackson, 
Robert N. Tams, Sarah E. Davis, Timothy E. Sparer, Todd B. Reynolds 
 
Chen T, Jackson JW, Tams RN, Davis SE, Sparer TE, Reynolds TB. 2019. Exposure 
of Candida albicans beta (1,3)-glucan is promoted by activation of the Cek1 pathway. 
PLoS Genet 15:e1007892. 
 
My contribution to this work capitalized on my expertise in flow cytometry. I assisted in 
generating a data pipeline for Dr. Todd Reynolds. My contributions to the first 
manuscript can be found in figure 7. And my contribution to the second manuscript can 
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be found in figures 3, 6, 8, and a portion of the manuscript's supplemental information. 
The abstracts from both articles can be found below. As these manuscripts house a 
substantial amount of information. Here I will provide insights used for data acquisition 
and analysis.  
 
Abstract: Candida albicans Cannot Acquire Sufficient Ethanolamine from the 
Host To Support Virulence in the Absence of De Novo Phosphatidylethanolamine 
Synthesis  
 
Candida albicans mutants for phosphatidylserine (PS) synthase (cho1ΔΔ) and PS 
decarboxylase (psd1ΔΔ psd2ΔΔ) are compromised for virulence in mouse models of 
systemic infection and oropharyngeal candidiasis (OPC). Both of these enzymes are 
necessary to synthesize phosphatidylethanolamine (PE) by the de novo pathway, but 
these mutants are still capable of growth in culture media, as they can import 
ethanolamine from media to synthesize PE through the Kennedy pathway. Given that 
the host has ethanolamine in its serum, the exact mechanism by which virulence is lost 
in these mutants is not clear. There are two competing hypotheses to explain their loss 
of virulence. (i) PE from the Kennedy pathway cannot substitute for de novo-
synthesized PE. (ii) The mutants cannot acquire sufficient ethanolamine from the host to 
support adequate PE synthesis. These hypotheses can be simultaneously tested if 
ethanolamine availability is increased for Candida while it is inside the host. We 
accomplish this by transcomplementation of C. albicans with the Arabidopsis 
thaliana serine decarboxylase gene (AtSDC), which converts cytoplasmic serine to 
ethanolamine. Expression of AtSDC in either mutant restores PE synthesis, even in the 
absence of exogenous ethanolamine. AtSDC also restores virulence to cho1ΔΔ 
and psd1ΔΔ psd2ΔΔ strains in systemic and OPC infections. Thus, in the absence of de 
novo PE synthesis, C. albicans cannot acquire sufficient ethanolamine from the host to 
support virulence. In addition, expression of AtSDC restores PS synthesis in 
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the cho1ΔΔ mutant, which may be due to causing PS decarboxylase to run backwards 
and convert PE to PS. 
 
Abstract: Exposure of Candida albicans β (1,3)-glucan 1 is promoted by activation 
of the Cek1 pathway. 
 
Candida albicans is among the most common causes of human fungal infections and is 
an important source of mortality.  C. albicans is able to diminish its detection by innate 
immune cells through masking of β (1,3)-glucan in the inner cell wall with an outer layer 
of heavily glycosylated mannoproteins (mannan).  However, mutations or drugs that 
disrupt the cell wall can lead to exposure of β (1,3)-glucan (unmasking) and enhanced 
detection by innate immune cells through receptors like Dectin-1, the C-type signaling 
lectin. Previously, our lab showed that the pathway for synthesizing the phospholipid 
phosphatidylserine (PS) plays a role in β (1,3)-glucan masking. The homozygous PS 
synthase knockout mutant, cho1Δ/Δ, exhibits increased exposure of β (1,3)-glucan. 
Several Mitogen Activated Protein Kinase (MAPK) pathways and their upstream Rho-
type small GTPases are important for regulating cell wall biogenesis and remodeling. In 
the cho1Δ/Δ mutant, both the Cek1 and Mkc1 MAPKs are constitutively activated, and 
they act downstream of the small GTPases Cdc42 and Rho1, respectively. In addition, 
Cdc42 activity is up-regulated in cho1∆/∆. Thus, it was hypothesized that activation of 
Cdc42 or Rho1 and their downstream kinases cause unmasking. Disruption of MKC1 
does not decrease unmasking in cho1∆/∆, and hyperactivation of Rho1 in wild-type cells 
increases unmasking and activation of both Cek1 and Mkc1. Moreover, independent 
hyperactivation of the MAP kinase kinase kinase Ste11 in wild-type cells leads to Cek1 
activation and increased β (1,3)-glucan unmasking. Thus, upregulation of the Cek1 
MAPK pathway causes unmasking, and may be responsible for unmasking in cho1∆/∆.  
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1. Introduction  
 The flow cytometer and fluorescently activated cell sorter (FACS machine) are 
arguably the most powerful tools for immunological based research. This is because 
flow cytometers allow for single cell analysis. Flow cytometers differentiate cells by size 
and intracellular complexity, and most modern flow cytometers are capable of 
identification of cells stained with fluorescent proteins. Fluorescent proteins used for 
flow cytometry (FC) are typically monoclonal antibodies that have been conjugated to a 
specific fluorophore. These proteins typically target cell surface or intracellular proteins 
for either eukaryotic or prokaryotic cells. The ability of these machines to recognize, 
depending on the machine, more than 50 unique fluorescent signals and evaluate more 
than a million individual cells during a single run; provides immunologists around the 
world with a tool to study the complex interactions of the immune system. While flow 
cytometers are generally associated with immunological research, other research fields 
rely of FC for data generation and acquisition. In this appendix I will highlight the 
functionality of FC for membrane analysis of C. albicans. Additional resources can be 
found in [1] which will help in instrumentation set up and generating correct controls.  
2. Methods and Data Analysis 
 Flow cytometry data is typically expressed in two different formats: a histogram 
(Figure A4.1A) or a FACS plot (Figure A4.1B). When only identifying one fluorophore, 
it is acceptable to present data in a histogram format. However, when more than one 
fluorescent channel is being used, data must be presented in a FACS plot. The 
mean/median fluorescent intensity or MFI can only be generated for one fluorophore at 
a time. As most of the data in both the above articles is represented as MFI, I will 
highlight pitfalls for analyzing and interpreting MFIs. First, it is important to explain what 
MFI is. MFI represents the geometric mean, the arithmetic mean, the median, or the 
mode of the samples fluorescent intensity. If the data is evenly distributed ,then median 
and mode are equal. Essentially MFI represents the average fluorescents of a sample. 
MFI can serve as a proxy for expression level of the ligand, which the fluorescent  
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Figure A4.1. Example of types of flow cytometry data. 
(A) Histogram representing the fluorescent intensity of a single fluorescent channel. (B) 
FACS plot representing a sample that has been stained with two fluorescent antibodies.   
 
 
antibody binds. MFIs can be compared across treatment groups to determine whether a 
certain treatment reduces the expression of a ligand of interest.  
 There are many factors that skew data and generate false positive results. First 
dead cells can be auto-fluorescent, and these cells are prone to non-specific antibody 
binding. Therefore, it is imperative dead cells are removed prior to data analysis. A live 
dead stain (Figure A4.2) or a DNA binding dye can be used to differentiate live cells 
from dead cells. Second FC is used to analyze single cells, but sometimes cells stick 
together when they pass through the machine. When this happens the two cells will 
register as one event, or one cell, if both cells are fluorescently labeled with the same 
fluorophore then the single event will register as 2X labeled. These two cells stuck 
together, but registering as a single event will falsely increase the MFI. Through the use 
of side scatter and forward scatter it is possible to identify two cells stuck together 
(doublets) and even three cells stuck together (triplets). Figure A4.3 represents the 
gating strategy to analyze a single cell population. The last panel of figure A3.3 Forward 
SCatter-Area x Forward SCatter-Width (FSC-A, FSC-W) displays 3 separate 
populations. There is a small doublet population followed by a larger triplet population. 
These cells were not gated on, thereby dismissing them from downstream analysis. 
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Figure A4.2 FACS plot of cells stained with a live dead stain. 
The dead cells took up Near-IR live dead stain and separated from the unstained 
population. The unstained population has been indicated with the rectangle.  
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Figure A4.3. Acquisition of single cell populations.  
Live cells were subjected to a gating strategy to acquire single cells. A single population 
was gated on from SSC-A, SSC-W. This population was then gated on FSC-W, FCS-A. 
The single cell population can be taken for down stream analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Single Cells
78.7
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
FS
C-
W
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
SS
C-
A
Live
75.9
10 0 10 1 10 2 10 3 10 4 10 5
Comp-APC-Cy7-A :: L_d
0
50K
100K
150K
200K
250K
SS
C-
A
Live/Dead	
	
SS
C-
A	
SS
C-
A	
FSC-A	
	
Single Cells
96.6
0 50K 100K 150K 200K 250K
SSC-W
0
50K
100K
150K
200K
250K
SS
C-
A
SS
C-
A	
FSC-A	
	
FS
C-
W
	
SSC-W	
	
Single	cell	popula7on	
for	downstream	
analysis	
 
 
196 
Single cell gating of live cells is imperative for accurate data analysis.  
 When working with more than one fluorphore, MFI is not used, but the same 
gating precautions previously describe should be used. The flow cytometer is capable of 
recognizing numerous different fluorescent channels, but some of these channels have 
spectral over lap. Therefore, the machine has to be compensated, or told what 
fluorophore is which. Compensating a flow cytometer is outside the scope of the 
appendix, but it must be taken into account when working in more than one fluorescent 
channel excited by the same laser. If fluorophores are chosen that are excited by 
different lasers then compensation is not required.  
 Here, I have briefly outlined the process of data analysis used in collaboration 
with Dr. Todd Reynolds. Through this collaboration we have been able to successfully 
characterize C. albicans unmasking and processes involved to induce this event.  
References 
 
1. Maecker, H.T. and J. Trotter, Flow cytometry controls, instrument setup, and the 
determination of positivity. Cytometry A, 2006. 69(9): p. 1037-42. 
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Appendix V: Evaluation of Innate Immunological Responses to 
Campylobacter jejuni in Collaboration with Dr. Jeremiah Johnson     
 
This appendix is a part of a publication by the title, The Host Antimicrobial Protein 
Calgranulin C Participates in the Control of Campylobacter jejuni Growth via Zinc 
Sequestration.  published in the journal Infection and Immunity in 2018 by Janette M. 
Shank, Brittni R. Kelley, Joseph W. Jackson, Jessica L. Tweedie, Dana Franklin, Steven 
M. Damo, Jennifer A. Gaddy, Caitlin N. Murphy,  and Jeremiah G. Johnson 
 
Shank JM, Kelley BR, Jackson JW, Tweedie JL, Franklin D, Damo SM, Gaddy JA, 
Murphy CN, Johnson JG. The Host Antimicrobial Protein Calgranulin C Participates in 
the Control of Campylobacter jejuni Growth via Zinc Sequestration. Infect Immun. 
2018;86(6). doi: 10.1128/IAI.00234-18. PubMed PMID: 29610259; PMCID: 
PMC5964530. 
 
My contribution to this work capitalized on my expertise in innate immunology. I assisted 
in data analysis for one figure of the manuscript, and data acquisition and analysis for a 
second figure of the manuscript. For these figures I wrote the figure legends, results, 
and material and methods. My contribution to the article was during the rebuttal 
process. Due to this, the manuscript has been truncated to highlight my contributions.  
 
Abstract 
Campylobacter jejuni is a leading cause of bacterially derived gastroenteritis worldwide. 
Campylobacter is most commonly acquired through the consumption of undercooked 
poultry meat or through drinking contaminated water. Following ingestion, 
Campylobacter adheres to the intestinal epithelium and mucus layer, causing toxin-
mediated inflammation and inhibition of fluid reabsorption. Currently, the human 
response to infection is relatively unknown, and animal hosts that model these 
responses are rare. As such, we examined patient fecal samples for the accumulation 
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of the neutrophil protein calgranulin C during infection with Campylobacter jejuni. In 
response to infection, calgranulin C was significantly increased in the feces of humans. 
To determine whether calgranulin C accumulation occurs in an animal model, we 
examined disease in ferrets. Ferrets were effectively infected by C. jejuni, with peak 
fecal loads observed at day 3 postinfection and full resolution by day 12. Serum levels 
of interleukin-10 (IL-10) and tumor necrosis factor alpha significantly increased in 
response to infection, which resulted in leukocyte trafficking to the colon. As a result, 
calgranulin C increased in the feces of ferrets at the time when C. jejuni loads 
decreased. Further, the addition of purified calgranulin C to C. jejuni cultures was found 
to inhibit growth in a zinc-dependent manner. These results suggest that upon infection 
with C. jejuni, leukocytes trafficked to the intestine release calgranulin C as a 
mechanism for inhibiting C. jejuni growth. 
1. Introduction  
 Campylobacter jejuni significantly impacts human health as it is the leading 
cause of bacterially derived gastroenteritis in the world [1]. This pathogen is fairly 
ubiquitous as it resides asymptomatically in the gastrointestinal tracts of cattle, pigs, 
poultry, and other livestock [2]. The most common route of infection in the developed 
world is through consumption of undercooked poultry, whereas in the developing world, 
infection most commonly occurs via drinking contaminated water [1]. Following 
ingestion, Campylobacter adheres to the intestinal epithelium and mucus layer, causing 
toxin-mediated inflammation and inhibition of fluid reabsorption [3]. This leads to the 
development of mild to severe diarrhea that may be accompanied by abdominal 
cramps, fever, and frank blood in the stool. While Campylobacter infection is often self-
limiting, campylobacteriosis can lead to serious postinfectious diseases such as 
Guillain-Barré syndrome, reactive arthritis, and inflammatory bowel disease [4]. In low-
resource settings, C. jejuni infection can also lead to persistence and stunting when 
acquired at a young age [5] In addition to problems associated with the frequency and 
severity of these infections, Campylobacter is becoming increasingly resistant to 
clinically important antibiotics such as ciprofloxacin and azithromycin, leading the CDC 
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and the WHO to classify it as a serious threat to public health [2]. Due to the increasing 
antibiotic resistance of C. jejuni, it is necessary that the field identify and develop new 
technologies to reduce Campylobacter infection in humans. Most of these efforts have 
focused on reducing colonization of poultry in an effort to prevent contamination of food 
and transmission to humans, while relatively less has been done to identify factors that 
contribute to colonization of humans and leveraging those observations to develop 
direct treatments [6, 7].  
 S100 proteins are calcium-binding regulators of several important cell processes 
in vertebrates, including energy metabolism, growth, motility, cell cycle regulation, and 
apoptosis [8]. Many of these proteins are commonly used as markers of gastrointestinal 
inflammation in humans. Calprotectin (also called S100A8/S100A9 or MRP 8/14) and 
calgranulin C (also called S100A12 or EN-RAGE) are quantifiable in feces and are 
elevated during intestinal inflammation. These proteins indicate the presence of 
neutrophils as they make up approximately 40% of all neutrophil cytosolic proteins [9]. 
Extracellularly, calprotectin has been shown to be chemotactic for neutrophils [10], while 
calgranulin C is chemotactic for monocytes and mast cells [11], thus promoting a 
proinflammatory response. Both calprotectin and calgranulin C have antimicrobial 
properties due to their abilities to sequester copper, manganese, iron, and zinc [8 , 12]. 
These proteins have been shown to inhibit the growth of fungi, certain bacterial species 
such as Staphylococcus aureus, and some parasites [13–15. The molecular details of 
the mechanism behind this antimicrobial action remains unknown, but it is speculated to 
be due to the inhibition of essential metal-dependent functions such as the reduction of 
superoxide [16].  
 Weaning-age ferrets have been used in previous studies to determine the effects 
of Campylobacter infection in an animal model because they are one of the few animals 
that display clinical signs similar to human campylobacteriosis although ferrets aged 6 
to 7 weeks tend to display more severe disease than ferrets aged 11 weeks and older 
[17, 18]. These signs include mild to moderate diarrhea and mucus and/or blood in the 
stool. Most of the previous studies simply looked at whether various C. jejuni strains 
could colonize and cause diarrhea and did not examine the effects of infection on the 
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animal. A more in-depth analysis of the host factors that are impacted by C. jejuni 
infection could contribute to understanding disease in humans. Our work here indicates 
that ferrets were successfully infected with Campylobacter and exhibited a productive 
immune response that was characterized by increased levels of systemic tumor 
necrosis factor alpha and increased leukocyte trafficking to the colon. This trafficking 
was found to contribute to increased gastrointestinal calgranulin C levels, which were 
subsequently found to effectively inhibit growth of C. jejuni in a zinc-dependent manner. 
This work represents the first observation of calgranulin C accumulation during 
Campylobacter infection and examination of the role of host-derived zinc sequestration 
as a mechanism of inhibiting Campylobacter growth. 
2. Results and Discussion 
Campylobacter infection results in leukocyte accumulation in blood and intestinal tissue. 
 Following observations that Campylobacter infection results in increased 
calgranulin C levels in the feces, a more invasive study was performed on male ferrets 
to examine intestinal pathology and leukocyte migration during infection.  
Extracted colonic tissue from these animals was imaged following hematoxylin and 
eosin (H&E) staining, which indicated an increase in macrophages and neutrophils in 
infected animals at days 1 and 3 postinfection (Figure A5.1). By day 7, the infected 
tissue became indistinguishable from that of the uninfected control tissue. In order to 
quantify the infiltration of the leukocytes into tissue, flow cytometry was performed on 
both blood and colonic tissue. This analysis found that both probable macrophages 
(Cd11b+ mononuclear cells) and neutrophils (Cd11b+/SSChighgranulocytes, where 
SSChigh indicates a high side scatter light-scatter phenotype) increase in the blood 
during early infection (days 1 and 3) and return to levels observed in uninfected controls 
by day 7 postinfection (Figure A5.2A and A5.2B). Restoration of levels to those of 
uninfected controls was presumably due to the chemotaxis of leukocytes toward the site 
of infection in the colon. To examine leukocyte infiltration into the intestinal tissue, we 
similarly quantified both probable macrophage and neutrophil populations in ferret 
colons. Similar to what was observed in the blood, both populations of leukocytes  
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Figure A5.1. Histology of ferret colonic tissue.  
Representative H&E-stained images from infected and uninfected ferret colons from 
days 1, 3, and 7 postinfection are presented. Apparent neutrophils (orange arrows) and 
macrophages (green arrows) are indicated. Magnification, ×40. 
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Figure A5.2. Quantification of leukocyte populations in ferret tissues.  
Mononuclear cell and granulocyte abundances were determined for both blood and 
colonic tissue in infected and uninfected ferrets at each time point. Counts for each cell 
type are presented as relative abundance compared to the level in the uninfected 
control for that time point. The mean and standard error of the mean are presented for 
each infected pair at each time point. 
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increased in intestinal tissue early in infection, peaked at day 3, and remained slightly 
elevated following clearance (Figure A5.2C and A5.2D). 
 One of the biggest concerns the reviewers had from the initial submission was 
that the presence of cytokines in the stool did not correlate with a cellular response to 
the colon. Therefore, Dr. Jeremiah Johnson at the University of Tennessee approached 
me with the opportunity for collaboration. As seen throughout the rest of my dissertation 
I am well educated in innate immunology and flow cytometry. Our data generated from 
figures A5.1 and A5.2 indicate that upon infection with C. jejuni  there is a robust 
immune response not only to colonic tissue but there is also a substantial systemic 
cellular immune response. This data validates that ferrets can be used a model system 
to study the immune systems response to campylobacter infection. Additionally this was 
the first report to our knowledge that analyzed ferret colonic tissue via flow cytometry.  
3. Materials and Methods  
Animals 
Twelve weaning-aged ferrets (5.5 to 6 weeks of age), six males and six females, were 
obtained from Marshall BioResources (North Rose, NY). Ferrets were individually 
housed at the Walters Life Sciences (WLS) Animal Facility at the University of 
Tennessee Knoxville. They were acclimated in the WLS animal facility for 7 days to 
allow the animals to recover following transportation. Ferrets were fed Envigo Teklad 
global ferret diet and given water ad libitum throughout this study, except for a 
restriction 2 to 3 h prior to inoculation with Campylobacter jejuni. All animal procedures 
were conducted under University of Tennessee IACUC protocol 2519. 
 
Preparation of H&E-stained colonic tissue 
The terminal 1 cm of the ferret colon was removed following sacrifice, and the lumen 
was washed five times with 1 ml of sterile, cold PBS. Tissue was placed in 10% 
buffered formalin and fixed for 4 h at room temperature. Fixed tissue was embedded in 
formalin, and 4-μm sections were stained with hematoxylin and eosin. Stained slides 
were visualized, and representative images are presented. 
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Purification and enumeration of leukocytes from whole blood and colon 
Whole blood collected by vena cava puncture was stored in lithium heparin tubes. 
Peripheral blood leukocytes (PBLs) were obtained by ammonium-chloride-potassium 
(ACK) lysis. 
Cells were isolated from colons the entire colon was removed from ferrets immediately 
following euthanasia. The lumen was washed with 5 ml of cold PBS and then separated 
into 1-cm sections. These sections were opened, exposing the lumen. These opened 
sections were placed in a petri dish and washed three times with cold PBS. Sections 
were minced into 1-mm sections and collagenase digested. Digested products were 
passed through a 40-μm-pore-size cell strainer using a 5-ml plunger to obtain single-cell 
suspensions. These single-cell suspensions were washed with cold PBS, counted, and 
then resuspended to the appropriate density in fluorescence-activated cell sorting 
(FACS) buffer. 
Flow cytometry assays were conducted as previously described [20]. Briefly, single-cell 
suspensions were Fc receptor blocked using 1% goat serum in FACS buffer. Cells were 
then washed and stained with an antibody recognizing ferret CD11b (clone M1/70-APC; 
Biolegend). Data were acquired using an LSR II instrument (BD Bioscience, San Jose, 
CA) and analyzed using FlowJo software (Tree Star, Ashland, OR). 
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